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Predicting the Outcomes of HIV Treatment 
Interruptions using Computational Modelling 
Andreas Hillmann 
Abstract 
In the past 30 years, HIV infection made a transition from fatal to chronic 
disease due to the emergence of potent treatment largely suppressing viral 
replication. However, this medication must be administered life-long on a 
regular basis to maintain viral suppression and is not always well tolerated. 
Any interruption of treatment causes residual virus to be reactivated and 
infection to progress, where the underlying processes occurring and 
consequences for the immune system are still poorly understood. 
Nonetheless, treatment interruptions are common due to adherence issues or 
limited access to antiretroviral drugs. Early clinical studies, aiming at 
application of treatment interruptions in a structured way, gave contradictory 
results concerning patient safety, discouraging further trials. In-silico models 
potentially add to knowledge but a review of the Literature indicates most 
current models used for studying treatment interruptions (equation-based), 
neglect recent clinical findings of collagen formation in lymphatic tissue due 
to HIV and its crucial role in immune system stability and efficacy. The aim 
of this research is the construction and application of so-called ‘Bottom-Up’ 
models to allow improved assessment of these processes in relation to HIV 
treatment interruptions. In this regard, a novel computational model based on 
2D Cellular Automata for lymphatic tissue depletion and associated damage 
to the immune system was developed. Hence, (i) using this model, the 
influence of spatial distribution of collagen formation on HIV infection 
progression speed was evaluated while discussing aspects of computational 
performance. Further, (ii) direct Monte Carlo simulations were employed to 
explore the accumulation of tissue impairment due to repeated treatment 
interruptions and consequences for long-term prognosis. Finally, (iii) an 
inverse Monte Carlo approach was used to reconstruct yet unknown 
characteristics of patient groups. This is based on sparse data from past 
clinical studies on treatment interruptions with the aim of explaining their 
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Almost four decades ago, a new type of lethal disease emerged rapidly among 
populations of homosexual males in the USA. This disease, termed Acquired 
Immunodeficiency Syndrome (AIDS), was associated with a variety of 
symptoms linked to immune system failure. Its cause, being subject of 
intensive research, was an infection with a yet unknown type of virus, termed 
Human Immunodeficiency Virus (HIV), (Barré-Sinoussi et al., 1983; Gallo 
et al., 1983). The virus was found to have unique capabilities not only by 
defeating the functions of the immune system but also by utilising them for 
its own replication and as a reservoir. At present time, HIV infection has 
grown to a major global health problem with approximately 38 million people 
infected with numbers still on the rise, mainly in resource-limited regions, 
(UNAIDS, 2019). Despite intensive research, neither a cure (removing the 
virus from the organism), nor an effective vaccine to prevent infection 
altogether appears within reach at the time of writing, (Fauci and Lane, 2020). 
However, the increase in knowledge of the viral replication cycle enabled 
the development of specific drugs acting as inhibitors for key steps, (Arts and 
Hazuda, 2012). Unfortunately, these drugs quickly become ineffective if 
applied in monotherapy due to the high mutation rate of the virus, 
(Braithwaite et al., 2007). Combining different drug classes, however, led to 
a breakthrough, since it largely avoided the drug resistance problem. This 
treatment, termed combination Antiretroviral Therapy (cART), still forms the 
base of today’s regimen, (Passaes and Sáez-Cirión, 2014). If applied properly, 
the virus becomes undetectable in the organisms with health and life 
expectance greatly improved. To achieve such a state, drug combinations 





These requirements, however, cause considerable problems for the 
affected patients. Anti-HIV drugs frequently cause adverse side-effects due 
to drug interactions and toxicities, (Nansseu and Bigna, 2017), as well as 
triggering psychological stress, (Katz et al., 2013). These factors lead to 
treatments often being interrupted (voluntarily) for limited time spans, thus 
resulting in adherence issues, (Robbins et al., 2007). Situations where 
interruptions occur involuntarily due to a dearth of drugs, restricted access to 
therapy, (Mann et al., 2013), or social pressure (Murray et al., 2009), are a 
common and persistent issue. 
As interruptions cause the drug concentrations in the organism being 
lowered, (Moreno-Gamez et al., 2015), the consequence is a reactivation of 
dormant virus. The so-called ‘latent viral reservoir’ is a key concern, as it is 
yet unreachable by treatment efforts. With very few exceptions, the 
consequence is a rapid increase in viral particle numbers, (Rothenberger et 
al., 2015). This immediate effect of treatment interruptions may result in 
serious implications for efficacy, making it necessary to treat with an 
alternative regimen, (Teklu and Yirdaw, 2017). Apart from this virological 
failure, less immediate effects, such as failure of the immune system to 
maintain an effective response, may follow treatment interruptions with 
detrimental effect to the immune system, (Imaz et al., 2013). The 
quantification of such effects, however, remains a challenge, hitherto 
assessed, in part, by clinical studies.   
Further aspects of the viral lifecycle, mechanisms of treatment and 
interruptions will be covered in more detail in chapter 2. 
1.2 Availability of Data 
To assess the physiological effects of treatment interruptions in a controlled 
clinical environment, structured treatment interruptions, following defined 





studies addressed questions of immune system boosting, reduction of 
overtreatment and relief of psychological stress. However, results regarding 
safety have been inconclusive to date, (Dubé et al., 2018). Hence, health 
authorities do not recommend treatment interruptions (AIDSinfo, 2019). 
Moreover, further direct clinical studies on structured treatment interruptions 
have been discouraged due to ethical reasons, (Hirschel and Flanigan, 2009), 
leaving the causes of inconclusive results of previous studies widely 
unknown. The resulting lack of sufficiently detailed and up to date clinical 
data impedes the assessment of treatment interruption impact on long-term 
prognosis of patients. Due to the ubiquity of treatment interruptions, 
therefore, any means of predicting failure or success without incurring patient 
harm would clearly be desirable. 
1.3 Motivation for Modelling 
In the context of the limited availability of suitable data from clinical sources, 
modelling has proved to be a powerful in-silico tool for investigation of 
treatment interruptions and can give indicative outcomes of such 
interventions, (e.g. (Bajaria et al., 2004; Hernandez-Vargas, 2017)). 
Originally used to explain population dynamics (Berryman, 1992), the 
underlying concepts have been employed at various scales and for problems, 
including viral propagation within the host. Such mechanistic models, which 
consider known biological mechanisms, underpinning the clinical data 
observed have also been applied for several years to study immunology in 
general, (Castro et al., 2016), and HIV infection in the blood stream, (Ho et 
al., 1995; Perelson and Ribeiro, 2013).  
However, model assumptions need to be carefully validated against 
available results from clinical trials or wet lab experiments to ensure that the 
model provides meaningful results. In contrast to population-based models, 





completely known while obtaining the necessary data with sufficient 
precision is not feasible with available assay techniques. Hence, modelling in 
the context of HIV has long focused on few, well-known mechanisms, 
(Hillmann et al., 2017a), best represented by variants of a common set of 
model equations. While well-established in the modelling community, these 
variants provide a somewhat limited view of the complexities of HIV 
infection, which have been discovered in recent years, (Appay and Sauce, 
2017).  
Some newer clinical findings require rethinking established model 
structures in the context of HIV together with complementary alternative 
approaches, where suitable. Due to the complexity of the underlying 
biological system, however, definition of model entities and their 
interrelations is typically non-trivial. Also, limitations of available data from 
clinical or lab sources, as noted for the case of treatment interruptions, impede 
calibration and validation of the underlying model assumptions. This 
situation is exacerbated with increased model complexity, (Castiglione and 
Celada, 2015), affecting the informative value.  
Further, the large body of clinical study data in existence for the case of 
treatment interruptions dates back several years to the point where further 
studies were discouraged on ethical grounds. Data obtained thus reflects 
knowledge on mechanisms of HIV infection only at the given time. However, 
more recent information on the nuanced biological mechanisms involved, 
may offer further elucidation of the sometimes-puzzling results of these 
earlier clinical studies.  
Information gained from traditional models can be limited due to their 
more rigid assumptions, so that use of computational methods and novel 
models offer potential added value. Well-established computational 
formalisms allow for improved biological realism while maintaining a 






1.4 Scope and Contribution 
The body of my research addresses the following:  
(i) Modelling in the context of HIV treatment interruptions. Identification of 
limitations in regard to the physiological effects of infection progression. 
(ii) Proposing a model with improved biological realism while maintaining 
simple rules. (Utilises computational capabilities currently available through 
the university and notes further improvements.) 
(iii) The application of the model developed in the context of several 
scenarios of interrupted treatment.  
(iv) The assessment of the impact of model interruption scenarios with 
reference to past clinical study data on structured treatment interruptions. 
These data are sparse and incomplete with regard to current knowledge. 
Hence, statistical augmentation of these data to compensate for information 
lacking is proposed. 
The thesis is structured in the following way to address the above issues, with 
initial chapters providing the groundwork for the models subsequently 
developed: 
Chapter 2 aims to provide an overview of the biological and medical 
foundations of HIV infection, treatment to date and difficulties for 
management, especially in the case of interruptions. The virus interacts with 
parts of the human immune system, itself highly complex, in manifold ways 
and shows emergent properties through interaction of a large number of 
components and different mechanisms. I therefore start with the description 
of major immune system elements and the related immune mechanisms. 
Further, I give an overview on how the HI virus interferes with the immune 





the system. State of the art treatment for HIV infection and a list of available 
drugs, classes and treatment regimen are discussed here, while this section 
also provides a basic view of the ways in which the drugs compromise the 
HIV lifecycle. Factors which impede treatment, (preventing a final cure for 
HIV infection to date,) such as drug resistance and viral reservoirs, are briefly 
reviewed. Finally, I give an overview of experiences with structured treatment 
interruptions (STIs). Possible reasons for treatment failures are listed and 
recent studies on treatment interruptions briefly summarised.  
Chapter 3 reviews the modelling literature for HIV infection and the special 
case of treatment interruptions (TIs). Emphasis is given to the modelling 
scale, which crucially affects outcomes of such studies. Relevant model 
techniques and related formalisms are briefly reviewed and their strengths 
and weaknesses for the HIV treatment interruption problem are highlighted. 
Further, gaps in these recent approaches are identified and suggestions are 
made how these may be overcome using bottom-up modelling techniques. 
Chapter 4 gives an overview of the methods, tools and algorithms used in 
this research. I briefly describe how these methods have evolved to the point, 
where newer developments are possible. Implementation and performance 
optimisation strategies of such methods in terms of practical computation are 
also covered briefly in order to provide the necessary mathematical and 
computational background for the work. 
Chapter 5 describes formulation of a model to provide improved description 
of the long-term prediction and effects of treatment interruptions. The model 
environment and rules are described in detail with relation to current 
knowledge on HIV pathology. Further, I conduct basic simulation 






Chapter 6 subsequently applies the model developed in Chapter 5 to explore 
different interruptions strategies. Results on detrimental effects on the 
immune system are evaluated. From these, recommendations for optimal 
treatment interruption patterns are formulated. 
Chapter 7 addresses the issue of missing or incomplete clinical data in the 
context of treatment interruptions. I suggest a way to address this problem 
using a simulation-based approach by adapting common statistical concepts. 
The capabilities of the approach are then demonstrated by augmenting 
incomplete clinical results with additional relevant data, with a few examples 
to prove usability of the method. 
Chapter 8 summarises all findings and gives an outline of proposals on 
further research challenges and points to consider, highlighted during the 






2 HIV Infection and Treatment 
2.1 Introduction 
The following sections on the Human Immunodeficiency Virus (HIV) 
provide an overview on the history and current state of the HIV infection 
pandemic and the structure and mechanisms of action for this virus and 
infection progression. The history of treatment options, currently available 
drug classes and their mechanisms of actions and state of the art treatment 
regimen are considered, together with limitations of treatment strategy given 
the HIV’s ability to evade eradication. Treatment interruptions are described 
in detail, including possible causes and effects on short and long-term 
progressions of disease. In the interest of conciseness, a detailed 
parametrisation discussion of the processes involved is deferred to Chapter 5. 
2.2 HIV and AIDS 
2.2.1 A Global Pandemic 
The first cases of a disease, termed AIDS (Acquired Immunodeficiency 
Syndrome), came to attention in the late 1970s in USA among homosexual 
males and intravenous drug users (Jaffe et al., 1983). The individuals 
concerned showed opportunistic infections, which were typified by a 
weakness of the immune system. The underlying cause, chronic infection 
with a new type of virus, termed Human Immunodeficiency Virus type 1 
(HIV-1) was discovered in 1983 (Barré-Sinoussi et al., 1983; Gallo et al., 
1983). The virus was found to closely resemble another virus of the same type 
(Simian Immunodeficiency Virus – SIV), which causes similar symptoms in 
certain kinds of apes, (Chakrabarti et al., 1987). Genetic analysis of preserved 
tissue samples suggested SIV as an ancestor of HIV-1, where the former 





al., 2008). HIV-1 is the most prevalent subtype both in Africa and the rest of 
the world. A much less prevalent subtype termed HIV-2 occurs 
predominantly in parts of West Africa, (Olesen et al., 2018). An infection 
with HIV-2 causes symptoms which are similar to HIV-1 infection, but the 
disease progresses more slowly and mortality rates for untreated infections 
are lower compared to those for HIV-1. It is currently believed that HIV-2 
emerged from another subtype of SIV, also by crossing the species barrier, 
(Santiago et al., 2005). In the work presented here, reference to HIV is to 
HIV-1, since this makes up far more than 90% of worldwide infections to 
date, with increasing prevalence in relation to HIV-2, (Olesen et al., 2018). 
2.2.2 Viral Transmission 
In contrast to other known viruses, HIV has the unique ability of evading the 
otherwise effective mechanisms of the human immune system (as well as 
sometimes using them to its advantage). A short summary of the basic 
components of the immune System and their normal function is given in 
Appendix A. 
The way in which HIV progresses through the human body after infection 
is still mostly unknown. The main point of entry for HIV virions (virus 
particles) are the mucosal tissues1 (e.g. vaginal, rectal). During passage 
through these barriers, the virus is assumed to infect dendritic cells2 residing 
in these tissues in large numbers. It is suggested that around 80% of infections 
originate from one single virus particle passing the mucosal barriers, 
(McMichael et al., 2010). How the infection further progresses through the 
underlying epithelial3 cells is not fully resolved, (Fackler et al., 2014). 
 
 
1 Layers of loose, constantly repleneshing connectivity tissue covering the surface of body 
openings for protection from pathogens. 
2 Cells responsible for binding pathogens to be supplied to immune recognition. 





Infected cells are assumed to reach the lymphatic system from where the 
infection spreads into other lymphoid and other tissues, where the exact 
mechanism is also not known, (Fackler et al., 2014). Transmission of the virus 
has been found to be most effective if it occurs through direct cell contact, 
although cell-free infection is also occurring but is much less pernicious, 
(Agosto et al., 2015; Zhong et al., 2013). Susceptible T-helper cells of CD4+ 
type4 reside in great numbers in lymph nodes with frequent contact to each 
other and move slowly through the lymphatic system. Therefore lymph nodes 
are considered as predominant anatomical compartments for viral 
propagation, (Pantaleo et al., 1993b). However, progression of the infection 
is determined by viral load as well as antagonistic CD4+ T-Lymphocyte 
levels in plasma obtained from peripheral blood5, (Mellors, 1997). Viral load 
levels in lymphoid tissue were found to correlate to blood plasma levels 
(Cavert et al., 1997), (where blood is easier to obtain for routine screening) 
although this equivalence has been questioned more recently, (Cohen, 2011).  
2.2.3 HIV Infection 
An active infection is commonly characterised by concentration of specific 
biomarkers6 in peripheral blood, e.g. inflammation enzymes, antibodies or 
viral components. Additionally, there are clinical conditions related to 
immune deficiency which are predominantly used to characterise the later 
stages of infection. These are commonly categorised into distinct stages of 
early HIV infection, (Fiebig et al., 2003). 
Specifically, the timespan from the infection to the first biomarkers 
becoming visible is termed the eclipse phase which takes 11 days on average. 
 
 
4 Specific protein (‚cluster of differentiation 4‘) on cell surface. 
5 Blood obtained from the circulation (excluding bone marrow or lymphatic system). 





Subsequently, HIV RNA becomes detectable in blood using PCR7 
diagnostics (stage 1). After a further 5 days, HIV-specific antigen (p21) can 
be detected (stage 2) using immune assays. Virus RNA concentration in blood 
samples reaches its peak and after 5 more days, anti-HIV antibodies can be 
found in blood (stage 3), also termed seroconversion.  
Subsequent to these initial stages, development of concentrations of virus 
particles in peripheral blood and T-helper cells show a characteristic course 
over time (see Figure 2.1), which is divided into three phases. 
 
 
Figure 2.1: Stages of HIV infection. Typical course of an untreated HIV infection over time (x-axis) 
as indicated by concentrations of CD4+ cells (blue) and virus particles (red) in peripheral blood along 
with infection stage (horizontal bars) and common symptoms (arrows).   
Image Source: Jurema Oliveira (2017) File:Hiv-timecourse.png, Wikimedia Commons, the free media 
repository. Available at: https://commons.wikimedia.org/wiki/File:Hiv-timecourse.png (Accessed: 6 





7 Polymerase Chain Reaction; a method to detect minute quantities of DNA and RNA by 





During the following primary phase of infection, flu-like symptoms (e.g., 
swollen lymph nodes, joint and muscle pain, rashes, fatigue) do normally 
occur. Infection rates are initially high with doubling times of viral 
concentrations of under a day. This turnover rate appears to slow down 
subsequently, (Ribeiro et al., 2010), indicating partial immune control of the 
infection. However, genetic diversity of the viral population begins to 
increase. It is assumed that viral mutants, which are not yet recognised by the 
adaptive immune response, undergo a positive selection (escape mutants), 
(McMichael et al., 2010). The above is valid for the T-cell mediated immune 
response (see Appendix A for an explanation). The B-cell8 response is usually 
more effective and provides long-term protection. For HIV infection, 
however, it has no marked impact, since the virus mutates too fast  for the 
response to build up, (Moir and Fauci, 2009).  
The concentration of virus decreases until it reaches an approximately 
stable level 3-6 months after infection, (Perelson and Ribeiro, 2013). This 
concentration is termed the viral set point and marks the beginning of the 
chronic infection phase. Considerable variability has been found for the viral 
set point between subjects. Clinical symptoms have usually passed by the start 
of the chronic phase; hence it is also termed the asymptomatic phase. This 
phase, however, is characterized by a persistent immune activation where the 
generation of CD4+ T-cells is permanently upregulated. This upregulation 
serves the purpose of improving immune response under normal conditions. 
Since CD4+ cells are the main target of  HIV, however, it fuels infection. 
After a few years, the function of the immune system starts to decline, which 
leads to a severe clinical condition associated with immune deficiency, 
including skin tumours, ulcers, excessive weight loss and prolonged fever. 
 
 
8 Cellular component of the immune system responsible for (most effective) response related 





The weakened immune defence also fosters infection in general (hence 
termed opportunistic diseases). The current suggestion is that overt AIDS 
disease emerges due to the depletion of naïve T-helper lymphocytes, (Doitsh 
et al., 2013), leading to terminal failure of the cellular immune system, which 
occurs approximately 10 years after infection, (Fauci et al., 1996), if not 
treated. However, despite the virus being able only to infect certain types of 
white blood cells (T-cells with CD4+ receptor), infection indirectly leads to 
damage of other parts of the immune system through systemic immune 
activation, (Zeng et al., 2012a). 
2.2.4 Viral Structure 
The structure of the virus has been researched extensively, (see (Seitz, 2016) 
for a comprehensive review). The diagram in Figure 2.2 highlights the key 
components of a viral particle.  
The viral genome consists of two copies of single-stranded Ribonucleic 
Acid (RNA) which encode for nine genes in total (15 proteins). This genome 
is enclosed in a protein shell (capsid) and an envelope, to enable protection 
and fusion with the host cell. Moreover, proteins and glycoproteins, both 
fixed to the structure or in solution, are needed for the correct function of the 
virus. The genome, of course, provides the code for all building blocks to 
produce new functional viruses and the simple structure enables the 
generation of large amounts of functional virus particles, where the small 
diameter of ~100 nm is assumed to ease the passage through the mucosal 







Figure 2.2: Schematic of a Human Immunodeficiency Virus (~100 nm diameter) with structural 
elements and proteins relevant for viral lifecycle. Diagram shows the env-Glycoprotein complex on the 
outer membrane which docks to receptors of CD4+ host cells and triggers fusion.  The capsid (centre) 
containing double stranded viral RNA and Reverse Transcriptase proteins are then injected into host 
cells where transcription to DNA is started. 
Image Source: Thomas Splettstoesser (www.scistyle.com) (2020) File:HI-virion-structure en.svg., 
Wikimedia Commons, the free media repository. Available at: 
https://commons.wikimedia.org/wiki/File:HI-virion-structure_en.svg (Accessed: 6 March 2020). Use 
permitted under the Creative Commons Attribution License CC BY-SA 
(https://creativecommons.org/licenses/by-sa/4.0) 
 
Normally, the genetic information of a cell encoded in the 
Deoxyribonucleic acid (DNA) in the cell core (or nucleus) is first transcribed 
into RNA which in turn is used to generate specific proteins (termed 
translation) which act as functional components of the cell. All known cell 
types and most viruses operate such that transcription is unidirectional from 
DNA to RNA. However, the key aspect of HIV and other retroviruses is the 
reverse transcription of RNA to DNA. This process, enabled by a specific 
protein (reverse transcriptase) supplied by the virus, leads to integration of 





addition, the enzyme of reverse transcriptase lacks proofreading, which is 
crucial in the normal (forward) transcriptase process to reduce transcription 
errors. This lack is an advantage for HIV as the high frequency of 
transcription errors leads to rapid emergence of viral mutations (not 
recognised by the immune system). This fast accumulation of viral mutants 
effectively ‘outruns’ the capability of the immune system to adapt to new 
pathogens (see Appendix A.2) thus contributing to persistent infection. 
Actively infected cells produce viral components in vast numbers leading 
to an eventual breakdown and death of the cell, approximately two days after 
its infection, (Ho et al., 1995). Due to the immune response and effective 
regeneration capabilities of CD4+ cells, losses are quickly replenished.  
However, the more critical aspect of HIV is fostered by a key property of 
CD4+ cells. These cells may assume a ‘dormant’ state after contact with a 
pathogen such as a virus giving rise to a kind of immune memory. Normally, 
this would be reactivated when re-infection occurs, leading to an advantage 
for the immune response. However, in the case of HIV, T-cells may also 
assume this state after integration of the viral genome into their DNA, 
becoming ‘latently’ infected, remaining in an inactive state for months or 
even years before being reactivated and then starting to produce new virus. 
This latent reservoir forms one of the key barriers to complete eradication of 
the infection. 
2.2.5 Long-Term Implications 
As stated above, the concentration of CD4+ cells in blood is a well-
established marker for assessing infection progression, although the cause of 
the slow decline in cell numbers has yet to be completely resolved, (Appay 
and Sauce, 2017). However, it has been argued that the fast cycle of HIV-
induced destruction and subsequent regeneration of CD4+ cells eventually 





alternative argument is that the elimination rate of such cells is slightly faster 
than their regeneration rate, leading to a slow decline in the cell pool. Another 
possible explanation involves the formation of immune memory, (McMichael 
et al., 2010). Due to the high mutation rate of HIV, the normal mechanism: 
‘recognition of a foreign substance (antigen) and response’, has been found 
to be too slow to provide effective clearance, (Moir and Fauci, 2009), leading 
to accumulation of different subspecies (and memory T-cells which are 
specific to these) together with corresponding loss of naïve CD4+ cells, 
capable of responding to novel pathogens.  
Other hypotheses attribute the acceleration of the normal ageing process 
of the immune system to viral activity, (Appay and Sauce, 2017). The 
parameterisation to quantify the above processes is discussed in Chapter 5. 
2.3 Antiretroviral Treatment 
2.3.1 Drug Development 
Since the discovery of the virus, intensive research has been devoted to 
development of drugs to cure the infection and prevent AIDS, (Broder, 2010; 
Günthard et al., 2014; Vella et al., 2012). In 1987, the first antiretroviral drug 
azidothymidine (AZT, later called zidovudine) was approved for treatment. 
This drug component used to act as antagonist for the HIV enzyme reverse 
transcriptase, a key enzyme in the viral replication cascade. However, despite 
an initial decrease in morbidity after treatment initiation, efficacy diminished 
after some weeks of treatment. The cause was found to be the high mutation 
rate which rapidly led to emergence of resistant viral strains where the drug 
was ineffective. Drug formulations developed subsequently, and based on the 
same mechanism as AZT, suffered from similar resistance problems and 
frequently caused adverse effects due to drug toxicity. Early Antiretroviral 





monotherapy, with the switch between these made after the virus had adapted 
to a specific drug. However, improvements in morbidity rates were modest. 
A breakthrough in treatment efficacy occurred in the mid-90s where new 
drugs were approved which targeted different parts of the viral lifecycle. 
While still leading to rapid viral resurgence or drug resistance if used in 
monotherapy, it was found that certain different drug types act in synergy if 
administered in combination. These discoveries led to the development of 
combination Antiretroviral Therapy (cART) which still forms the core of 
today’s treatment options. 
2.3.2 Principal Mechanisms 
Among the most widely used drug classes are Reverse Transcriptase 
Inhibitors (RTIs) and Protease Inhibitors (PIs), (Arts and Hazuda, 2012). 
RTIs reduce viral infectiousness of healthy cells by preventing integration of 
the viral genome into the host DNA. PIs cause infected cells to produce non-
functional virus by preventing a critical step in viral assembly. Figure 2.3 
shows a schema of their effect at cellular level.  
An overview of the classes of drugs currently recommended for state of 
the art highly active antiretroviral therapy (HAART) (AIDS.gov, 2009; FDA, 
2013; WHO, 2013) along with their structure and abbreviations is given in 
Table 2.1. The tendency to become ineffective due to resistance differs among 
the drug classes, with PIs being most susceptible to resistance, (Rosenbloom 







Figure 2.3: Effects of antiretroviral drug classes. Figure shows schematic of viral budding, fusion 
with host cell, reverse transcription and formation of new virus. Targets of antiretroviral drug classes 
are shown in red. Each target addresses a key protein in the viral replication cycle.  
Image Source: Thomas Splettstoesser (www.scistyle.com) (2018) File:HIV-drug-classes.svg, 
Wikimedia Commons, the free media repository. Available at: 
https://commons.wikimedia.org/wiki/File:HIV-drug-classes.svg (Accessed: 6 March 2020). Use 
permitted under the Creative Commons Attribution License CC BY 
(https://creativecommons.org/licenses/by/3.0) 
 
Table 2.1: Antiretroviral drug classes and mechanisms of action. 
Drug class Short 
name 







Short strands of RNA (NRTIs) or DNA (NtRTIs) bind 
competitively at virus RNA strand inhibiting Reverse 






nNRTIs Agents bind at allosteric centre of Reverse Transcriptase 
enzyme, non-competitive inhibition 
Protease Inhibitors PIs Inhibits viral protease enzyme which is necessary for a 
cleavage step leading to immature virus 
Integrase Strand 
Transfer Inhibitors 
INSTIs Inhibits viral integrase enzyme to block integration into 
genome 
Entry / Fusion 
Inhibitors 
- Inhibit virus entry into host cells by interfering with 
receptors (or coreceptors) on the surface of HIV or CD4+ 
cells or by preventing fusion of the membranes. 
Pharmacokinetic 
enhancers 
- Improve efficacy of other drugs by increasing their retention 
period in the organism. 





2.3.3 Treatment Regimen 
The concentration of T-helper lymphocytes (CD4+) in blood serves as a 
biomarker for infection stage and treatment efficacy, (Fauci et al., 1996). In a 
healthy person, this concentration ranges from 500 to 1200 cells/µl blood, 
(AIDS.gov, 2010). In HIV infected persons these levels are decreased. 
In their current recommendation, (WHO, 2013), World Health 
Organization sets the limit to start HAART to CD4+ levels below 500 
cells/mm³ for adults. Compared to the previous recommendations, (WHO, 
2010) where the limit was lower (350 cells/µl), this is an indication for 
treatment to start as early as possible in accordance with the results of current 
studies (Sáez-Cirión et al., 2013). About 20 different drugs have been 
approved for HAART, (United States Food and Drug Administration, 2014). 
A list of these drugs along with current combination recommendations is 
given in Appendix B. 
The currently recommended combinations depend on the actual treatment 
‘experience’ of the patient i.e. whether resistant strains have already built up. 
For ‘first line’ treatment, WHO recommends a ‘backbone’ of two NRTIs 
(refer to Table 2.1 for abbreviations) and one nNRTI, (WHO, 2013). If these 
medications lose effectiveness to suppress viral load, it is recommended to 
replace the nNRTI-based component with PIs. An NRTI component should 
remain as part of the regimen but a switch should be made to another drug, 
(i.e. AZT or TDF), depending on what was previously administered.  
In contrast to the WHO-guideline, the guidelines coming from European, 
(European AIDS Clinical Society, 2014), and U.S. authorities, (U.S. 
Department of Health and Human Services, 2014), offer more options for 
first-line treatment. Combinations of NRTIs with nNRTIs or PIs or Integrase 





2.4 Limitations of ART 
2.4.1 Viral Reservoirs 
Even though treatment with HAART leads to very low viral loads in 
peripheral blood, this does not imply complete healing. On cessation of 
therapy, viral rebound occurs within days, (Fischer et al., 2003). The only 
cases of apparent healing of an HIV infection after treatment removals are 
associated with special circumstances, such as a stem cell transplant 
following cancer chemotherapy, (Yukl et al., 2013), or treatment of a new-
born child, (Persaud et al., 2013). However, in the latter case, the virus was 
found to have re-emerged several years later, (Cohen, 2014). 
Under normal circumstances, it is not possible to eradicate every copy of 
the virus from the organism with available therapies. Latently-infected 
memory T-cells have been identified as viral reservoirs, (Chomont et al., 
2009) where viral RNA has been integrated into cellular DNA. Other immune 
cell types, like macrophages and dendritic cells are also suspect in terms of 
infection retention, (Spiegel et al., 1992).  
Another source of viral reservoirs are the so-called ‘sanctuaries’, which 
are physical compartments in the organism, which cannot be fully penetrated 
by antiretroviral drugs, (Cory et al., 2013; Solas et al., 2003). Concentrations 
of ART drugs in intracellular fluid of biopsies of lymphatic tissue were 
reported to be lower than in blood plasma, by orders of several magnitudes, 
remaining low even months after treatment initiation, (Fletcher et al., 2014). 
Also, measurements of viral RNA showed detectable concentrations in tissue 
despite total suppression in plasma. 
The role of pharmacokinetics and drug penetration has been revealed only 
in recent years, (Cory et al., 2013; Moreno-Gamez et al., 2015). In particular, 





nervous system (CNS) have variously been identified as sanctuaries, (Svicher 
et al., 2014). 
2.4.2 Drug Pharmacology 
Treatment efficacy of antiretroviral drug over time and concentration within 
a host are quantified by Pharmacokinetics and Pharmacodynamics, 
respectively.  
Pharmacokinetics (PK) describes the course of the drug concentration in 
an organism over time following its administration. Pharmacodynamics (PD) 
describes the physiological effect of the drug over its concentration. To have 
a complete view on drug effect over time a combination PK/PD profile is 
required. HIV drugs are well characterised in terms of PK and PD parameters, 
with large differences between single drugs, (Sampah et al., 2011). HAART 
requires a strict regime with administration of at least one and up to three 
doses per day. Values for plasma half-life vary from several days to 4 hours, 
(Rothenberger et al., 2015). The primary WHO recommendation is for drugs 
with longer half-life, needing administration only once or twice a day, (WHO, 
2013). However, all pharmacological parameters are based on drug 
concentrations obtained in vitro from serum, (Rosenbloom et al., 2012), 
which may not reflect true drug efficacy for the organism as a whole, (Cohen, 
2011).  
2.4.3 Drug Resistance 
Certain mutations in the HIV genome lead to resistant strains which respond 
less well to antiretroviral therapy leading to positive selection of these 
mutants. This may cause the current drug regimen failure to keep viral 
replication under control, making it necessary to switch to other drug classes, 
(WHO, 2013), (not always guaranteed to be available in resource-limited 





Pharmacodynamics of individual antiretroviral drugs found a connection 
between dose-response ratios and drug resistance, (Rosenbloom et al., 2012; 
Sampah et al., 2011). 
2.5 Discontinuation of ART 
2.5.1 Treatment Adherence 
Since HAART cannot eradicate the virus completely from the host, HIV 
infection is considered a chronic condition, requiring life-long treatment 
administration. The mandatory daily doses (to ensure effective viral 
suppression) necessitate a high degree of adherence and frequently cause side 
effects. Hence, (unstructured) interruptions of antiretroviral treatment are 
common in all regions of the world, (Kranzer and Ford, 2011). The reasons 
for such interruptions are many: relief from antiretroviral drug side effects 
(Ammassari et al., 2001), desire to conceal infection due to fear of stigma, 
(Katz et al., 2013; Murray et al., 2009); lack of knowledge and false beliefs 
regarding HIV infection, (Nozaki et al., 2013); inadequate access to therapy 
in resource limited regions, (Mann et al., 2013), are among the most common. 
Knowledge of the virologic and immunologic implications in suspension of 
treatment is consequently of importance for successful treatment 
management. 
Consequences of HIV treatment interruptions identified to date are multi-
faceted, occurring over very different time scales. Drug pharmacology effects 
are observable in the short-term, (i.e. of the order of hours), even where rise 
in viral activity is not yet measurable, a higher risk of drug resistance mutation 
may apply, (Rosenbloom et al., 2012). Virus levels becomes detectable in 
blood about ten days after interrupting therapy, (Rothenberger et al., 2015). 
Options for relief include ‘drug holidays’ or a personalised regimen, where 





Over longer time scales, moreover, several clinical studies, (e.g. (Lau et 
al., 2019)), have been conducted to investigate the effects of treatment 
interruption by applying them in a structured manner. These investigations 
are summarised briefly here. 
2.5.2 Structured Treatment Interruptions 
Several hypotheses have been explored in the context of structured treatment 
interruptions, (Benson, 2006), with medication cost reduction being one 
target, and immunological aspects another. Regarding the latter, treatment 
removal was thought to provide a re-activation of the immune response, 
ideally stimulating the immune system’s ability to control infection without 
requiring further medication, (Rosenberg et al., 2000). Other clinical studies 
assessed the potential of treatment interruptions to remove drug resistant 
mutations from the organism. It was hypothesised that (drug susceptible) 
wild-type9 virus would outgrow drug resistant viral strains (which are usually 
less fit) during interruptions which would lead to improved response to 
treatment upon re-initiation, (Benson et al., 2006). 
Accordingly, two basic designs of STIs have been proposed, 
(Ananworanich and Hirschel, 2007). In the simplest case, decisions on 
treatment removal and re-initiation depend on fixed time periods. These 
treatment interruption schedules are termed ‘fixed cycle’ with different 
durations explored, e.g. ‘one week on, one week off’ (treatment), (Dybul et 
al., 2001), or ‘two weeks off, eight weeks on’, (Fagard et al., 2003), among 
others. These fixed-cycle interruption patterns were somewhat crude, since 
they were independent of individual patient characteristics such as infection 
 
 





progression speed or pre-existing immune system depletion and results were 
mixed.  
To better consider the immune system state of an individual patient, more 
sophisticated approaches were suggested. Since the CD4+ count is a key 
marker in infection progression and fitness of the immune system, it was 
employed by various clinical studies (see Appendix E) to make treatment 
interruption decisions. The diagram in Figure 2.4 shows an example where 
treatment is interrupted once the CD4+ count of a subject exceeds 350 cells/µl 
blood and is re-introduced once it drops to 250 cells/µl. Other limits have 




Figure 2.4: Effect of CD4+ guided structured treatment interruptions on viral load and T-cell 
levels. For CD4+ counts (blue) above 350 cells/µl, Antiretroviral Treatment (ART) is suspended 
followed by an increase of viral load (red) and decline of CD4+ count. ART is re-initiated at CD4+ 
counts below 250 cells/µl, thus allowing for a safety distance to critical CD4+ levels.  
Image source: Battegay, M. et al. (2006) ‘Immunological recovery and antiretroviral therapy in HIV-1 
infection’, Lancet Infectious Diseases, 6(5), pp. 280–287. doi: 10.1016/S1473-3099(06)70463-7. 





Nevertheless, results have been found to be contradictory and sometimes 
controversial, (Lau et al., 2019). While immune boosting capabilities have 
been observed only in rare cases, (Rosenberg et al., 2000), safe margins for 
treatment interruptions are still a matter of discussion, (Hirschel and Flanigan, 
2009). As a consequence, medical authorities continue to recommend that 
treatment should be administered continuously, (WHO, 2013), in the interest 
of patient safety, while further clinical studies on treatment suspension are 
discouraged. However, the incidence of such interruptions is frequent so that 
wider knowledge of their impact remains desirable. 
2.6 Summary 
HIV infection poses a complex and persistent threat. The need for lifelong, 
continuous treatment requiring perfect adherence and drug availability is a 
weakness of the otherwise potent state of the art combination ART. Treatment 
interruptions are inevitable, but knowledge of their implications is limited. 
Due to contradictory results of clinical trials on structured interruptions, 
further human-based studies are currently discouraged, with data on the issue 
scarce and sometimes outdated. The known mechanisms of HIV infection can 
be used, however, to construct models to complement clinical trial data and 
aid interpretation. Considerations of model type and construction are 





3 Mathematical and Computational Models for 
HIV Infection 
3.1 Introduction 
3.1.1 Scale Considerations 
Scale and the level of detail are key factors for the informative value of any 
model. Hence, a brief overview on commonly used formalisms in Biology for 
large to small scales is relevant here. 
In the 18th century, Malthus investigated population growth in relation to 
available resources, (Malthus, 1798). Another major milestone was the 
description of constrained growth using the logistic equation, first reported 
by Verhulst, (see e.g. (Cramer, 2002)). This model used a ‘carrying capacity’ 
to describe an upper population limit, where growth slows down as this is 
approached. In the early 20th century, Lotka and Volterra formulated a model 
of two interacting species (predator and prey) represented by two coupled 
Ordinary Differential Equations, (ODEs, see e.g. (Berryman, 1992)), and 
based on the logistic equation. Hugely successful in helping to understand 
population fluctuations observed in nature, the predator-prey model was 
subsequently modified and extended to address related problems, such as 
transmission of infectious diseases, (Anderson and May, 1979). More 
recently still, models based on individuals and aggregated for population 
behaviour have grown in popularity. 
The choice on formalisms chosen to cover interactions between cells, 
whether microorganisms or cells within larger organisms, is quite similar. The 
ODE approach can be applied to approximate a cellular population. However, 
treating a discrete number of cells as a continuous flow limits the power of 





(Graw and Perelson, 2013), is now widely recognised. Extending the ODE 
system by an additional derivative for space leading to a system of Partial 
Differential equations (PDE), (Marinho et al., 2012; Su et al., 2009), adds 
realism but also complexity. Discrete Agent-Based Models are, however, 
especially suitable at this scale. 
At the lowest level, Biology consists of complex biochemical reactions 
which take place all the time inside a cell. As more and more of these 
pathways have come to light, a vocabulary for expressing these interactions 
has become necessary. In consequence, both ODEs and formal methods from 
concurrent systems have been applied to biological systems, mainly to 
metabolic pathways, signal transduction pathways or genetic regulation. An 
example of the latter approach is pi-calculus, (Miller et al., 1992), one of an 
extended group of process calculi used to describe these biological reaction 
networks. Since these formal description languages were originally invented 
for computer science, the suitability of the vocabulary for biological systems 
is not comprehensive, hence kappa-calculus has also been employed, (Miller 
et al., 1992).  
3.1.2 Modelling Strategies 
While scale is important, so is deciding how to view the system; a common 
modelling strategy is to look at the whole system in a top-down fashion and 
describe it by simple rules while considering what is known about its 
mechanisms. Ideally, such top-down approaches reduce the problem to a set 
of mathematical equations, enabling mathematical analysis and modest 
computational resources for numerical solution, (which might explain their 
popularity). However, many of the HIV top-down approaches are derived 
from chemical reaction models, which assume equilibrium and a well-mixed 
environment, which is typically an oversimplification for the problem, 





An alternative strategy is bottom-up modelling of the system in terms of 
its component small entities. Systemic properties emerge as a consequence of 
the behaviour of multiple entities, reflecting a system, which is more than the 
sum of its parts, (Bianca and Pennisi, 2012). 
Given the importance of scale (e.g. ranging from an isolated biochemical 
reaction cascade inside a single cell to world-wide population dynamics), a 
third modelling strategy is frequently mentioned for biology – namely middle 
out, (Castiglione et al., 2014). The idea is to start by focusing on an 
intermediate scale where the cellular level has been suggested as an ideal 
foundation, (Walker and Southgate, 2009). From this base, extensions are 
incorporated either to larger units (e.g. tissue) or smaller (e.g. genome) thus 
resulting in a multi-scale model.  
In terms of modelling strategy, ODE formalisms are typically used for top-
down modelling and the agent-based paradigm and variants for bottom-up or 
middle-out modelling. Some relevant examples and applications for model 
formalisms are given in Appendix B. In the following, their use for aspects of 
HIV infection is highlighted. 
3.2 Top-Down Modelling 
3.2.1 Model Forms 
The advantage of ODE-based approaches is that they enable a wide range of 
mathematical means. Linear Algebra may be used to extract powerful metrics 
on the behaviour of the system, with the solution of more complex systems 
using numerical methods well researched, (e.g. (Miao et al., 2011)) and 
computationally inexpensive due to availability of potent mathematical tools, 
(MathWorks, 2015a). Typically deterministic, these require, in principle, just 
one simulation run to obtain desired characteristics. With Maximum 





in principle, is modest. However, the power is limited in the sense that a high 
level of abstraction applies to values obtained. Discrete events, which 
contribute to these, are not considered, which limits conclusions on the 
underlying causes of system behaviour. Nevertheless, top-down methods 
have been widely applied in Biology, (see (Gratie et al., 2013) for an 
overview). 
3.2.2 Application to HIV Progression 
Top-down models were used at an early stage to describe HIV progression, 
(Perelson and Nelson, 1999; Perelson and Ribeiro, 2013; Xiao et al., 2013). 
Initially, a system of ODEs was used to model the spread of the epidemic in 
communities, (Anderson et al., 1986), re-formulated to deal with within-host 
progression, considering aspects of population dynamics, (Perelson et al., 
1993), to include immune response, (Nowak and Bangham, 1996), resistance, 
(Nowak et al., 1996), drug response, pharmacology, (Bonhoeffer et al., 1997), 
and so on. Typically, these models involve multiple linked equations, known 
as compartments10, with each DE in the system representing one cell type or 
virus.  
In this context, the most commonly used to describe short-term effects of 

























This model has 3 compartments, where T denotes number (or 
concentration) of healthy T-helper (CD4+) cells, I of infected T-helper cells 
and V of free virus particles in the blood stream. This environment was chosen 
since the model form only works under the assumption of properties (or 
reactants) being sufficiently well-mixed, (as assumed the blood stream). The 
DEs then describe rates of change of infection over time with positive terms 
adding into the respective pool and negative terms reducing it.  
Healthy cells T are produced at constant rate λ in the bone marrow. Death 
of these cells (due to causes not related to infection) is modelled by removing 
a fraction d at a given time interval. Finally, the number of cells removed 
from T due to infection and entering the infected state I is proportional to both 
virus V and healthy cell concentration T, where infectiveness is denoted by 
factor β. Infected cells I have no other source than from infection of healthy 
cells and their death occurs at a constant fraction δ, which is typically higher 
than d. Each infected cell sheds a number k of virus V at each time interval 
with a constant fraction c of virus removed due to immune system activity. 
This simple model can be used to observe some characteristics of acute 
HIV infection and to establish the viral set point. While the assumption of 
constant rates is overly-simplistic, insight was nevertheless provided e.g. on 
high turnover rates of both infected CD4+ cells and virions over the course of 
infection (Ho et al., 1995). Obtaining closed form solutions, however, is not 
trivial. Model reduction is required to obtain a simplified statement to 






This class of models may be extended with additional compartments or 




































This approach, (Xiao et al., 2013), includes treatment with two drug 
classes (RTI and PI) and one additional compartment VNI which denotes non-
infectious virus particles. Effectiveness of treatment with the respective drug 
class is represented by η while the other parameters are as for (3.1). It can be 
seen that RTI has a direct effect on the rate of infection of T-cells, whereas PI 
influences the non-infectious virus fraction. Although the above model 
provides granularity between the effects of different treatments, it is still 
unsuitable for treatment interruption studies since it omits the latent reservoir 
of infected cells. Expression (3.3) describes an ODE model more suitable for 
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The compartment L denotes a pool of latently infected cells where the 
growth rate is given by a fraction αL of the overall number of cells becoming 
infected at each time interval. These latently infected cells multiply 
(proliferate) through cell division with a rate ρ or die with rate dL. Activation 
of the latent reservoir is modelled by a fraction a exiting the compartment of 
latently infected cells and entering I at each time interval. 
The model in expression (3.3) also includes an active immune response 
represented by property E (‘Effector cells’) causing reduction of infected cell 
number I. This reduction is proportional to the numbers of infected and 
effector cells and a factor m. Dynamics of E depend on a constant 
replenishment rate for Effector cells λE and a proportional death rate µ. 
Multiplication due to immune activation and death due to cytotoxic activity 
are represented by two terms based on Michaelis-Menten (M-M) kinetics, 
(Michaelis and Menten, 1913). Rates of Effector cell multiplication and death 
are given by their maximum values bE and dE, and the M-M constants KB and 
KD respectively, (where these define the values of I where the rates reach half 
of their maximum values). 
This more comprehensive and complex model was used to assess viral 
reservoir kinetics and viral control after treatment discontinuation, (Conway 
and Perelson, 2015), using numerical solution methods. However, the basic 
model building block (expression (3.1)) remains clear.  
The effort to improve biological realism has led to further modifications 
of the ODE formalism. For example, during early HIV infection, viral 
numbers are low and random events may have greater impact, accounted for 
by inclusion of stochastic terms to form Stochastic Differential Equations 
(SDEs), (Perelson et al., 1993), where multiple model runs with the same 





1998). The intracellular delay associated with HIV infection11, has also 
prompted use of Delay Differential Equations (DDEs), with the ODE 
formalism incorporating delay terms associated with system rates, 
(McGuinness, 2012). Partial Differential Equations (PDEs) also permit 
inclusion of more dependencies into the DE system e.g. spatial relations, (Su 
et al., 2009), or the age structure of cells, (Wang et al., 2015). 
In summary, the choice of model granularity depends on the question 
which is to be addressed. The addition of more compartments allows 
inclusion of more detailed biological mechanisms, but additional parameters 
inevitably increase complexity while baseline values cannot always be 
obtained from clinical data which may lead to ‘overfitting’ the model to 
existing data. 
3.3 Bottom-Up Modelling 
3.3.1 Attempts to Describe 
Bottom-up models typically observe emergent behaviour of individual, 
discrete entities. Description in terms of equations is less viable and no 
unified language exists to describe such models, although common grammars 
have been proposed. Prominent examples include state charts, (Harel, 1987), 
which aim at describing complex systems in a graphical way. The proposed 
hierarchical graphs (higraphs), (Harel, 1988) combine entities and relations 
with hierarchies. A similar concept is represented by P-Systems, (Păun, 
2000), which relate the hierarchical graphs to biological cells with organelles 
and compartments separated by membranes. Similar ideas are exploited to 
describe business processes and software architecture (e.g. Unified Modelling 
 
 





Language, UML), but adoption for Biology has been slow, (Roux-Rouquié et 
al., 2004); in part this may be due to poor accessibility and discipline-specific 
experience needed for effective use of such concepts.  
In consequence, a unified approach has not yet been adopted for HIV 
models, where descriptions often omit sufficient detail, thus impeding 
reproducibility, (Bauer et al., 2009). 
In considering discrete entities in a virtual environment, Cellular Automata 
(CA) approaches handle mobility well and are discussed in detail in the next 
section. In short, CA assumes cells are fixed on a grid, controlled by global 
rules which are executed in constant discrete time steps. More generally, 
agent-based models (ABMs) deal with autonomous agents. The distinction is 
often difficult to draw, since more complex CA models also assign properties 
to lattice cells and even allow for movement, (Lin and Shuai, 2010; Mannion 
et al., 2002). Nevertheless, true agents possess autonomy to a certain degree, 
have individual properties and event cues and means of communication with 
the environment and other agents, (Wooldridge and Jennings, 1995). ABMs 
are widely used in Economics, (Fagiolo et al., 2019) and Social Sciences, 
(Keuschnigg et al., 2018), but also in Physics, (Sornette, 2014), Chemistry, 
(de Korte and Brouwers, 2013), and Biology, (Shinde and Kurhekar, 2018). 
3.3.2 Examples for HIV Progression 
Earlier work, (Grilo et al., 2002), reported a multi layered model with a lattice 
populated by autonomous agents, while a multi-agent model proposed, 
(Zhang and Liu, 2005), demonstrated the 3 phase dynamics commonly 
associated with HIV infection. Further, focus on direct modelling of a lymph 
network, (Perrin et al., 2010), saw effective use of distributed computing to 
handle mobility.  
In achieving detailed biological representation of system response to 





activation was proposed, (Celada and Seiden, 1992). A central concept is the 
assignment of bit strings of variable length to immune cells which are 
generated at random, with antigen also represented by a bit-string. The 
Hamming distance measures probability of a successful interaction between 
string entities. To interact, two cells have to occupy the same site, so the 
model permits basic movement. Extensions include additional immune 
interactions, e.g. (Baldazzi et al., 2006; Castiglione et al., 2019) or adaptations 
to specific organisms, e.g. fish, (Madonia et al., 2017). One important aspect 
is the effect of treatment on immune system components, (Castiglione et al., 
2007; Mancini et al., 2012). 
3.4  Modelling Treatment Interruptions 
3.4.1 Commonly used Model Forms 
A comprehensive review of the Literature on the model forms commonly 
used to assess treatment interruptions was undertaken, (Hillmann et al., 
2017a), and indicated a decided preference to date for top-down forms. This 
result was confirmed by a repetition of the search in August 2020. In total, 
we identified 44 separate studies relying on mechanistic models. These are 
summarised in Table 3.1 according to formalism used and inclusion of 
biological features.  
 
Table 3.1: Summary of model forms used in treatment interruption studies. 
  











ODE 35 14 20 12 13 0 
ABM 5 5 0 0 5 5 
Exponential 1 0 0 0 0 0 
SDE 1 0 1 0 0 0 





Models of ODE type, which build on the basic form as in expression (3.1), 
have been amended to include certain biological features important for HIV, 
including details of immune response and a latent reservoir (included in 
(3.3)), as well as emergence of drug resistance and pharmacology details. 
Antiretroviral Therapy was incorporated into these models, typically in terms 
of a reduction of infection rates with effectiveness factor η ranging from zero 
to unity (as for expression (3.2)). 
Subsets of the models identified have been used to investigate treatment 
interruptions and the conditions under which treatment failure may occur. The 
effect of missed doses on the Basic Reproductive Ratio12 of both wild type 
and drug-resistant viral strains has been examined, (Wahl and Nowak, 2000). 
Another modelling approach suggests dynamics of infected cell numbers 
exhibiting damped oscillations being the cause of treatment failure associated 
with STIs, (Breban and Blower, 2006). However, the underlying assumptions 
could not be validated in vivo, (Oña et al., 2013). 
Finding an ideal STI regimen by employing optimal control theory, 
(Adams et al., 2004; Ernst et al., 2006; Krakovska and Wahl, 2007; Kubiak 
et al., 2001; Kwon, 2007; Neri et al., 2007; Pannocchia et al., 2010; Xu et al., 
2014), has been found to be another prominent application for ODE models. 
Unfortunately, formulation of an optimal control model requires rather 
detailed knowledge of the underlying processes of disease spread, together 
with a biologically realistic range of values for every parameter, which are 
seldom available. In consequence, these approaches often omit biological 
facts such as the clinical infeasibility of a continuous dataflow for CD4+ and 
 
 
12 Commonly denoted R0, is a measure for the average number of new infections caused by 
one infected individual. First used in epidemiology, it has also found application for within-
host modelling where susceptible and infected cells are observed.  Values of R0 > 1 indicate 






virus concentration from patient blood, acknowledged, (Attarian and Tran, 
2017); the immune system is far more complex than a thermostat, (Louzoun, 
2007). The underlying reasons for failure are not elaborated in the reported 
work.  
In summary, treatment interruption models based on ODEs typically have 
a single specific focus in order to restrict the number of differential equations 
and parameters to be estimated.  
3.4.2 Bottom-Up Approaches 
Treatment interruptions have not been found to be extensively studied using 
bottom-up approaches. Exceptions include simulations with the ImmSimm 
platform, (Castiglione et al., 2007; Mancini et al., 2012). The latter is based 
on the C-S model, (Celada and Seiden, 1992), focusing on antigen recognition 
and immune activation. 
However, simulations with ImmSim and variants are computationally 
expensive as the model scope includes an array of immune reactions, 
demanding high computing power or the omission of certain feature details, 
as a compromise to biological exactness. ImmSim studies on treatment 
interruptions examine the effectiveness of three fixed STI regimen by 
challenging the simulated immune systems with an opportunistic disease. All 
STI regimen were found to be inferior to continuous treatment in terms of 
mortality of the virtual patients. An optimal STI regimen was investigated 
subsequently, using the same modelling setup but an inverse problem 
approach; a Simulated Annealing algorithm with a fitness score depending on 
health and drug uptake of the ‘virtual patients’ was applied.  
However, introduction of treatment and introduction of opportunistic 
disease were assumed to occur at fixed time intervals for each simulation 
which is not realistic, as timing of treatment initiation has important 





of basic fixed-cycle form and no adaptive mechanisms (such as CD4+ 
guidance) were considered.  
Furthermore, neither drug resistance, nor pharmacodynamics aspects of 
antiretroviral drugs were taken into account. In the context of treatment 
removal, (Paci et al., 2011), also used the ImmSim platform to examine viral 
rebound after interruption by analysing clinical data and comparing with 
model results. They found that initiation at a very early phase of the disease, 
(before seroconversion), facilitates viral suppression during a subsequent 
treatment removal with the model qualitatively replicating this behaviour. 
3.4.3 Model Parameterisation 
Complex bottom-up models, such as ImmSim require accurate estimates for 
numerous parameters, relatively few of which are known to sufficiently high 
precision. The inevitable cumulation of errors may have major implications 
on simulation outcomes as described, (Castiglione and Celada, 2015).  
Unfortunately, the same applies for higher order equation systems in top-
down models employed to facilitate improved biological ‘realism’, e.g. 
(Ferreira et al., 2011). Parameter values must be assumed if not available from 
the Literature with solutions typically obtained by numerical simulation, 
(non-trivial, particularly for PDE systems, (Marinho et al., 2012)).  
From our extensive review of the Literature, (Hillmann et al., 2017a), the 
strong indication, (despite intensive HIV research), is that very few clinical 
data suitable for model calibration or even validation appear to exist at all for 
the case of treatment interruptions. While ethical considerations clearly have 
priority, this lack does prohibit a clear-cut answer to regular practitioner 
queries on what data are used in modelling, with corresponding reservations 
on credibility of the results obtained. Understanding of the data limitations 
and more informed inter-disciplinary interaction remain critical to exploit 






Modelling approaches for treatment interruptions have almost exclusively 
focused on short term effects and ODE modelling. Models describing long 
term effects of HIV infection are scarce and rely on assumptions which ignore 
newer clinical findings such as lymphoid tissue involvement.  
In addition, clinical data, available for validation of these models, remains 
limited, with implications for perceived overall value. In these circumstances, 
bottom-up models offer potential for a better understanding of treatment 
interruption effects. This might be achieved with some reduction in 
complexity (e.g. compared to ImmSim), whilst specifically taking into 






4 Methods for Bottom-Up Models 
4.1 Introduction 
Elaborating on techniques and methodology introduced previously, I briefly 
illustrate the history of the CA formalism and expand on its applications in 
immunology, for HIV infection and for the present research. The background 
to both forward and inverse MC simulations is given and implementation 
options for optimal performance on modern cluster architectures are 
discussed. 
4.2 Cellular Automata 
4.2.1 Early Developments 
The Cellular Automata (CA) formalism idea is to compute neighbourhood 
effects by approximating the system in question by a regular grid, which, in 
theory, is not constrained in dimensionality or topology, (Ulam, 1962). The 
diagrams in Figure 4.1 illustrate topologies (and neighbourhoods) for the case 
of 2 dimensions. The concept was subsequently developed in combination 
with automata, (theoretical machines), which may assume states from a finite 
set, where state changes were based on a finite set of rules, (von Neumann, 
1969). The resulting Cellular Automata formalism was successfully applied 
to address problems in computer theory. A noteworthy model in this context 
is the Universal Constructor, a theoretical machine able to replicate itself 
using CA rules. Ultimately, the whole universe might be taken to consist of 
lattice-like structures, which change states due to deterministic rules giving 
rise to phenomena based at quantum level, (Zuse, 1969).  
Due to limitations in digital computing power, CAs remained mostly a 
theoretical concept until the 1980s. An exception and an implementation, 





1971). The CA on a two-dimensional grid with relatively simple rules could 
produce effects, which appeared life-like or chaotic, despite being completely 
deterministic. The potential for modelling phenomena in all natural sciences 
was stimulated, (Wolfram, 2002, 1983), where these examples were mostly 
based on the progression of a simplistic model of a 1-dimensional CA, giving 








Figure 4.1: Different lattice types and neighbourhoods (solid wireframes and shaded overlays). (a) 
left: Square lattice - von Neumann neighbourhood; right: hexagonal lattice; (b) left: Square lattice - 





4.2.2 Use in Immunology 
The use of discrete models in Immunology evolved from the concepts of 
Immune Network Theory, (Jerne, 1974), (for more detail see Appendix C.3). 
Notably, a discrete deterministic model describing key properties of the 
immune system was proposed, (Kaufman et al., 1985), based on an earlier 
approach to model gene regulation, (Kauffman, 1969). A set of Boolean 
variables was used to represent whether a specific type of immune cell was 
present or not, hence the state space could be described conveniently using 
decimal numbers resulting from bit combinations of the different states. State 
changes occurred due to a set of Boolean rules representing known biological 
mechanisms on the immune system, such as T-cell activation. Thus, each 
initial state of the system (written as a bit string) yielded a pattern of 
transitions to other intermediate states prior to reaching an equilibrium state. 
The approach was extended to more complex immune mechanisms, 
(Weisbuch and Atlan, 1988), still assuming states to be present at the same 
location (mean field) and updated synchronously.  
While these types of model could be used to explore the complex state 
space of the underlying Boolean network and to identify certain attractors, 
spatial effects were not accounted for. This was addressed, (Dayan et al., 
1988), by transforming the Boolean network rules to a two dimensional lattice 
and employing nearest-neighbour interactions while preserving deterministic 
rules. A major extension of this approach was reported, (Pandey and Stauffer, 
1989), retaining the representation of entities as Boolean variables but with 
execution of CA rules subject to discrete probabilities; the first attempt to 
describe immune system heterogeneity with Stochastic Cellular Automata 
(SCA). Subsequently, major effects of HIV infection on the immune system 
were observed with a modified SCA model for the first time, (Pandey, 1991) 
and extended for effects of mutation and cellular motility, (Pandey, 1998). 





asynchronous updating of lattice sites. In contrast to updating all sites at once, 
(as in all previous models), cells were updated one-by-one, taking into 
account specific neighbourhood configurations at the time of update, where 
this variant is arguably more suitable for biological environments. 
4.2.3 Applications for HIV 
The impact of HIV on Boolean immune system interactions, taking into 
account viral mutation, was described, (Mielke and Pandey, 1998), and 
extended for cellular mobility, (Mannion et al., 2000). These models (also 
based on Boolean network interactions) were limited to early infections and 
treatment effects were not included. 
A hybrid formulation for HIV infection, using concepts from CA and the 
Celada-Seiden (C-S) model was reported, (Lin and Shuai, 2010). The CA 
rules are relatively simple but reflect biological functions of T-cells 
proliferation. Additionally, bit strings were used to model receptor shapes, 
while interaction probabilities are determined by the Hamming distance 
between two strings. While the 3 phases of HIV infection in a human host 
could be successfully reproduced, the validity of the underlying assumptions 
remains untested.  
In an influential paper, a new type of CA model, (denoted ZdSC model 
from henceforward), was proposed, (Zorzenon dos Santos and Coutinho, 
2001). In contrast to the former models, this focused on discrete states 
assigned to lattice sites (e.g. healthy, infected) along with a set of simple rules 
(details elaborated in Appendix D). Despite its less complex state space, the 
model faithfully reproduces the three-phase dynamics of HIV infection and a 
number of variants has been proposed, e.g. to introduce aspects of varying 
viral load, (Shi et al., 2008) and to consider coupling of lymphatic tissue to 
the blood stream, (Moonchai et al., 2010). An alternative approach, due to 





CA model making use of Conformon-P systems. However, some 44 rules 
(compared to 4 in the ZdSC model) were required and consequently 
validation of the results was both difficult and questionable, having little 
apparent relation to biological mechanisms observed in the context of HIV. 
However, as pointed out, (Strain and Levine, 2002), interpretations in 
terms of clinical relevance of results obtained with the ZdSC model (and its 
variants) are also unsatisfactory due to the very loose relation of CA states 
and parameters to biological entities and mechanisms. Due to the 
deterministic nature of the ZdSC model, lattice configurations typically show 
wave-like structures of infected sites slowly progressing over the 2-
dimensional lattice, (see Figure 4.2), used to approximate lymphatic tissue. 
Such regular structures appear to be artefactual rather than relating to the 
biological context of HIV. Despite the suggestion that such patterns follow 
Markovian behaviour and might be useful to assess treatment effects, 
(Hawkins and Molinek, 2015), their value remains questionable.  
Few CA based models have considered effects of antiretroviral treatment. 
Initially, non-uniform CA were used to extend the ZdSC model based on a 
stochastic alteration of model rules, (Sloot et al., 2002). However, this leads 
to disruption of the wave-structures (as in Figure 4.2) due to underlying 
deterministic assumptions, radically altering model behaviour with the 
simulated infection progression being drastically accelerated and the lattice 
being completely covered by irregular structures after few ‘simulated 
weeks’,(González et al., 2013a). With respect to treatment interruptions, 
application of CA-based models is even more limited, with few examples 
available, (Haines and Corne, 2006; Rana et al., 2015), which did not re-
evaluate the underlying assumptions of the ZdSC model. 
However, subsequent research has aimed at partially addressing questions 
on biological plausibility of the ZdSC model and its variants, (Precharattana 
and Triampo, 2014). Here, the model focuses on spatial immune response 





been linked to biologically meaningful analogues and parameters obtained, 




Figure 4.2: Lattice segment of the ZdSC model during simulated infection. Lattice sites may either 
assume a ‘healthy’ (red) or ‘infected’ (yellow/white) state. Simulated infection depends on ‘infected’ 
sites in the neighbouring of ‘healthy’ sites. Image shows wave-like structures of alternating ‘infected’ 
and ‘healthy’ sites. These structures are propagating slowly, eventually covering the whole lattice. 
 
4.3 Monte Carlo Simulation 
4.3.1 Direct Monte Carlo 
Monte Carlo (MC), a term coined by Ulam to denote the inherent stochasticity 
of the simulation method, aims at the solution of a system, which is not 
tractable by other means, through repetition of numerous random sampling 
experiments to estimate relevant parameters. Outcomes of simulation runs are 
assessed to provide a numerical score (or ‘energy’ in the original sense of 
MC) to determine if the cycle of parameter modification, simulation and 
evaluation has converged on an estimate value or the system has attained 
equilibrium. While practical applicability was limited in the early days, MC 
methods found application in numerous areas of science and technology, with 





Subsequently, both direct and inverse Monte Carlo methods have found 
wide application. The direct (or forward) case requires a faithful parametrised 
representation of the system in computational terms. Results of random 
experiments conducted on this idealised system are thus comparable to results 
of the underlying ‘real’ system. An example of forward method might be the 
determination of the pi number by MC simulations (see Figure 4.3).  
Unfortunately, while knowledge of a system may be sufficiently detailed 
to define a system function for some physical systems, for most (realistic) 
cases (not least in biology and medicine) it is not. However, where data are 
available, inverse MC methods may be used to obtain parameter estimates. 
 
 
Figure 4.3: Approximation of pi using direct MC simulation. Samples are placed at random on a 
unity square. Objective function determines whether samples are inside (red) or outside (black) a 
quarter circle with unity radius. The proportion of red samples approaches π/4 for large sample sizes. 
Image source: Springob (2004) Pi_statistisch, Wikimedia Commons, the free media repository. 
Available at: https://commons.wikimedia.org/wiki/File:Pi_statistisch.png (Accessed: 15 June 2020). 






4.3.2 Inverse Monte Carlo 
Biological systems are inherently complex and multi-faceted and detailed 
knowledge on all underlying mechanisms is typically limited. Despite 
intensive clinical research, this is also still the case for HIV pathology. 
Clinicians and Biologists thus have to rely on data from clinical trials and in 
vitro experiments to reconcile knowledge on the mechanisms involved.  
This poses an Inverse Problem, (Tarantola, 2005), where the aim is to 
identify likely model parameterisations (commonly written as parameter 
vector θ) in the light of the experimental data. Hence, a cycle of inverse MC 
(iMC) typically draws samples from the available parameter space for a 
mechanistic model. The model with sampled set of parameters is then 
executed and the output is scored against available experimental data. The 
iMC cycle involves numerous iterations with the aim of exploring the 
parameter space, approximating the distribution of parameters.  
Thus, the inverse process is essentially Bayesian. A simple Bayes formula 
















Here, P(y|θ) is the Likelihood that data y is observed with the given 
parametrisation θ with P(θ) the probability distribution assumed for θ in 
absence of data. In the simplest case, a uniform probability distribution over 
the parameter space might be used (uninformed Prior). The probability 
distribution P(y) of obtaining the data is usually not known. 
In the context of iMC, regions in the parameter space where the Likelihood 
is high are obviously the most interesting. Hence, drawing random samples 
from any location is not efficient, so an algorithm such as Metropolis-





on the Markov Chain principle, which in this case means that it is aware of 
the scores of the set of parameters sampled in the previous steps; if the score 
improves, the new sample is accepted. If accepted, it serves as a mean value 
for subsequent samplings and so on. Hence, the M-H algorithm, circumvents 
a common problem of ‘hill-climber’ algorithms of becoming ‘trapped’ in a 
narrow region with a local score maximum. It is therefore very powerful in 
terms of exhaustively exploring high-scoring regions in parameter space. The 
schematic in Figure 4.4 highlights principal algorithm steps. However, due to 
the underlying Markovian property, which requires computations to be 
executed in strictly sequential order, it is less efficient on modern, parallel 
computing architectures.  
An alternative is to use the Sequential Monte Carlo technique, also termed 
Particle Filtering (PF), (Doucet et al., 2001). The basic algorithm, originally 
proposed to analyse time-varying noisy signals, consists of more steps than 
the M-H algorithm making it slightly more complex but can improve 
performance. In an inverse MC setting, multiple samples of candidate 
parameter sets are drawn from parameter space forming a cloud of ‘particles’. 
After this ‘bootstrap’ sample, scores are obtained from simulations with these 
proposed parameter sets. These score values are used to assign weights to the 
particles, with low-scoring particles below a certain threshold rejected 
immediately. The remaining particles are then resampled around the 
weighted particles, where the number of samples drawn depends on the 
weight of the respective particle. After this step, termed ‘importance 
sampling’ the PF cycle is repeated. A graphical representation of the 
algorithm is given in Figure 4.5.  
In comparison to the M-H algorithm it is possible to analyse a large region 
of the parameter space simultaneously, which is particularly suitable for 
parallel computing architectures. Given sufficient parallel processing 
capability, the application of the PF method may be expected to yield marked 






Figure 4.4: Schematic of operation of the Metropolis-Hastings (M-H) algorithm. The unknown 
Posterior distribution of parameter vector θ can be approximated from some prior by a sequence of 
samples (grey dots w. arrows). Samples leading to lower scored than the previous sample may be 
rejected (dashed dots and arrows). (Lb -lower bound; Ub – upper bound)  
Image source: Lee, J., Sung, W. and Choi, J. H. (2015) ‘Metamodel for efficient estimation of capacity-
fade uncertainty in Li-Ion batteries for electric vehicles’, Energies, 8(6), pp. 5538–5554. doi: 




Figure 4.5: Schematic of operation of the particle filtering (PF) algorithm. Random samples (yellow 
dots) are drawn in parameter space and weighted against their Likelihood of fitting the data. Weighted 
samples (blue dots) are then resampled where the number of samples corresponds with the respective 
weights. 
Image source: Doucet, A., de Freitas, N. and Gordon, N. (2001) Sequential Monte Carlo Methods in 
Practice, Sequential Monte Carlo Methods in Practice. Edited by A. Doucet, N. Freitas, and N. Gordon. 






4.4 Implementation of Bottom-Up Models 
4.4.1 Tool Options 
From the beginning of the 1990s, when large processing power became 
widely available, numerous toolkits for discrete models evolved, see (Nikolai 
and Madey, 2009) for a comprehensive review. Despite the range of 
methodologies proposed (e.g. (Macal and North, 2010)), however, there is no 
unified principle on technical implementation. The vast majority thus employ 
the syntax of popular programming languages like C or Java in addition to 
proprietary concepts. 
General purpose mathematical tools also have been applied to agent-based 
modelling. MATLAB, (MathWorks, 2015b) has been a particularly popular 
choice for CA models, (Jafelice et al., 2009; Precharattana et al., 2011; Shi et 
al., 2008) due to its matrix-based architecture, which facilitates lattice 
representation.  
The advantages of using modelling toolkits lie in their extensive 
documentation, the existence of a user community, the availability of 
examples and easy accessibility, (especially for scientists with no 
programming background). However, the tools have been designed with 
‘typical’ scenarios in mind and often lack functionality or flexibility for 
specialised investigation. Performance is often a disadvantage as an agent-
based model run is computationally expensive if a large number of agents is 
involved and has to be executed multiple times in stochastic terms. Modelling 
tools thus have a high calculation overhead compared to a high-level 
programming language. Of course, not all high-level languages are equally 
good either. Programs written in Java (due to its VM architecture) perform 
poorly compared to languages which access hardware more directly. 
Conversely, low-level programming languages like Assembler need 





Consequently, no general recommendation exists on an optimal tool for 
implementation of an ABM.  
The C++ language represents a compromise between performance, 
complexity and maintainability (as it utilises the object-oriented approach). A 
high level of control on hardware resources is possible, together with some 
low-level programming knowledge, but significantly better performance can 
be achieved than for other high level languages, (Hundt, 2011).  
4.4.2 Model Design 
The model to be constructed needs to be meaningful in terms of the Biology 
and have measurable properties enabling comparison and verification against 
clinical data. While very large simulation size is advisable statistically, this 
numerical requirement must be balanced against computational resources 
available. Although a wide set of mechanisms on HIV interaction with the 
immune system has been the subject of research, a comprehensive model is 
both too complex and correspondingly limited in flexibility and predictive 
capability. One universal model example is that of ImmSim applied to HIV, 
(Paci et al., 2009). While the model is true to biology for wide-ranging 
immune mechanisms, computational requirements tend to be high limiting 
the number of simulations and time-line possible. A possible solution is to yet 
further increase scale and deploy even more computational resources to get 
closer to the actual system size (i.e. in terms of type and number of cells). 
While this has been attempted by Immunogrid (an EU-funded project), 
(Halling-Brown et al., 2010), results are still outstanding, indicative of the 
difficulty of the task. Moreover, despite its complexity, ImmSim still lacks 
basic features of HIV propagation, such as viral mutation and its effect on 
other cell types or tissues other than the cellular immune system. This implies 
at best partial view on some questions, such as HIV treatment interruptions, 





Alternatively, a less complex model focusing on a subset of biological 
features, identified as important for the progression and this directly 
impacting on consequences of treatment interruptions, may be immediately 
useful. Biological features, having a minor role demand less detail, (for 
example, cellular infection with HIV and the immune response are typically 
events measured in time ranges of hours or days). To observe infection 
progression over an extended period, detail on these short-term effects can be 
simplified to reduce computation overheads in order to include mechanisms 
occurring at longer time scales. While this limits study of some interactions 
of the immune response, this modelling approach is in line with my objectives 
of obtaining an overall assessment of key factors influencing HIV progression 
following treatment suspension.  
4.4.3 Computing Resources 
Performance is also inevitably affected by availability of the computing 
hardware. The co-founder of Intel, Gordon Moore, predicted a doubling of 
processor speed every 2 years, a relation which became commonly known as 
Moore’s law, (Moore, 1965). The prediction mostly held for about 40 years 
but, due to physical limitations, the increase in processing speed for single 
processor units reached a limit a few years ago, (Kish, 2002). To cope with 
this issue, modern processor architectures combine multiple processing cores. 
However, these still behave like separate processors which is a 
consideration for many-body programming. When using a high-level 
programming language, this can be achieved by splitting up the program into 
different threads executed in parallel. In some cases, threads can be run totally 
independently (‘embarrassingly parallel’), but normally data exchange is 
required at some point. The necessary time needed for synchronisation and 
communication means resources run idle at times, inevitably impairing 





this end, libraries for high-level programming languages have been developed 
to reduce programming complexity and provide necessary functions in a 
convenient way. The Message Passing Interface (MPI) presents a de-facto 
standard for the implementation of programs running on distributed systems, 
(MPI Forum, 2019). The standard defines routines and describes their syntax 
and semantics for various programming languages, with various 
implementations available, the most common being OpenMPI, (Open MPI 
Project, 2020) and MPIch, (MPICH Collaborators, 2019). Where MPI puts 
focus on running threads on separate physical machines, the OpenMP library, 
(OpenMP Architecture Review Board, 2019), offers similar functionalities 
for shared memory systems with parallel processing capabilities (such as 
multiprocessor desktop computers). 
4.4.4 Parallelisation Techniques 
One utilisation of parallel processing for this research is to perform a large 
number of model runs with different parameter settings in order to analyse 
model behaviour and gain meaningful statistics. Since each run is 
independent, no communication overhead occurs, hence optimising 
computational resources. 
However, this is not really possible as more complex models may be too 
demanding to run on a single thread. Hence, the components of the model 
have to be split in a sensible way to ensure best parallelisation. One needs to 
consider whether to split up computations into many small tasks, (small-
grained) or to use less but larger tasks (coarse-grained) and run in parallel. 
The optimal choice may be a compromise between these two, depending on 
the model and computational resources available. In terms of a CA model, 
one can intuitively split up the simulation space in equally sized parts to run 
in parallel. Communications among parallel processes then need to ensure 





comprised solely of directly-adjacent sites, communication can be 
conveniently solved by introducing an additional layer of sites around each 
part of the simulation space. Communication is restricted to the sites of these 
‘boundary layers’. If a site updates its state due to local CA rules, the updated 
state is copied to the corresponding site in the neighbouring part of the 
simulation space, (Perrin et al., 2006). If the number of sites in boundary 
layers is small compared to the size of each lattice part, parallel performance 
is markedly improved, (Hecquet et al., 2007). 
4.5 Summary 
This chapter highlights the principles and evolution of SCA methods for 
immune modelling and HIV. Foundations of MC simulations, tool choices 
and options to achieving a detailed model, with strong performance are also 
considered. Application of these methods to the problem of HIV treatment 






5 Two Models for Lymphatic Tissue Changes 
5.1 Introduction 
In this chapter, I propose a novel computational model using a bottom-up 
approach with the CA formalism. Each aspect of the model is rooted in 
biological facts, using recently available data. To this end, additional required 
biological background is given. In subsequent sections I describe construction 
of a stochastic Cellular Automata model for tissue collagenation, translating 
known biological mechanisms into model rules. The model is further 
extended to investigate effects of CD4+ cell motility, adding further to our 
published work, (Hillmann et al., 2019). I focus briefly on implementation to 
demonstrate impact of the different parallelisation strategies highlighted in 
the previous section. Preliminary results are presented, and forms of 
simulated treatment introduced. 
5.2 Biological Effects 
5.2.1 Functions of Lymphatic Tissue 
The way in which this complex system maintains its balance (homeostasis) 
and the cause of its stability has long been a target for research: e.g. on the 
importance of lymphatic tissue for both functionality and stability of the 
immune system, (Mueller and Germain, 2010). The pathogenesis of HIV 
infection has long been known, (Brenchley et al., 2004; Pantaleo et al., 
1993a), but only recently novel analysis techniques have enabled further 
insight into live tissue processes, (Schacker et al., 2002). These recent efforts 
suggest that the cells of tissue in lymph nodes play a key role in maintaining 
the delicate balance. The current knowledge and major mechanisms of the 
immune system in this context are briefly summarised in Appendix A, while 





Besides hosting most motile lymphocytes, connective tissue (or stromal) 
cells of lymph nodes also play a key role. Lymphatic tissue is roughly 
differentiated into T-cell zone and B-cell zones, similar to predominant 
immune cell types, (von Andrian and Mempel, 2003). Reacting to stimulus, 
immune cells migrate into the respective tissues, encountering antigen and 
binding to different types of antigen-presenting cells. A successful match 
triggers maturation and proliferation of the given cell type.  
The B-cell zone tissue consists largely of Follicular Dendritic Cells 
(FDCs), providing an immobile matrix of antigen presenting cells. These cells 
are known to be a viral reservoir for HIV since they are able to bind viral 
particles, and release them slowly, (Spiegel et al., 1992).  
The T-cell zone tissue makes up about 25% of total lymph node volume, 
(Mueller and Germain, 2010) and mainly consists of Fibroblastic Reticular 
Cells (FRCs), (Fletcher et al., 2015). These cells form a network structure, 
the Fibroblastic Reticular Cell network (FRCn), due to their association with 
fibres of connectivity tissue. In consequence, the function of these cells was 
thought to be limited in providing tissue structure for a long time. However, 
recent studies suggest that the FRCn plays a crucial role in guiding naïve T-
cells which encounter antigen-loaded Dendritic Cells (DCs) by moving along 
network fibres, (Brown and Turley, 2015).  
Structural aspects of the FRCn have not been widely researched. However, 
a recent study of murine experiments, aiming at quantifying regeneration 
capabilities of FRCs following ablation, suggested that the FRCn topology 
has aspects of both regular lattice and small-world13 networks, (Novkovic et 




13 A network topology where most nodes can be reached from any other node with a small 






Figure 5.1: Topology of a subset of the murine FRCn reconstructed from microscopic imaging. 
Scale bar in bottom left corner represents 30µm 
Image source: M. Novkovic et al,. Topological Small-World Organization of the Fibroblastic Reticular 
Cell Network Determines Lymph Node Functionality, PLOS Biol. 14 (2016) e1002515. 
doi:10.1371/journal.pbio.1002515). Use permitted under the Creative Commons Attribution License 
CC BY (https://creativecommons.org/licenses/by/4.0/) 
 
There is also a strong indication of a link between FRCs and naïve14 CD4 
T-cells, the main target of HIV, (Zeng et al., 2011). The presence of FRCs 
appears to improve the survival of naïve T-cells in their neighbourhood by 
secreting signalling molecules (cytokines) of type Interleukin-7 (IL-7). In 
response, naïve T-cells provide another cytokine, Lymphotoxin beta (LT-β) 
which, in turn, preserves fitness of FRCs (see Figure 5.2). This give-and-take 
relationship is assumed to play an important role in maintaining constant 











Figure 5.2: Effects of chronic infection on FRCs. Prolonged exposure to inflammation signals lead to 
an increase in collagen around FRCs. Collagenation limits the exchange of cytokines, e.g. for CD4+ T-
cells, leading to increased apoptosis. 
Image source: A.L. Fletcher, S.E. Acton, K. Knoblich, Lymph node fibroblastic reticular cells in health 
and disease, Nat. Rev. Immunol. 15 (2015) 350–361. doi:10.1038/nri3846, copyright 2015. Reproduced 
by permission from Macmillan Publishers Ltd: Nature Reviews 
 
5.2.2 HIV Infection on Cellular Level 
HIV infection has a dramatic impact on both tissue structure and function in 
lymph nodes. Starting in the early infection phase, tissue images reveal the 
disruption of designated structures like B- and T-cell zones along with loss of 
functional tissue (see Figure 5.3). While these tissue alterations have been 
known for some time, (Haase et al., 1996), the causes have been subject to 
debate. 
However, current research suggests that due to HIV-induced reduction of 
CD4+ cell populations, levels of LT-β also decline in the lymph nodes which 
in turn decreases the number of FRCs. In this context, the function of 
Regulatory T-cells (Tregs) has been the subject of recent clinical research on 
HIV, (Kinter et al., 2007; Kleinman et al., 2018). This specific subset of T-
cells also carries the CD4 receptor, together with additional receptors (FoxP3 







Figure 5.3: HIV induced alterations on lymphatic tissue structure. Diagram shows typical 
composition of a lymph node with stromal cell types and zones for T- and B-cells. Enlarged portion 
(top left) illustrates the structure of healthy lymphatic tissue. Image portion on bottom left indicates 
pathogenic alterations due to HIV infection.  
Image Source: Dimopoulos, Y. et al., 2017. The Lymph Node in HIV Pathogenesis. Current HIV/AIDS 
Reports, 14(4), pp.133–140. Available at: http://link.springer.com/10.1007/s11904-017-0359-7. 
Reproduced by permission from Springer Nature 
 
Unlike T-helper cells, Tregs oppose and dampen general immune response 
once activated. By reducing T-cell activation, Tregs limit the cellular immune 
response as well as downregulate cellular signals causing inflammation, 
(Yamaguchi et al., 2011). Their function has been found to be crucial in 
providing tolerance to certain types of antigen and in reducing systemic 
damage through ongoing immune activity. The role of Tregs in HIV-infection 
has been partly elucidated only recently, (Hasenkrug et al., 2018). Given the 
presence of the CD4 receptor, Tregs also constitute an HIV target, but as the 





has actually been found to increase (Nobrega et al., 2016; Presicce et al., 
2011). The reason for this apparent immunity from infection, relative to other 
CD4+ cells, is as yet unknown (Kleinman et al., 2018).  
However, Tregs become activated under HIV infection, expressing several 
cytokines, with both benign and malignant effects for the organism, 
(Chevalier and Weiss, 2013). In the former case, immune activation is in 
general damped down preventing damage originating from systemic 
inflammation due to infection while T-cell activation is reduced, limiting the 
number of HIV targets. Conversely, Treg activity also dampens the response 
of Effector cells (CD8+), reducing both their cytotoxic capacity and ability to 
target infected cells.  
5.2.3 Implications for Lymphatic Tissue 
Fibrosis is the process of a pathogenic proliferation of (non-functional) 
connectivity tissue, mainly consisting of collagen fibres, often combined with 
functional impairment of the affected organ, (Wynn, 2008). In the case of 
lymphatic tissue, massive collagen deposition (or collagenation) has been 
observed following infection by HIV as illustrated in Figure 5.3. It is assumed 
that, when activated Tregs excrete tissue growth factor beta 1 (TGF-β1) in the 
vicinity of stromal cells, these start to produce collagen by elongation of 
existing fibres, (Fletcher et al., 2015; Theron et al., 2017). In the context of 
lymphatic tissue, this reaction affects the FRCn, whereby collagenation of the 
stromal tissues occurs gradually over time, (Maina et al., 2016; Nilsson et al., 
2006; Zeng et al., 2012c, 2011).  
A potentially harmful effect of this collagenation has been found to be the 
blocking of functional FRCs from the LT-β of naïve CD4+ cells, (Fletcher et 
al., 2015), rendering them prone to apoptosis (see Figure 5.2). Tissue 
imaging, as illustrated in Figure 5.4 indicates a replacement of FRC-rich 





impeded due to the collagen, which permanently reduces their number in 
lymphatic tissue, (Schacker et al., 2005; Zeng et al., 2012a). Experimental 
data suggest an ongoing ‘vicious cycle’ of CD4+ cell reduction, Treg 
activation, collagenation and FRC reduction during untreated HIV infection 
(see Figure 5.5). This ongoing process is assumed to contribute to the 
breakdown of the immune system, (Zeng et al., 2011), as observed in the 










Figure 5.4: Distinct stages of lymphatic tissue collagenation. Imaging of lymphatic tissue for (a) 
uninfected, (b) early, and (c) late stages HIV infection. Green-staining denotes functional tissue, red-
staining represents non-functional collagen.  
Image source: Zeng, M. et al. (2012) ‘Lymphoid Tissue Damage in HIV-1 Infection Depletes Naïve T 
Cells and Limits T Cell Reconstitution after Antiretroviral Therapy’, PLoS Pathogens. Edited by G. 
Silvestri, 8(1), p. e1002437. doi: 10.1371/journal.ppat.1002437. Use permitted under the Creative 






Figure 5.5: Cycle of HIV induced collagenation and decay of T-cell. Mechanisms associated with 
HIV infection (highlighted red) drive a reaction cascade leading to T-cell death and collagen deposition 
in lymphatic tissue. 
Image source: Zeng, M., Haase, A. T. and Schacker, T. W. (2012) ‘Lymphoid tissue structure and HIV-
1 infection: Life or death for T cells’, Trends in Immunology. Elsevier Ltd, 33(6), pp. 306–314. doi: 
10.1016/j.it.2012.04.002. Reproduced with permission from Elsevier 
 
5.2.4 Clinical Observations and Treatment 
Considering varied rates of HIV infection progression, the disease experience 
of infected, but untreated persons can be markedly inhomogeneous, (Nilsson 





approximately 10 years if untreated, by which stage symptoms of immune 
deficiency become evident, (Fauci et al., 1996). However, cases of fast 
progression taking as little as 3 years have also been observed for CD4+ 
counts, (Maina et al., 2016), reaching levels below 200 cells / mm3 blood. 
Conversely, cases of so called non-progressors or elite-controllers also occur, 
where high levels of CD4 counts are maintained over a long period, despite 
detectable viral loads in blood and absence of treatment, (Hunt et al., 2008). 
These subjects have been found to have higher numbers of effector cells in 
their blood, (enabling more efficient immune response), together with 
generally lower Treg activity, (Shaw et al., 2012). However, while some 
consideration has been given to Tregs suppression as a target for therapy to 
control infection, (Kleinman et al., 2018), this is inhibited by apparent higher 
incidence of inflammation-related conditions, such as cardiovascular and 
renal disease in elite controllers, (Hsue et al., 2009; Sanchez et al., 2015). 
Further experiments, involving initiation of antiretroviral therapy, have 
produced evidence that the ability of FRCs to regenerate is largely dependent 
on the state of infection, (Zeng et al., 2012a). Conversely, collagenation does 
not appear to be reversible even after several months of treatment, (Zeng et 
al., 2012c). Further, while introduction of treatment leads to increase in 
numbers for all CD4+ cells, the Tregs proportion increases briefly prior to 
relatively slow decline, (Presicce et al., 2011). The proportion of Tregs may 
remain elevated for as long as 2 years after initiation, (Nobrega et al., 2016), 
increasing TGF-β1 concentrations and thus facilitating collagen formation.  
Despite intensive research, quantification of Treg cell activity and the 
collagenation-mediated loss of FRCs under HIV infection, both with 
antiretroviral treatment and in its absence, remain difficult. Such 
quantification would be of clear benefit in investigation of Tregs as a potential 





5.3 Stochastic Cellular Automata (SCA) Model 
5.3.1 Surrounding Conditions 
In the SCA model, the focus is specifically on FRC depletion and its relation 
to maintaining homeostasis. Comprehensive inclusion of the numerous 
factors connected with the depletion of immune functions under HIV, (Appay 
and Sauce, 2017), is not the objective here. Specifically, two effects, 
responsible for the depletion of CD4+ cells, (as reported by clinical studies), 
(Schacker et al., 2005), are considered, (i) HIV-induced direct killing of 
susceptible CD4+ cells and (ii) impairment of survival through depletion of 
FRCs and collagenation in the T-cell zone. Both factors influence the 
concentration of CD4+ cells in lymphatic tissue, with the time-scale of the 
former relatively short (days to weeks), (Cavert et al., 1997), while the latter 
is effective at longer timescales (months to years), (Zeng et al., 2012c). 
However, due to the regenerative capabilities of CD4+ cells, the first effect is 
reversible under antiretroviral treatment while only minimal regeneration has 
been observed for the second, (Zeng et al., 2012c). To be able to effectively 
simulate treatment interruptions, a model time step of one week is defined. 
This choice enables us to reproduce the clinical regimen on treatment 
interruption patterns and real-time adherence with appropriate time resolution 
while avoiding excessive computational costs, such as those for detailed cell-
set-scale models (e.g. ImmSim), due to the prolonged simulation runs 
required. 
We further assume that each cell has a connection to its four immediate 
neighbours, broadly in line with in-vivo imaging data, (Novkovic et al., 2016), 
and with regular topology. In terms of Cellular Automata computation, this 
corresponds to a von Neumann neighbourhood. To rule out artefacts due to 






An average lymph node measures about 1 cm in diameter and is of 
approximately spherical shape. From murine experiments, it is known that the 
mean separation of the centres of mass of single FRCs is ~ 23 µm, (Novkovic 
et al., 2016). A human lymph node therefore consists of around 40 Million 
FRCs. A simplified view is acceptable in this case since it is not intended to 
aim at reproducing an anatomically correct representation of the organ (see 
e.g. (Kislitsyn et al., 2015)). My simulations are based on a smaller fraction, 
namely a 2-dimensional slice through a lymph node, consisting of 
approximately 250,000 single cells and representing less than 1% of the total 
volume. While clinical data provide little information on progression of 
collagenation over time, microscopic images, (see Figure 5.4) suggest that 
formation of collagen clusters occurs. I therefore assume that collagenation 
starts at random locations across the tissue matrix and that its increase occurs 
predominantly through elongation of existing collagen fibres. These 
assumptions give rise to the model rules described in the following. 
5.3.2 Model Rules 
Before simulated infection occurs, the lattice is populated with both healthy 
FRCs and co-located CD4+ cells. In accordance to earlier research, (Graw 
and Regoes, 2012), it is assumed that each FRC is associated with the same 
number of CD4+ cells. In the initial, uninfected state, CD4+ cells are assumed 
to maintain equilibrium (homeostasis) as well as a stable concentration in 
lymphatic tissue, (Fletcher et al., 2015). However, on introducing simulated 
HIV infection, two effects are observed: Not only are CD4+ cells diminished 
directly by viral infection and mechanisms of cellular apoptosis but Treg 
activity is increased also, (Fletcher et al., 2015), due to preferential selection 
of this subset of T-cells. Though Tregs are not included in the model as 
separate entities, their activity is modelled by increase of tissue growth factors 





As suggested by clinical observations, (Zeng et al., 2012c), the fraction of 
CD4+ cells, which are co-located with the collagenated tissue, tends to exhibit 
poorer survival than usually observed for co-location with healthy tissue. In 
addition, CD4+ survival is impaired by effects directly relating to viral 
infection of those cells. Treatment ameliorates the latter, however, which also 
reduces Treg activity due to reduction of viral load, (Nobrega et al., 2016). 
CD4+ cells and FRCs are therefore regenerated and the collagenation 
processes in lymphatic tissue are slowed down. Nevertheless, upon 
reinstatement of Treg activity (e.g. due to a treatment interruption), 
homeostasis is disrupted again. This gives rise to the state transition model 
shown in Figure 5.6, which contains the four possible combinations of CD4+ 
cells and collagen status as well as permitted changes. Transitions depend on 
stochastic parameters, which are described in Table 5.1. Transition rules are 
defined in the following: 
Initialisation: The rectangular grid is seeded with collagenated cells C with 
probability hev, otherwise cells are assigned the healthy state H. Hence, each 
lattice site is occupied by either C or H. 
Rule 1: A healthy cell H may assume a healthy collagenated state HC with 
probability treg for each cell with state C or HC (nc and nhc respectively) in 
its Moore neighbourhood. The latter considers only the 8 directly adjacent 
sites of the healthy cell on the rectangular grid, hence (nc+nhc) may assume 
values from 0 to 8. Thus, the transition probability to the collagenated state 
represents a binomial distribution for having ‘success’ with probability treg 
and at least one sample of size of (nc+nhc) as given by expression (5.1): 
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This collagenation resembles the activity of tissue growth hormone, normally 






Rule 1a: A healthy cell H may die and assume state D (representing an 
unoccupied site on the lymph network) with probability ap which resembles 
programmed cell death, (also upregulated in untreated HIV infection). 
Rule 2: A vacant site D may become a collagenated site C with probability 
treg for each collagenated site (C and HC) in its Moore neighbourhood as 
given by equation (5.1). 
Rule 2a: A vacant site D may be regenerated to H with probability reg of self-
regeneration of lymphatic tissue. 
Rule 3: A HC cell may become collagenated C with probability cyt, which 
represents the cytotoxic effect of the collagenation (see. Figure 5.6, left).  
Rule 4: A collagenated site C may regenerate into healthy collagenated state 
HC with probability reg. 
Rules are applied in a synchronous manner, i.e. each site is updated at the 
same time. Each simulation step represents a week in real time. Model 
parameters are listed in Table 5.1 together with value estimates, where these 
could be identified from the literature. Model simulations give both an 
approximation of tissue destruction at the microscopic level (see Figure 5.7) 
as well as of immune system stability at the macroscopic level. The model 
can thus be used to assess effects including the way in which different levels 
of adherence to antiretroviral treatment impact on immune system damage.  
Data from quantitative imaging analysis of lymphatic tissue, (Haase, 
1999), suggest that in untreated HIV the (naïve) CD4+ cell counts are reduced 
to about 26% of those for the uninfected case. As mentioned above, initiation 
of antiretroviral treatment may also stimulate partial CD4+ cell count 
recovery. However, as it is reported to be less effective in tissue than in blood, 
(Fletcher et al., 2014), I assume only partial suppression of the viral lifecycle 
(and thus CD4+ depletion) under treatment in these experiments. An increase 





months after treatment initiation is suggested as realistic according to the  
clinical data, (Haase, 1999). 
Considering these data, valid parameter estimation for the SCA model is 
still not trivial due to effects resulting from nonlinearities in the model. Monte 
Carlo methods were used therefore to ensure that parameter outcomes 
correspond well with available (published) data and to determine parameter 
sensitivity, - described in the next section.  
 
 
Figure 5.6: State change diagrams of model rules.  H: healthy CD4+ cell; HC: healthy CD4+ cell co-
located with collagen; D: dead CD4+ cell (empty); C:  empty site co-located with collagen. Transition 
probabilities and rules are described in the main text. 
 
 
Figure 5.7: Image of the lattice (SCA model). Lattice configuration shows simulated lymphatic tissue 
in latent phase of HIV infection (300 time steps / weeks) with initially 1% of cells were collagenated.  






Table 5.1. Model parameter value selection for CD4+ cell and collagen build-up dynamics. 
Param. Description Value Ref 
PT Treatment effectiveness 0.0 - 
0.9 
(Cohen, 2011) 
PINF Infection induced inflammation 0.06 (Zeng et al., 2012c) 
PREG CD4+ cell / FRC regeneration 0.08 (Haase, 1999; Novkovic et al., 2016) 
PAP CD4+ cell / FRC death through infection 
(apoptosis) 
0.08 (Haase, 1999) 
PCYT CD4+ cell / FRC death due to signalling 
(cytokines) 
0.9 (Zeng et al., 2012c) 
 
5.3.3 Parameter Sensitivity 
To assess the model with regard both to sensitivity to parameter changes and 
comparison with available clinical data, distinction is made between the 
clinical phases of HIV infections, (Fauci et al., 1996). The SCA model is able 
to simulate each of these phases, as illustrated in Figure 5.8.  
 
 
Figure 5.8: Simulation data from SCA model showing phases of HIV infection. Simulated data for 
amounts of healthy (blue) and collagenated (red) cells in a simulated fraction of lymph tissue. Acute/ 
early phase occurs (3 to 25 weeks); pre-symptomatic phase - until proportion of healthy cells falls below 






The Mean Squared Error, as defined in expression (5.2), is used as a simple 
cost function to evaluate model performance for given parameter selection.  
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The subscript i represents the infection phases, as highlighted in Figure 
5.8, where any phase is weighted equally for cost function purposes. For any 
of the three phases ˆiY denotes the model output for a given parameter vector 
(treg, reg, cyt, ap) in phase i, while iY  signifies the corresponding clinical 
measure. Full factorial model design experiments were used for an initial 
sensitivity check to assess the impact of parameter selections on overall 
outcomes (25 model runs).  
SCA(a) A sensitivity analysis for parameter treg, (Figure 5.9) suggests a 
marked impact of changes of parameters treg and ap to outcomes of the cost 
function with the response pattern ideally requiring a more fine-grained 







Figure 5.9: Illustrative overview of sensitivity analysis of a selection of model parameters reg, cyt, 
ap with treg (vertical axis). Color-coding represents Mean Square Error serving as a cost function. 
Diagram highlight complex interactions between the parameters. 
 
Monte Carlo simulation and the Metropolis-Hastings algorithm was used 
to perform a local random walk on the parameter space and obtain 
approximate distributions of the model parameters. In the case of treg, reg, 
ap and cyt, a Normal distribution was assumed, which presents a reasonable 
choice for biological population data. However, there is some evidence that 
distributions of reg and ap may be skewed towards higher values, (Novkovic 
et al., 2016). The distribution for hev was chosen to be Log-Normal due to 
high variability of the HEV network, (Kumar et al., 2010). Simulation outputs 
for the sample model parameters were compared against available clinical 
data, (Zeng et al., 2012c). The resulting model error was used to either reject 
or accept the sampled parameter set, with the latter used to refine distributions 
for the next round of sampling. I obtained 6000 subsequent samples, each 
with 24 repetitions during the Metropolis Monte Carlo process, allowing for 
1000 steps of burn-in to reduce dependencies on initial values. Execution took 
about 15 hours (wall clock time) with available computational resources. A 





sample from a parameter distribution together with closeness of the 
corresponding simulations to clinical data.  
 
 
Figure 5.10: Cost functions against proposed parameter value (x-axis vs. y-axis). Results for treg, 
ap, reg and cyt (from top left to bottom right). Only the 1000 samples with lowest overall cost are shown 
to facilitate visualisation. 
SCA(b) In addition, the detailed response surface for any promising 
parameter combination was obtained. The structure generated by the 
combined effects of reg and ap, as depicted in Figure 5.11 suggests a 
nonlinear relation with a (critical) region where the cost function changes 
very rapidly. With respect to estimation of optimal parameter ranges, data in 
Figure 5.10 suggest that best fits for treg, ap and reg converge within a narrow 
region of the parameter-space, (with values in good general agreement with 
indicative values as in Figure 5.8). Alternative values for the parameter cyt, 







Figure 5.11: Response surface visualisation of reg and ap against cost function. Illustrative example 
shows significant distortion of surface (-see arrow) indicating possible transition (or critical) points. 
 
5.4 CD4+ Motility (CM) Model 
5.4.1 Model Overview 
As with the previous model, the lattice represents a fraction of the FRCn of a 
lymph node, with sites in either a healthy or impaired state. Again, each site 
of the lattice is assumed to represent one FRC, directly connected to its n 
nearest neighbours. However, for this model, I take into account the small-
world topology of the FRCn which has been suggested by analysing 
microscopic imaging data, (Novkovic et al., 2016). These small-world 
features provide (additional) connections to more distant sites, allowing for 
non-local (as opposed to neighbourhood) effects. In CA terms, these small-





randomly selected sites with state changes obtained through neighbourhood-
effects, (Yang and Yang, 2010).  
For CD4+ motility, I adopt the assumption of a random walk suggested by 
microscopic data, (von Andrian and Mempel, 2003). Thus, I have a 
reasonable basis to assume that CD4+ cells enter the simulated lymphatic 
network only at High Endothelial Venules (HEVs), (Ager and May, 2015) 
and perform a random walk over simulated FRCn from these conduit sites. It 
is worth noting that T-cells may also enter lymph nodes via other routes (e.g. 
afferent lymphatics). However, the quantities of T-cells migrating through 
such routes in relation to HEVs are not sufficiently known. One possibility is 
that the process may be regarded as a baseline reduction of CD4+ cells, 
independent of spatial considerations such as those explored here for 
collagenation.  
The assumed ‘1 week’ granularity of the model time step was chosen to 
better enable the assessment of both mid- and long-term-effects. These are 
typically occurring over weeks and years, like depletion of CD4+ cells, (Fauci 
et al., 1996), and collagenation (Zeng et al., 2012c), in contrast to effects 
directly related to viral dynamics, occurring over days, (Ho et al., 1995). 
Further, the present model considers the spatial effects of collagen formation 
and depletion of CD4+ cells. This reduction in cell numbers is due either to 
direct viral effects or to collagenation of the lymphatic tissue matrix where, 
under ART administration, the former is reversible but not the latter, (Zeng 
et al., 2012a).  
To account for the marked computational cost required to track a large 
number of separate CD4+ cells passing through lymphatic tissue, I generate 
a probability distribution for a given cell being present at any lattice site. The 
cellular automata model was implemented in the C++ programming language 
with key features illustrated in Figure 5.12, with separate elements and their 







Figure 5.12: Fundamental concepts of on-lattice collagenation model. Left side: Solid 
arrows indicate neighbourhood effects. Originating from HEVs (black dots), collagen (solid 
grey boxes) spreads to adjacent non-collagenated / healthy sites (white boxes). Right side: 
Probability of CD4+ cells found present (grey shading/overlay) decreases quadratically with 
distance to HEVs, based on current assumptions of slow movement due to a random walk. 
In the event of more rapid T-cell dispersion (or influx from other sources) probabilities close 
to HEV regions would be relatively low, which corresponds to a more uniform distribution. 
5.4.2 Model Setup and Rules 
Simulation Environment 
A 2-dimensional square lattice with each site representing a single FRC forms 
the basis of all simulations. The actual FRCn occupies a 3-dimensional space 
in the approximately spherical lymph node. Human lymph node sizes range 
between 0.5 and 2 cm, (Ward et al., 2018). Diameters larger than 1.5 cm (short 
axis) are usually considered pathological, (Ganeshalingam and Koh, 2009; 
van den Brekel et al., 1998). For this study, an average diameter of ~1 cm is 
assumed, as for the SCA model, acknowledging that other sizes in the above-
mentioned range are possible. Microscopic imaging data on the FRCn has 
been obtained using histological cuts of the actual organ, (Novkovic et al., 





network. Translating this data into an exact computational representation of 
the network structure along with different functional areas in a lymph node 
has been a focus of recent work, (Bocharov et al., 2015). However, to address 
broad questions of collagenation in the context of HIV, simplifications can 
reasonably reduce complexity while retaining enough information about the 
system. In this context, reduction of dimensions is used to address the 
problem in a ‘layered’ fashion and has been commonly employed in the 
context of investigating the spread of HIV in tissues, (González et al., 2013b; 
Precharattana, 2016; Strain et al., 2002). Considering clinical literature to 
date, a 2D representation and parameter ranges can capture qualified tissue 
features on which to base further hypotheses. 
The mean distance between the centres of reticular cells (FRCs) has been 
determined to be in the range of 21 – 30μm, (Graw and Regoes, 2012), or of 
the order of 23μm according to recent murine experiments, (Novkovic et al., 
2018). In any case, a histologic section through the whole organ would 
correspond to a square lattice with side length of approximately 500, again in 
line with the SCA model. Experimental data also suggest FRCs to be 
connected to 6 to 11 (median 8) other cells, (Novkovic et al., 2016). These 
connections either go to cells in the direct neighbourhood or to cells further 
away. To simulate these small-world properties in the CM model I consider 
the 8 nearest-neighbours (Moore neighbourhood) while a site might 
additionally be connected to a randomly-selected site with a probability PS, 
(Yang and Yang, 2010). For each lattice site, I further assume one of two 
states: H (healthy FRC, no collagen), and C (covered by collagen, no FRC). 
During model initialization, all sites of the 500x500 lattice were assigned a 
state H, except for a random fraction PHEV representing HEVs as entry points 
for CD4+ cells, with special state CH. The density of HEVs in the T-cell zone 
of a lymph node remains inconclusive and is apparently variable depending 





density of about 18 per square millimetre, (Shen et al., 2014), which translates 
to an estimate of ~0.01 for PHEV. 
 
Tissue Collagenation Rules 
State changes (or transitions) at lattice sites follow a probabilistic set of rules, 
where at unit time step t, change from state x to a state y is represented by a 
probability Px→y ; (indices are assigned for clarity). While some transition 
probabilities have fixed values, others depend on the neighbourhood of a 
given site.  
Updates are performed in discrete time steps, where each step represents 
~1 week in real-time. This choice of interval reflects the fact that 
collagenation occurs over years, i.e. slowly compared to other aspects of HIV 
infection (such as infected cell turnaround and corresponding immune 
response).  
The model rules for collagenation spread are as follows, (designated by 
cell state type and mechanism). 
1. Rule H→C (neighbourhood-driven): 
PH→C (N) = (1 – (1 – PINF)
N) 
2. Rule H→C (random – small world): 
PH→C (S) = PS 
3. Rule C→H (regeneration) 
PC→H = PR = 0 
Description: Initially, collagenation is seeded by assigning state CH with 
probability PHEV to random sites, which serve as origins of collagenation 
while all other sites are assigned to state H.   
1. The first rule expresses the chance that a given site may become 
collagenated, depending on the amount of collagen already present in the 
neighbourhood, (as suggested by microscopic data), (Zeng et al., 2012c). The 





Growth Factor β1 (TGF-β1), (Theron et al., 2017) which is commonly 
excreted by regulatory T-cells (Tregs). The number of these cells is high 
during HIV infection, possibly related to inflammation processes, (Hasenkrug 
et al., 2018):  TGF-β1 in the model here is taken to be a scalar represented by 
probability PH→C (N) which depends on the number of collagenated neighbours 
and is thus non-uniform. Each of N collagenated neighbours of a site with 
state H may cause collagenation of a given site with a probability PINF (of 
inflammation) at each time step: the contribution to PH→C (N) is thus Binomial. 
It is assumed that N may take values from 0 to 8, (Moore neighbourhood). 
2. Given the evidence of the FRCn having small-world topology, (Novkovic 
et al., 2016), state changes can also be ascribed to neighbourhood effects at 
random sites. Changes are triggered with probability dependent on the 
interconnection between different clusters, (Yang and Yang, 2010), where 
high values of interconnection lead to approximation by a random network. 
A cut-off distance for this random inclusion of sites, which might offer greater 
realism, does not apply here to keep the model simple.  For random 
collagenation, therefore, the CA model mimics this process by introducing an 
alternative rule for H→C, where a site selected at random assumes state, C, 
with a probability PS. This rule is applied at each iteration in addition to rule 
1 and leads to an accumulation of collagen at random sites (in addition to 
local accumulation). However, use of this rule is confined to preliminary 
experiments (see results) to determine an estimate for PS while considering 
only the special case of PS = 0 for subsequent experiments to emphasize local 
collagenation. 
3. Finally, I note that, while some clinical data do provide evidence of a small, 
albeit significant, FRC regeneration once antiretroviral treatment is initiated, 
(Zeng et al., 2012c), the strong general evidence is that collagenation is 
irreversible. Regeneration is thus assigned a probability of zero in these 






T-Cell Degradation Rules 
Collagenation progression is slow compared to traversal of CD4+ cells 
through the FRCn; a discrete probability is thus associated with random 
occupation of a given lattice site by a cell at each time step. Cell movement 
can be taken as random from entry points, as suggested by earlier modelling 
studies (Donovan and Lythe, 2012). Thus, the average distance of a cell from 
its entry point increases in a linear manner with the square root of time 
elapsed. Conversely, the distances of a large number of cells from their point 
of entry are assumed to follow a 2-dimensional Normal Distribution with 
discrete steps around the location of the HEVs as the mean. The Standard 
Deviation can then be validated from clinical data: Assuming an average cell 
movement time of 10 hours within a lymph node and a diffusivity of 60 µm² 
/ minute, (Ganusov and Auerbach, 2014), with average path length of 23 µm, 
(Novkovic et al., 2016), a Standard Deviation of ~8.5 lattice sites from HEV 
locations is indicated. The resulting distributions (P1…Pn) describe the 
probability of a lymphocyte being present around each of the n HEVs in the 
model. Conflating these n distributions yields the overall probability 
distribution P(L) of presence of a lymphocyte for any lattice location. The 
heat map in Figure 5.13 illustrates this spatially heterogeneous probability. 
We further state that an individual CD4 cell has a probability P(AP|L) of 
undergoing apoptosis when close to a collagenated site. A link between 
terminal tissue fibrosis and AIDS disease has been suggested, where AIDS is 
associated with an approximate reduction of 80% or more of CD4+ cells from 
baseline, (Fauci et al., 1996). This means that when collagenation spans the 
whole T-cell zone, like it is the case in the terminal phase of infection, CD4+ 
cells are reduced to about 20% of the amount found in a healthy state.  In 





to patient-specific variations of the amount of CD4+ cell decline until AIDS 
emerges, other values within the range (0.7, 1.0) are also possible.  
 
 
Figure 5.13: A (500 x 500) lattice section for lymphatic tissue showing spatially 
heterogenous probabilities of CD4+ cell presence.  Regions around HEVs (conduit entries 
for CD4+ cell movements; red) are associated with high probabilities, compared to non-HEV 
areas (blue). 
 
Bayes Theorem is employed, (given in general form, expression (4.1),) and 
rearranged for P(y), where the latter relates to the overall probability 
distribution P(AP) (apoptosis of a CD4+ cell at any lattice site). Since 
apoptosis may only occur for a site with Lymphocytes present, P(θ|y) 
(relating to P(L|AP)) in the denominator becomes unity, hence, P(AP) is 
calculated by the simple product of P(AP|L) and P(L) (P(y|θ) and P(θ)) The 
resulting spatially dependent probability distribution for apoptosis is 





5.4.3 Parameter Estimates 
Parameter estimates, as described above, are summarized in Table 5.2, with 
clinical data sources cited. Obtaining estimates for PINF and PS which control 
collagenation progression in the model is challenging due to the difficulty of 
obtaining lymph tissue samples over the time course of HIV infection. A pool 
of patients was studied, (Zeng et al., 2012c), with individuals assigned to one 
of three disease stages of HIV infection, (healthy, pre-symptomatic, AIDS), 
based on their CD4+ counts. The patients who did not receive antiretroviral 
treatment prior to the study were subject to lymph node biopsies, where 
analysis gave rise to quantification of FRCn and collagen. The procedure was 
repeated some months after patients started Antiretroviral Therapy. A 
remarkable result was that collagen accumulation remained constant after 
months of treatment, while FRCn levels recovered to a certain degree. These 
classifications provide coarse guidance on progression of collagenation with 
time, but since the asymptomatic phase of HIV infection can last for 10 years, 
granularity is low. 
Table 5.2: Parameter estimates for the spatial CA Tissue Model (from the literature). 
Parameter Parameter value (range) Source 
PHEV 0.01 (0.006; 0.016) (Shen et al., 2014) 
PR 0 (-6.3E-3; 7.7E-03) (Zeng et al., 2012c) 
P(L) N ~ 0, 8.5 (Ganusov and Auerbach, 2014) 
P(AP|L) 0.8 (1.0; 0.65) (Fauci et al., 1996) 
Lattice side length 500 ± (250; 1000) (Novkovic et al., 2018) 
Neighbourhood 8 (7.91; 8.558) (Novkovic et al., 2016) 
 
However, the amount of collagenation over  a period of time has been 
found to be inversely correlated with CD4+ cell count in lymphatic tissue, 
(Estes, 2013), similar to findings for blood. In consequence, I utilize clinical 
data on progression of CD4+ counts in blood (Fauci et al., 1996), where these 
show linear decline. Assuming a similar relation for lymphatic tissue in this 





no treatment is applied. As stated in section 5.2.4, this value is based on a 
population average of ~10 years from infection until AIDS symptoms emerge 
(in absence of treatment). Extreme cases e.g. with a period as short as 3 years 
to AIDS symptoms (‘fast progressors’) has been observed, (Ruffault et al., 
1995), ranging to decades without visual depletion (‘elite controllers’). It 
should be noted, however, that such cases (specifically the latter) are 
extremely rare. A more detailed exploration of these extreme values must 
motivate future sensitivity analysis. 
5.4.4 Simulation Setup 
Our primary aim is to assess the contribution of spatial effects on the overall 
decrease of CD4+ cells through lymph tissue collagenation and the related 
FRC loss. In this context, it is interesting to observe differences in the overall 
result if spatial effects are cancelled out, i.e. if collagenation is allowed to take 
place exclusively due to random effects. In the latter case, only random 
collagen growth is permitted i.e. lattice cells may change their state from H 
to C with a fixed probability Prand at each time step (termed ‘random model’ 
in the following). To determine spatial contribution, an amount of collagen in 
the context of apoptosis risk (used as a measure for CD4+ survival), is 
assigned by implementing computer simulations for the two models (spatial / 
random model), highlighted above.  
In this context, specific parameter estimates (PINF, PS, Prand) cannot be 
obtained directly from the literature, so required implementation of an inverse 
Monte Carlo approach, (McGreevy, 2001). This enabled exploration of the 
parameter spaces of the respective models (the ‘spatial’ or localized/small 
world and random versions). Repeated sampling is used to find candidate 
parameter combinations which are scored on the basis of closeness of the 
simulated CD4+ apoptosis rates to CD4+ decline rates from clinical data, 





great patient-specific variability with AIDS symptoms emerging from three 
years to decades post infection, (e.g. (Okoye and Picker, 2013)). For this 
study, I use a population average obtained, (Fauci et al., 1996; Greenough et 
al., 1999), indicating a constant CD4+ cell loss of 0.19% per week from 
baseline (zero order). Depending on the score change at each iteration the 
candidate parameter refinement is either accepted (and used as the new basis 
for sampling) or rejected, while employing a typical M-H algorithm to avoid 
local minima. 
Finally, in order to show the contribution of spatial heterogeneity to CD4+ 
count decrease during antiretroviral treatment interruptions, treatment 
initiation was mimicked by effectively stopping simulated collagenation 
(setting respective probabilities to zero) at different simulated infection 






5.4.5 Simulation Results 
From the simulations with the CM model, the following results were 
obtained: 
CM(a) For calibration of the spatial model 5000 inverse Monte Carlo steps 
were performed in total, with different starting values for PINF and PS chosen 
at random every 1000 steps. Figure 5.14 shows results for a subset of the 
generated data, namely the 1000 points with near-optimal scores, where 
candidate values of the parameter describing neighbourhood effects PINF are 
plotted against their score function (RMS). The curve indicates a minimum 
RMS around values of PINF between 0.0015 and 0.0045 depending on the 
setting of the ‘small world’ parameter PS chosen. I found PINF and PS  to be 
correlated in a power law fashion as suggested, (Yang and Yang, 2010), with 
PINF = 0.0021 * PS 
-0.195 in this case. While linking these directly to clinical 
outcome is tentative, however, due to insufficient data about the degree of 
small world in lymph tissue, the potential for refinement is clear.  Given the 
availability of more detailed data, it should be possible to narrow down the 
range of possible values for PINF and PS, which would in turn provide a more 
exact representation of FRCn structure in the CA model with corresponding 
improved viability of simulation outcomes. As noted above, I assume the 
special case of PS to be zero for subsequent spatial model simulations since 
my emphasis is on local collagenation patterns. The random model with one 
parameter was calibrated using 1000 Monte Carlo steps, where a clearly 
defined minimum in terms of RMSE could be identified at Prand ~↨ 0.0035 







Figure 5.14: Result of 1000 inverse MC steps for the spatial model. The X-axis denotes 
possible values for spatial collagenation parameter PINF while the Y-axis corresponds to 
RMSE w.r.t. clinical data match. Marker colouring indicates value of corresponding ‘small 
world’ parameter PS. 
 
 
Figure 5.15: Result of 1000 inverse MC steps for the random model. The X-axis denotes 
possible values for random collagenation parameter Prand while the Y-axis corresponds to 





CM(b) To account for the heterogeneous progression rates of untreated 
HIV infection observed in clinical practice, I varied the CD4+ decline rates 
used for model calibration, using known extreme values in both directions. 
Hence, to account for fast progressors I used a decline rate twice as high as 
the average case. Conversely, I used a decline rate half the normal rate to 
account for long term (non-) progressors. Estimated data for PINF and Prand 
obtained by inverse MC simulations for a range of progression speeds are 
presented in Table 5.3. Such a sensitivity analysis is useful to test model 
robustness and to determine valid parameter ranges. Results indicate clearly 
defined parameter ranges for PINF and Prand; however, for steeper slopes of 
CD4+ decline (as for fast progressors) the range of possible parameter values 
is wider, (i.e. is less precise). Also, both parameters appear to change 
proportionally with progression speed. Doubling or halving progression 
speed is reflected in similar proportional changes in PINF, while the factor for 
Prand is around three.  
 
Table 5.3: Estimates for Pinf and Prand obtained by inverse MC simulations in relation to 
different infection progression speeds. Values denote averages and standard deviations of the 
50 lowest scoring MC samples. 
 Infection progression (years until CD4+ depletion) 
Parameter Fast (5 years) Average (10 years) Slow (20 years) 
PINF 0.0093 (0.0011) 0.0042 (0.0028) 0.0024 (0.00024) 
Prand 0.011 (0.0027) 0.0035 (0.00070) 0.0012 (0.00028) 
 
The different dynamics for the random and spatial model are illustrated in 
Figure 5.16. Both panels show collagenation patterns for 100 time steps (~2 
years) after simulated infection for a similar degree of CD4+ apoptosis. For 
the spatial model (Figure 5.16 a) it is clear that collagen is concentrated in 
specific regions (coloured red), predominantly around HEVs where CD4+ 
cells have a high probability of being present, whereas for the random model 
(Figure 5.16 b), collagen is more diffused (coloured blue) over the simulated 





apoptosis are illustrated in Figure 5.17. The ratio of the total reduction of 
CD4+ cells due to collagenation to total collagen accumulation is defined here 








Figure 5.16: Lattice snapshots of simulated collagen localisation for spatial model (a) and 
random model (b), at simulation time step 100 (equivalent to ~2 years). Collagenation forms 
more distinct clusters (a) compared to (b). Colors indicate simulated collagen density (red – 
high; blue – low; white - none). 
 
CM(c) Since collagen formation starts at sites with high CD4+ throughput 
(HEVs) for the spatial model (Figure 5.17 a), relative apoptosis starts high 
but reaches a plateau over time as collagenation spreads to regions with fewer 
CD4+ cells. In contrast, relative apoptosis remains constant for the random 
model since collagen appears at random locations, irrespective of CD4+ cell 
occupation. Thus, for total collagen percentage over time, as shown in Figure 
5.17 b, curve shapes are markedly different. Despite constant decay of CD4+ 
cells (zero order), neither curve is linear, suggesting that exact mechanisms 
of collagen formation patterns are yet to be completely identified. 
Nevertheless, these results clearly show that both spatial and random models 
agree with clinical data in terms of showing CD4+ count decline. However, 





areas (relative apoptosis) are obtained, since collagenation is more marked in 
the spatial model. The fact that both models do not give the same results 
concerning collagen accumulation and CD4+ decline, may provide a link for 








Figure 5.17: Apoptosis rates per collagenated area (a) and log-log plot of profiles of 
collagen growth over time (b) for the spatial model (thick blue line) and random model (thin 
red line). Y axis denotes ratio between the total reduction of CD4+ cells due to collagenation 
and total collagen accumulation. (Parameters. spatial model: PINF = 0.035, PS = 0; random 





5.5 Implementation Performance 
5.5.1 Parallelisation Performance 
Details of the computing platform used are given in Table 5.4, with 
processing power divided between 96 single processors (cores). To capitalise 
on its power, multi-threading is attained in various ways, depending on the 
programming language used and the underlying programming model, (Diaz 
et al., 2012).  
 
Table 5.4: Specifications of the set up used for experiments with the SCA model. 
Server hardware 2 x 12 core 2.4 GHz Intel Ivy Bridge processors, 64 GB RAM, FDR 
InfiniBand network adaptor 
Nodes 4 
Total TFlops  1.75 
 
Here, for code developed in C++, the implementation employed the 
Message Passing Interface, (OpenMP / MPI) (MPI Forum, 2019; Open MPI 
Project, 2020). A hybrid MPI-OpenMP approach was used to combine 
distributed memory parallelisation and shared memory parallelisation 
between and within computational nodes respectively, (Rabenseifner et al., 
2009). The OpenMP library, (OpenMP Architecture Review Board, 2019), 
was chosen for parallelisation within a simulation run by dividing up the 
lattice into evenly-sized fragments (spatial parallelisation), with MPI, 
(MPICH Collaborators, 2019), chosen for parallelisation between simulation 
runs (time parallelisation), (Hecquet et al., 2007). A first step in balancing 
these approaches consisted of finding the optimal setup for spatial 
parallelisation. Intuitively, while a high number of spatial fragments is 
advisable in this context, the more frequent communication and 






Thus, an analysis of relative run times for different OpenMP setups (see 
Figure 5.18) indicates a minimum run time for the lattice divided into 6 parts, 
but gains in performance diminish for higher number of spatial segments due 
to communication demand between threads. Since a setting of 4 parts 
performed almost as well, it was adopted for subsequent experiments with 
remaining threads used for time parallelisation. 
 
 
Figure 5.18: Comparison of run times. Diagram shows averages of 24 parallel runs with different 
degrees of spatial parallelisation for 700 simulation steps with a 500 x 500 lattice. 
5.5.2 Lattice Size 
In initial experiments, (Hillmann et al., 2017b), a lattice size of 500×500 was 
chosen to represent a small section of a lymphatic organ, specifically a 
‘cellular layer’ of a cross-section of the lymph node, (Kislitsyn et al., 2015). 
To estimate the number of experimental repeats needed for reliable statistical 
inference, I investigated the effect of lattice size on between-run variation. 
Results for different sizes (Figure 5.19) indicate that variations are small 
irrespective of lattice size until simulation times of around 450 steps. 
Subsequently, larger lattice size runs showed markedly lower variance. Since 





time span of around 10 years), the lattice dimension (tissue cellular-layer 
cross-section) of 500 was retained and achieved good precision.  
 
 
Figure 5.19: Influence of square lattice size on inter-run variance (250 runs respectively with 700 
simulation steps each) by simulation step. Variance increase (red colour) occurs towards end of 
simulations due to incremental stochastic error (less pronounced for larger sizes). Overall variance is 
low for sample size chosen. 
 
5.6 Summary 
We have developed models to investigate effects of treatment interruptions 
on lymphatic tissue. To account for lymphatic tissue collagenation I 
constructed a novel Stochastic Cellular Automata model, in which principal 
mechanisms were obtained from recent clinical findings. Parameters were 
assessed for sensitivity, where I discovered a complex response surface with 
defined transition areas as in SCA(a,b). Furthermore, the model was adapted 
with the aim of exploring the impact of CD4+ motility (CM model). Using 
this model, I explored the influences of random collagen spread (as opposed 
to spatial spread). In the next chapter these findings are used to explore how 





6 Effects of Treatment Interruptions on 
Lymphatic Tissue Structure 
6.1 Introduction 
In seeking to evaluate the impact of treatment interruptions I refer to past 
clinical findings and simulate designs of unstructured and structured 
treatment interruptions with the SCA model. The CM model of the previous 
chapter is also used to address different aspects of spatial infection 
progression, such as the impact of clusters of collagen, augmenting our recent 
article, (Hillmann et al., 2020). 
6.2 Clinical Studies 
Most clinical trials for structured treatment interruptions were conducted in 
the late 1990s and early 2000s. Major trials together with their designs are 
listed in Appendix E. The largest clinical trial on STIs, the SMART study, 
(Siegel and El-Sadr, 2006), represents the main source of knowledge on the 
effects of treatment interruption to date. The study was of type ‘CD4+ 
guided’, i.e. when the CD4+ count in blood for a patient falls below a certain 
limit, treatment is reintroduced and subsequently interrupted if the count 
exceeds an upper boundary, (Benson, 2006). However, data from this trial 
showed an increase of serious events such as opportunistic disease and effects 
not generally associated with HIV, such as cardiovascular risk or cancer. 
These events tended to emerge months or years after initialisation of 
treatment interruption, indicating the possible long-term downstream 
consequences of such actions, (Silverberg et al., 2007). As a result of these 
findings, a general ban on interrupted treatment has been advocated by some 
researchers, but the design of the SMART study has been subject to criticism 





cell concentrations, chosen for interruption and re-initiation of therapy (250 
and 350 cells/µl), are considered to be too low by current guidelines, (WHO, 
2013), which recommend at least 500 cells/µl (see Section 2.3). In addition, 
the study did not consider participants’ prior immune system status. Serious 
HIV/AIDS opportunistic disease events are associated with low CD4 counts 
and high viral load, indicating that a weakened immune system may 
contribute to harmful outcomes of treatment interruption, (El-Sadr et al., 
2006). A similar study, LOTTI, (Maggiolo et al., 2009), conducted around 
the same time as SMART used slightly higher ranges of CD4+ counts for 
treatment removal and re-initiation. It did not, however, report a rise of 
adverse events for patients with treatment interruptions. In contrast, harmful 
effects associated with drug toxicities, were significantly lower under STI. A 
comparison of the two study setups is given in Appendix F. Also, several 
newer studies involving patients at early stage HIV, with immune function 
predominantly unimpaired, showed no adverse effects to (short-term) 
interruptions, (Goujard et al., 2012; Grijsen et al., 2014). 
Unstructured treatment interruptions, on the other hand, where the main 
cause is lack of adherence, have been associated with formation of drug 
resistance mutations, necessitating regimen switching, (Glass and Cavassini, 
2014). However, increasing viral levels despite treatment (i.e. virologic 
failure), often observed for the drug class of protease inhibitors (PI) is not 
completely understood, (Rabi et al., 2013).  
In summary, treatment interruptions have been commonly associated with 
treatment failure and possibility of drug resistant mutations. The mechanisms 
underlying these relations, such as involvement of immune system damage, 
however, have been partially investigated only to date, (Hammer et al., 1997). 
Increased knowledge of these mechanisms may help in exploiting potential 
benefits of treatment interruptions, preventing adverse side effects and 





6.3 Treatment Simulation 
6.3.1 SCA Model Setup 
With the parameterisation specified for the SCA model, the aim was to test 
the long-term effect of different patterns of unstructured interrupted treatment 
on collagenation (and thus immune system degradation). To simulate 
interrupted treatment, ‘average’ adherence was assumed: (the probability that 
the simulated patient takes the medication regularly each week), (Glass and 
Cavassini, 2014). Further, the effect of treatment initiation timing was 
assessed, where clinical studies have indicated possible impact on long-term 
progression, (Lundgren et al., 2015). Table 6.1 summarizes parameter values 
chosen for the simulation runs. After the treatment period (corresponding to 
~ 5 years), increase in collagenation, compared to that at treatment 
initialization, is determined.  
 
Table 6.1: Simulation parameters for treatment interruptions using the SCA model. 
 Value range 
Time step 1 week 
Treatment initiation 0, 50, 100, 150, 200 timesteps 
Treatment adherence 0%, 20%, 40%, 60%, 80% 100% 
Treatment period duration 250 timesteps 
Total simulation length 500 timesteps (~ 10 years) 
 
Additionally, the effects of structured treatment interruptions are 
investigated, with an illustrative example of a fixed-cycle approach shown in 
Figure 6.1. However, in the following I am adopting the CD4+ guidance 
approach, pursued in multiple clinical trials, (Benson, 2006). This uses a 
threshold value of CD4+ cell count in a patient as a surrogate marker to 
decide on interruption or initiation of antiretroviral treatment. Limits obtained 
in two previously mentioned CD4+ guided clinical studies, SMART, (El-Sadr 





model, where these reported highly diverse outcomes despite their similar 
structure. Due to practical reasons, follow-up for each patient was restricted 
on average to 48 months (SMART) and 50 months (LOTTI). In order to 
attempt an explanation for the clear lack of agreement, the SCA model was 
used to investigate the effects of the respective interruption thresholds for 
prolonged periods of simulation, with outcomes observed after 500 model 
timesteps (equivalent to weeks).  
 
 
Figure 6.1: Effect of a structured treatment interruption period on model behaviour. Continuous 
treatment initiated at time step 50 (arrow). Start of STI period (fixed cycle – 4 weeks on 4 weeks off) 
from step 400 to 600, followed by resumption of continuous treatment (c.t.). Enlarged portion of the 






Transition probabilities for Rules 1 and 2 (H to HC and D to C) also depend 
on the number of collagenated 4 directly adjacent neighbouring sites N 
(according to von Neumann definition) and the cumulative binomial 
probabilities calculated using the expression: 
 
 ( ) ( )( )1 1 1 NT INFP P− − −  (6.1) 
In a similar manner, ART is assumed to limit the effects of CD4+ 
apoptosis, calculated according to the expression: 
 
 ( )1 T APP P−  
(6.2) 
In both expressions, parameter PT denotes effectiveness of ART, limiting 
both the spread of collagenated regions and elimination of CD4+ cells. ART 
has found to be less effective in lymphatic tissues than in blood, (Fletcher et 
al., 2014), which is reflected by parameter choices (see Table 5.1).  
To investigate treatment, interrupted in an unstructured way, ART is 
assumed administered with fixed probability during the week, (i.e. an 
adherence measure). Non-administration of ART (non-adherence) is 
simulated by setting the probability of the drug being effective (PT) to zero 
for the duration of the time step. This simplified notion follows the definition 
of ‘taking adherence’, in clinical settings (Glass et al., 2010).  
To explore the importance of a patient’s underlying immune status, 
(Hirschel and Flanigan, 2009), and its influence on outcomes, I use the SCA 
model to simulate different levels of prior immune damage and assess their 






6.3.2 Unstructured Interruptions 
An example model run is depicted in Figure 6.2, illustrating the effects of 
unstructured treatment interruptions (e.g. due to incomplete adherence) on 
levels of collagen and CD4+ counts. I simulate these by randomly missing 
out a week of treatment using Bernoulli probability. Clearly, this is a 
preliminary check, as adherence has been found to be a dynamic process, with 
patterns changing over time, (Glass et al., 2010). 
 
 
Figure 6.2: Dependency of collagenation and CD4+ concentration. Collagenation (blue line) and 
population of CD4+ cells (red line), grey rectangles superimposed on periods of treatment. Treatment 
starting at time step 100 with 90% effectiveness. During treatment period, there is a 10% probability 
that treatment is left out for a week to simulate incomplete adherence which is visible as temporary 
decrease of CD4+ counts during treatment. Extended period (12 timesteps) of ‘drug holiday’ from time 
step 150. 
 
Our data show a rapid drop in the count of CD4+ cells after simulated 
infection at timestep zero (characteristic of the acute phase). The decline then 
continues, albeit at a slower rate, during the chronic phase of infection. Upon 





number of CD4+ cells occurs. Incomplete adherence to the treatment regime, 
simulated by a random chance of omitting treatment for time step (10% in 
Figure 6.2) causes a temporary drop in cell numbers (signified by the irregular 
saw tooth pattern), as well as an overall decline in the long term. This decline 
accelerates as the treatment period persists. Collagenation, however, exhibits 
constant increase, albeit with less-pronounced slope during treatment.  
The influence, of treatment initiation timing and subsequent adherence, on 
collagenation build-up was also investigated, (Figure 6.3). The concave shape 
of the respective classes of relative collagen increase is caused by potential 
sites already being saturated with collagen for late treatment initiation. Hence, 




Figure 6.3: Effect of treatment adherence and initiation timing on increase of collagenation. 







Treatment initiation timing appears to have a less-pronounced effect than 
adherence to treatment. Nevertheless, if treatment is introduced during the 
early phases of infection (within the first 2 years), it has greater impact than 
if initiated at a later stage in disease progression. However, with good 
adherence to treatment (80% and above), collagenation can still be kept 
within acceptable bounds even for late treatment initiation. An acceptable 
outcome is taken to be a total collagenated area of less than 75% at the end 
of the simulated 10 years, where this is guided by clinical data, (Zeng et al., 
2012c), and indicates a threshold above which onset of AIDS or AIDS-related 
disease is imminent.  
6.3.3 Structured Interruptions 
Prior to simulation, absolute values of CD4+ count limits from clinical 
literature were normalized for use with the SCA model by assuming an initial 
cell count of 1000 cells/µl. Results were again obtained after 500 timesteps 
(~ 10 years). The projected results (see Table 6.2) show a marked difference 
for both collagenation and CD4+ count for the earlier studies.  
 
Table 6.2: Experimental results for CD4+ guided structured treatment interruptions. 
 CD4+ count limits [cells/µl] Simulation results 
(timestep 500) 
Clinical study Interruption  Resumption Collagenation  CD4+ count 
SMART (El-Sadr 
et al., 2006) 
350  250 97% 260 
LOTTI 
(Maggiolo et al., 
2009) 
700 350 81% 380 
 
Using the thresholds of the LOTTI study for a prolonged period would still 
yield average CD4+ counts which are well above the critical value of 200 
cells per microliter. 
A further SCA model experiment on CD4+ guided structured treatment 





system impairment) in conjunction with different thresholds of treatment re-
initiation where the latter had been suggested to be crucial in clinical STI 
studies, (Hirschel and Flanigan, 2009). The simulation setup included (i) 
allowing CD4+ counts to decrease to the respective threshold and (ii) no 
collagenation to be present at the start. Treatment resumption thresholds were 
then varied and simulated tissue collagenation observed. Figure 6.4 shows 
that the collagenated area appears inversely proportional to the treatment re-
initiation threshold only for the case of no previous impairment. Where pre-
existing collagenation exists and is already high, the re-initiation threshold 
does not appear to have any influence. These results indicate that immune 
system failure is likely to occur if pre-existing immune damage exists at the 
start of CD4+ guided treatment interruptions, irrespective of the re-initiation 
threshold chosen. The results may also allow quantification of the pre-
existing immune system impairment and may in part explain the negative 
outcome of the SMART study, given its patient characteristics.  
 
 
Figure 6.4: Effect of different treatment re-initiation thresholds on long term progression of 
collagenation. Model simulation with CD4+ thresholds normalized to values before infection. Percent 
area covered by collagen evaluated after 520 timesteps (~ 10 years in real time). ‘preserved’: Treatment 






6.4 Impact Assessment of STIs 
6.4.1 SCA Model 
Experimental Setup 
While the model is useful to gain general insights into long-term tissue 
dynamics associated with HIV-infection, I now focus on the aspects of 
treatment and interruptions. Specifically, I want to assess the effect of 
treatment initiation timing on the outcomes of subsequent treatment 
interruptions to probe the contradictory results of treatment interruption 
studies. Further, I aim to investigate the impact of unstructured interruptions 
or adherence on long-term prognosis. 
The objectives of my experiments here are as follows: 
SCA(a) The amount of collagenation is measured both before and after a 
brief treatment interruption, together with the progression of collagenation 
over the experimental period. Additionally, the effect of the timing of the 
interruption itself on overall collagenation is evaluated. 
SCA(b) Further, the effect of various levels of adherence on FRC decline 
and collagen accumulation is investigated. In this regard simulated treatment 
is started at time step (week) 50 to allow the FRC level to stabilize, after 
which different adherence protocols are applied by defining a discrete 
probability of ‘missing a dose’ at each time step. In terms of the model, this 
is achieved by setting treatment effectiveness PT to zero for random time steps 
according to a probability defined by the level of adherence, (providing a 
slight simplification of the adherence patterns observed in clinical practice), 
(Glass and Cavassini, 2014). Every 50 timesteps (approx. one year), no doses 
are missed to allow for observation of FRC regeneration and to determine its 
peak. In total, four periods are introduced for each level of adherence. 
SCA(c) Here, the aim is to quantify treatment initiation timing in 





beneficial effect of early treatment initiation has been the subject of recent 
clinical research, (Lundgren et al., 2015), its impact on FRCn integrity is not 
well understood. 
SCA(d) The intent here is to assess the impact of a heterogeneous 
distribution of cytokines in the microenvironment of the FRCn, an important 
aspect and a matter of recent discussion, (Dimopoulos et al., 2017). A 
homogenous distribution would lead to collagen depositions which spread 
randomly over the network, yet imaging data suggest that collagen build-up 
has a localised structure. To simulate variations of neighbourhood effect 
contribution, I introduce an additional probability for random collagenation 
with no neighbourhood dependency contributing to PH→Hc; D→C in this model. 
With this modified model I perform multiple simulation runs while reducing 
the effect of the neighbourhood-induced collagenation (by lowering 
parameter PINF) in such a way that the overall collagen build-up after 10 
simulated years remains constant. 
Parameters along with estimated values from clinical sources are listed in 
Table 5.1, (see chapter 5.3.2). Parameter estimates represent population 
averages. Different treatment interruptions patterns (see above) are applied to 
this population. To account for stochasticity, results are obtained by taking 
the average of the outcomes of 100 simulation runs with identical setup. 
Sample values for simulated collagenation and FRCs were obtained for each 
simulated week from the averaged runs. 
 
Results 
From the simulation experiments, the following results are obtained: 
SCA(a) Analysis of regeneration capabilities of FRCs after treatment re-
initiation following a treatment interruption of 50 steps indicates a decrease 
for both baseline and maximum proportions (see Figure 6.5), which appears 





treatment periods where doses were missed (starting at 50, 150, 250, 350 steps 




Figure 6.5: Interruptions affect FRC baseline. Graphs shows FRC densities (Y-axis) before 
(blue) and after (red) treatment re-initiation for four subsequent interruption periods (X-axis). 
The respective interruption patterns were 50 weeks of no treatment followed by 50 weeks of 
treatment with perfect adherence. 
 
SCA(b) A dependency between FRC regeneration capabilities and 
different adherence protocols is marked (see Figure 6.6).  Lower probabilities 
of missing a dose show more of a gradual decrease in contrast to higher 
probabilities where decrease is parabolic suggesting the impact of pre-
existing damage fuelling decay. This result corresponds to the build-up of 
collagen between subsequent periods where different adherence protocols 







Figure 6.6: Treatment adherence effect on FRC regeneration. FRC levels (Y-axis) after 
multiple periods (X-axis) of occasional treatment, which was only applied in a proportion of 
weeks (see legend) The respective patterns were 50 weeks of occasional followed by 50 
weeks of full treatment for each period. 
 
In summary, these results indicate marked impact of treatment 
interruptions or infrequent drug taking in terms of progression of lymph tissue 
fibrosis and loss of FRCs. Different probabilities of missing a dose together 
with interruption duration, affect these properties non-linearly where 
degradation is faster for pre-existing damage. Upon treatment re-initiation a 
high degree of FRC regeneration can be observed, possibly contributing to 
CD4+ increase and restoration of immune functions. However, results also 
show that FRC loss for treatment interruptions is highly dependent on the 
accumulation of collagen, as suggested, (Zeng et al., 2012c). In consequence, 
the level of lymphatic tissue collagenation may be a ‘missing piece in the 







Figure 6.7: Collagen build-up depends on adherence level. Coloured bars indicate collagen 
coverage after multiple periods (X-axis) of occasional treatment, which was only applied in 
a proportion of weeks (see legend) and after treatment interruption periods (X-axis) using the 
interruption pattern of 50 weeks of occasional followed by 50 weeks of full treatment. 
 
SCA(c.1) Early treatment initiation, during primary phase of the infection, 
has been found to be associated with lower declines of CD4+ count following 
an interruption (Fidler et al., 2013; Sáez-Cirión et al., 2013), with immune 
system functions largely preserved. Considering this apparently key factor of 
treatment initiation timing, I varied simulated treatment onset while keeping 
the time of interruption constant. Further, my experimental setup considered 
clinical findings of incomplete antiretroviral drug penetration into lymphatic 
tissue, (Cohen, 2011), by assuming a treatment effectiveness less than 100%. 
According to my results, the progression of collagenation over time following 
infection diagnosis, (see Figure 6.8), indicates strong dependency for overall 
collagenation on start of treatment (i.e. the state of disease progression which 
it commences). This important result reinforces outcomes of recent large-
scale clinical studies on treatment initiation timing, endorsing the earliest 







Figure 6.8: Treatment initiation timing affects collagen build-up. Shaded lines indicate 
different times of treatment initiation (0 – 240 weeks, see legend). Treatment interruption 
displayed takes place between weeks 500 to 505, visible as brief, rapid increase in collagen 
build-up. Treatment effectiveness was assumed to be 90% on average. 
 
SCA(c.2) Results further show that, for each week that treatment initiation 
is delayed, irreversible collagenation grows quadratically. This is a vital 
finding as it provides a metric. Findings show conclusively that the 
collagenation increase after later treatment initiation occurs at a faster rate 
than when treatment is introduced earlier, (something not reported previously 
in the literature). From Figure 6.8, this effect appears to be less pronounced 
than pre-treatment collagenation. However, looking at the rates of 
collagenation in more detail (see Figure 6.9), they appear to increase in a 
linear fashion with treatment initiation times. This finding also reinforces the 
hypothesis that early initiation is essential to limit the infection progressing, 






Figure 6.9: Collagenation rates under treatment depend on treatment initiation timing. 
Markers show rates of collagenation (Y-axis) after treatment initiation against time of 
treatment initiation (X-axis) after infection. Treatment effectiveness was assumed to be 90% 
on average. 
 
SCA(c.3) The persistent effects of treatment interruptions also appear to 
be related to treatment initiation timing or pre-existing immune damage. 
Treatment interruption shows an increase in collagenation (see Figure 6.8, 
time step 500), which is halted but not reversed after re-initiation. Details of 
this sharp increase, displayed in Figure 6.10, indicate that the amount of 
interruption-induced extra collagenation increases steadily over time of 
treatment initiation. This result is interesting since one would expect a 
constant increase for each interruption, because interruptions have the same 
time span. However, simulations indicate that larger areas of collagen (as 
present in late stages) tend to spread in a more rapid manner if treatment is 
removed. A reason for this behaviour might be that collagenated areas have a 









Figure 6.10: Collagenation following interruptions depend on treatment initiation timing. Markers 
denote total increase in collagenation (Y-axis) during the interruption period against time of treatment 
initiation (X-axis). Treatment interruption displayed takes place between weeks 500 to 505. Treatment 
effectiveness was assumed to be 90% on average. 
 
SCA(d) The introduction of random effects (in addition to neighbourhood 
effects) leads to variations in the collagenation patterns (Figure 6.11). 
Stronger neighbourhood dependencies lead to clustering of collagen, as 
observed in microscopic imaging, (Zeng et al., 2011). A steady build-up in 
collagenation, as suggested by clinical data, (Zeng et al., 2012c), is only 
achieved by a combination of random and neighbourhood effects.  
If only random effects are considered (0% contribution from the 
neighbourhood), collagen accumulation does not increase in a linear manner. 
It is noted that, after a comparatively quick build-up at the start, the curve 





setup included imposing periodic boundary effects, edge effects are less likely 
here. Hence, my assumption is that this is actually ‘saturation’, i.e. lack of 
available non-collagenated cells. A stronger focus on neighbourhood effects, 
however, leads to attenuated collagenation, which starts slowly then exhibits 
accelerated collagen build-up until the end of simulation, probably due to 
increase in the overall contact area of collagenated with healthy tissue, 
fuelling the process.  
 
 
Figure 6.11: Collagenation patterns obtained by alteration of neighbourhood effects in 
comparison to tissue imaging. Panels on left, centre-left and centre-right show simulation 
results obtained at time step of 250 weeks. Regions with red colours indicate collagen and 
healthy cells coloured green. Colour coding applies for simulated and stained tissue. 
Leveraging settings for effects of neighbourhood collagenation account for different 
collagenation patterns. Percentages indicate whether sites are collagenated at random (0% 
neighbourhood effects) or mainly due to neighbourhood effects (97%). Panel on right shows 
an image of FRC tissue during chronic phase of HIV infection showing curved line separating 
areas with different collagenation densities.  
Image source (right):Zeng, M., et al., PLoS Pathog. 8, e1002437 (2012). Use permitted under 
the Creative Commons Attribution License CC BY 
(https://creativecommons.org/licenses/by/4.0/) 
 
The change in shape observed in the resulting curves (Figure 6.12) is 
marked, suggesting significant influence of the neighbourhood effect. An 
approximately (at best) linear relation is observed when neighbourhood 
effects contribute around two thirds of total collagenation. However, for 
neighbourhood effects predominating, non-linearity is less marked, given the 
long-time scale of FRC decline during untreated HIV. 
    







Figure 6.12: Contribution of modelled neighbourhood effects to total collagenation 
progression. Model parameters were chosen that after 500 timesteps (weeks), 80% of the 
tissue matrix would be covered with collagen, resembling the terminal phase of infection. 
Legend shows proportion of neighbourhood effects vs random effects. In this context, 0% 
represents no collagenation due to neighbourhood effects (i.e. all collagenation caused by 
random effects). Values were chosen arbitrarily for illustration purposes and double 
logarithmic scale was chosen for better comparability. 
 
6.4.2 CM Model 
For the CD4+ Motility model, persistent effects of treatment interruptions 
also appear to be related to treatment initiation timing or pre-existing immune 
damage, (Hillmann et al., 2017b). Using either the spatial or the random CM 
model, treatment interruption shows as an increase in collagenation, which is 
halted but not reversed after re-initiation. This sharp increase, (Figure 6.13), 







Figure 6.13: Differences in collagenation increase following interruptions for spatial and 
random model. Increase depends on amount of pre-existing collagenation for spatial (blue 
circles) and random model (orange squares). Markers denote total increase from baseline in 
collagenation (Y-axis) during subsequent interruption periods starting at specific time steps 
(X-axis) with respective duration of 50 time steps / weeks. 
 
CM(a) For both, spatial and random models, results indicate that the 
amount of collagenation, caused by repeated treatment interruptions of the 
same length, is not constant. Instead, a steady change (increment or 
decrement) in the amount of collagen can be observed for any subsequent 
interruption and re-initiation.  
However, the slope directions differ markedly in the spatial and the 
random model, as indicated in Figure 6.13. Considering only random collagen 
spread, the rate of collagen formation is more pronounced for the first few 
treatment interruptions, presumably due to the high availability of healthy 
cells. When more and more cells become collagenated, the collagen increase 
appears to slow down slightly (for the four points of data obtained). 
Conversely, the spatial model exhibits an inverse slope, with the slow rate of 
collagenation for early treatment interruptions increasing for each subsequent 





areas, (present at later stages of infection), will inevitably spread more rapidly 
in the spatial model if treatment is removed, since the contact boundary with 
healthy areas is also larger. Periodic boundary conditions, as imposed for the 
SCA model, prevented visible artefacts resulting from edge effects. The 
implications of the nature of collagen deposition for treatment interruptions 
are particularly clear. While few interruptions are less deleterious only if 
collagen spread occurs due to neighbourhood effects, a deposition of collagen 
at random locations implies that a first interruption is associated with the most 
severe collagen increase. The question, of which type of collagen deposition 
(spatial/random) predominates in real terms, remains open. 
6.5 Summary 
The potential of the present modelling approach for simulating treatment 
interruptions is demonstrated by results, which show a distinct relation 
between duration of the interruptions, pre-existing damage and damage 
caused by the suspension of treatment, as indicated respectively by 
SCA(a,b,c,d). In particular, pre-existing damage was not comprehensively 
considered by earlier clinical studies. Further, results in CM(a) indicate the 
marked influence on overall progression for multiple interruptions in terms 
of the way in which collagen spread occurs, (spatial/random). 
However, to fully understand and offer explanation of results of past 
clinical trials on STIs, I need to upscale my approach to simulate a whole 
study population. In the next chapter, I propose such a ‘clinical trial model’ 
and demonstrate its capabilities for parameter estimation and distribution 






7 Upscaling: iCTS Model Components and 
Inverse MC 
7.1 Introduction 
Having considered treatment interruptions at the cellular and tissue level in 
previous chapters, I now turn to the ‘population scale’ of clinical study 
cohorts. While a review and extension of clinical trial designs would be a 
thesis topic of its own, I will focus on trial formats of studies previously used 
to investigate structured treatment interruptions. Lacunae in clinical trial 
design can be addressed only by new trials, but recent research may throw 
light on previous findings, which are not clear-cut.  
Further, clinical trial simulation, with different designs simulated using 
virtual patient groups have now achieved some measure of popularity, in 
order to consider alternative design options in a cost-effective way. In this 
chapter, I rely on the findings obtained previously to simplify and upscale my 
approach to simulate treatment interruption trials with a large group of 
patients. Inverse Mont Carlo methods are used to draw conclusions on 
specific properties of the patient populations, not considered in the original 
study, but of potential importance in explaining outcomes.  
7.2 Data from Clinical Sources 
7.2.1 Clinical Evidence 
The common approach to obtaining evidence on efficacy of some treatment 
is to assess the emergence over time of so-called clinical endpoints, (defined 
at the design stage). These endpoints may be specific events, such as 
emergence of disease or death or less drastic biomarkers, such as event-free 





these endpoints were defined as various types of adverse effects, which a 
patient with HIV infection might encounter, e.g. AIDS-related disease, non-
related diseases or death (due to AIDS or any cause). A common way to 
display information collected on events over time is by a ‘survival’ model 
(displayed e.g. as a Kaplan-Meier chart), which indicates the fraction of 
patients remaining free of a specific event. Statistical correlation is used 
typically in clinical studies to compare randomised treatment and control 
groups and assess efficacy (or non-efficacy) of a treatment, (Sackett, 1997). 
Rather less emphasis is placed on how results occur, with the study effectively 
a ‘black box’, with defined inputs and statistical outputs (see Figure 7.1, left).  
 
 
Figure 7.1: Example (cardiac drug) demonstrating drug efficacy through evidence-based and 
mechanistic reasoning. Left diagram shows purely evidence-based approach by observing inputs and 
outputs and treating the system as a ‘black box’. Consideration of mechanisms (middle) enables 
improved system insight but bears risk of false results if not all relevant mechanisms are known. 
Image source: J. Howick, P. Glasziou, and J. K. Aronson, ‘Evidence-based mechanistic reasoning,’ J. 
R. Soc. Med., vol. 103, no. 11, pp. 433–441, Nov. 2010. Use permitted under the Creative Commons 






Whereas this approach is sufficient to infer statistical properties, it is less 
suitable to obtain insight into the underlying biophysical mechanisms (see 
Figure 7.1, middle). Such knowledge is usually not incorporated in these 
studies, since the corresponding mechanisms introduce additional uncertainty 
and risk omission of important side effects (see Figure 7.1, right). 
Nevertheless, useful additional insights may be provided, especially in cases 
where data are sparse, (Howick et al., 2010). 
7.2.2 Clinical Trial Simulation 
In addition to factors above, multi-phase clinical trials are expensive and 
time-consuming with a large patient sample required to provide reliable 
statistical evidence, (Holford et al., 2010). To minimise patient (and other) 
risks, Clinical Trial Simulation (CTS), (Ogenstad, 2018), has been proposed 
to test certain trial designs in silico by utilising prior knowledge of the 
biophysical mechanisms associated with intervention, and with the aim of 
selecting the most promising for assessment.  
Most applications of CTS follow a ‘forward’ approach i.e. their aim is to 
provide optimal design for clinical studies based on prior knowledge (see 
Figure 7.2). Models used in this context mostly originate in Pharmacokinetics 
/ Pharmacodynamics (PK/PD) and put emphasis on the drug or active 
component, (Mould and Upton, 2013; Sheiner and Steimer, 2000). 
Pharmacokinetic models obtained from in vitro data have been considered a 
valid approximation for data obtained in vivo under certain circumstances 
(termed in vitro in vivo correlation), (Emami, 2006). Apart from this 
promising approach, regulatory authorities have been slow to adopt the whole 
concept of CTS as a complement of in vivo trials, (Pappalardo et al., 2018). 
However, recent approaches have seen some amelioration of the wholly 
pharmacologically centric view to allow for more general simulation of 





simulation were used, (Abbas et al., 2008), to optimise trial design for 
antiretroviral therapy interventions, while an agent-based epidemiological 
model was employed to assess different interventions to prevent infection, 
(Cuadros et al., 2014). Further, a stochastic CTS model was employed, 
(Braithwaite et al., 2005), to investigate co-morbidities under HIV infection 
with adherence to antiretroviral therapy considered. This model was extended 
also to take into account additional intervention types and covariates (such as 
age, gender, alcohol consumption), (Ruggles et al., 2017). While these recent 
examples highlight the potential of CTS, they still rely on forward simulation 
for prospective study planning and have not been widely adopted for STIs. 
In Chapters 5 and 6 I built computational models to study immune system 
fitness decline due to lymph tissue damage in conjunction with treatment 
interruptions. My previous results can be used, therefore, to construct a model 
permitting inversion of the CTS process (Figure 7.2).  
 
 
Figure 7.2: Concept model for CTS studies showing the three main steps and subtasks. 
 
The resulting concept of inverse clinical trial simulation allows 
predictions for patient population characteristics, using outcome information, 
together with knowledge of the biological mechanisms involved. 
Consequently, the re-use of existing data on historical clinical trial outcomes 
is possible, even where these are relatively sparse or incomplete in current 
terms. The aim is to derive plausible information on patient population 




















clinical trial, (including lymphatic tissue status and immune system 
impairment in this case). 
In the following, mechanistic modelling of HIV is briefly reviewed, and 
construction of a simplified version of the LT-model, (Hillmann et al., 2020, 
2017b), is discussed. Model capabilities are demonstrated in ‘forward 
simulation’ and subsequently apply an inverse approach to simulated and 
original STI clinical trial data and outcomes. 
7.3 Mechanisms and Data 
7.3.1 Observed and Hidden Data 
In chapter 3, I noted that models, which incorporate known biological 
mechanisms of HIV infection are still predominantly of predator-prey 
compartmental type. In these, the virus acts on cells from the immune system, 
where the basic setup consists of three compartments, each represented by an 
Ordinary Differential Equation (ODE) and describing concentration changes 
of a specific property over time. In the case of HIV these are commonly 
concentrations of the virus and a type of white blood cells (CD4+ T-cells), 
the main target of the virus. A core condition of this class of models is that all 
‘reactants’ are sufficiently well mixed, (arguably true for the bloodstream, 
(Beauchemin, 2006)). The dynamics of such ODE-systems have been widely 
researched and the basic model has been refined over time (e.g. (Conway et 
al., 2019)). However, recent clinical results strongly suggest that HIV 
infection is much more multi-faceted in terms of its impact on various 
components of the immune system than model assumptions allow, (Appay 
and Sauce, 2017).  
One major aspect, which has largely been neglected to date, is lymphatic 
tissue degradation through collagen deposition, as described in Section 5.2. 





signalling, (Fletcher et al., 2015; Schacker et al., 2005; Zeng et al., 2012a). 
Antiretroviral therapy has been found to slow down this process but not to 
reverse it, (Zeng et al., 2012c), leaving permanent impairment of immune 
function, despite apparent CD4+ restoration. The intervals between structured 
treatment interruptions may also influence these alterations, but this has not 
yet been observed directly. Figure 7.3 illustrates the impact of direct and 
indirect adverse effects of HIV infection and treatment interruptions, as 
observed in clinical studies.  
 
 
Figure 7.3: Relationship diagram for a treatment interruption study. Grey boxes denote 
data captured during the clinical study while ovals denote factors at least partially hidden e.g. 
replacement of lymphatic damage with something like immune damage where the former is 





Adverse events may be caused directly, (e.g. through destruction of CD4+ 
T-cells, due to the virus) or indirectly, (from immune system depletion). In 
the SMART study, events directly attributable to HIV infection (i.e. through 
opportunistic disease) were rare and numbers did not differ significantly from 
the control group. However, a statistically significant increase in non-HIV 
infection related cases (of cancer and even death) was detected, (Silverberg 
et al., 2007). More recent research has associated such events with ageing of 
the immune system, (Appay and Sauce, 2017).  
Antiretroviral treatment limiting the viral concentration in body fluids may 
thus have the twofold effect of preventing direct infection of CD4+ cells 
(allowing regeneration) and restoring cellular signalling to ‘normal’ levels 
preventing further permanent damage. The detailed mechanisms of infection 
progression responsible for those outcomes are described and quantified in 
the next section. 
7.3.2 Infection Progression 
During untreated HIV infection, different kinetics for various biomarkers can 
be observed. In addition to the concentration of viral copies in peripheral 
blood, and proteins used for cellular signalling (cytokines), (Duprez et al., 
2012), CD4+ T-cell concentration is the most commonly used marker for 
determination of  the status of infection progression, (Fauci et al., 1996). This 
concentration (denoted CD4+ count) exhibits a marked decline during 
untreated infection (see Figure 7.4).  
As remarked in section 2.2.3, the decline is roughly categorised by three 
distinct phases: In a healthy person, the CD4+ count is in the range of 800 - 
1500 cells/mm³ blood. In the acute phase (first 12 weeks after HIV infection), 
a rapid decline and subsequent (incomplete) recovery of CD4+ T-cell levels 
occurs, accompanied by flu-like symptoms; (CD4+ counts in blood then 





chronic phase, which is largely asymptomatic, levels of CD4+ concentrations 
tend to decrease in a steady manner, (Fauci et al., 1996); the final phase, 
associated with immune system breakdown and AIDS-related disease, is 
defined by CD4+ concentrations dropping below 200 cells/mm³. Clinical data 
suggests an acceleration of CD4+ level decline accompanied by emergence 
of AIDS-related symptoms and opportunistic disease leading to death within 
a few months, (Fauci et al., 1996). In the following, I focus on the chronic 
phase, (the greater part in HIV infection progression). Nevertheless, the time 
period involved is subject to patient-specific variations. These have been 
identified and described earlier in terms of fast-progressors, slow progressors 
and the rare cases of elite controllers or non-progressors (Section 5.2.4). In 
any case, all available data sets record a steady decline of CD4+ 
concentrations in blood, typically of the order of 5.25 cells/mm³/month, 
(Fauci et al., 1996; Greenough et al., 1999).  
 
 
Figure 7.4: Histograms of CD4+ counts for groups of HIV-uninfected (left) and infected (right) 
individuals. Increase in fatalities due to low CD4+ cunts lead to asymmetric distribution shape for the 
HIV infected group. 
Image source: A. Malaza, J. Mossong, T. Bärnighausen, J. Viljoen, and M.-L. Newell, ‘Population-
Based CD4 Counts in a Rural Area in South Africa with High HIV Prevalence and High Antiretroviral 
Treatment Coverage’ PLoS One, vol. 8, no. 7, p. e70126, Jul. 2013. Use permitted under the Creative 
Commons Attribution License CC BY (https://creativecommons.org/licenses/by/4.0/) 
 
To obtain a more detailed picture of the underlying distribution of 
progression times in a patient population, I analysed publicly available data 





Study, (Coutinho, 1998). The patients were observed over the whole course 
of infection until AIDS symptoms emerged. The risk data presented in Figure 
7.5 (a) indicates a variable event rate, increasing from year 3 after infection, 
levelling off for times above 10 years. This observation is in line with other 
sources, (Fauci et al., 1996; Greenough et al., 1999), of fast- and slow- or 







Figure 7.5: Distribution of time-to-AIDS in a patient cohort. (a): Risk chart indicating 
proportion of patients with no HIV (at risk, y-axis) against time since seroconversion (years, 
x-axis); sample size n=125. (b): Histogram of relative incidence (y-axis) of CD4+ decline 
rates (cells/mm³/day, x-axis), pooled in 0.1 intervals until AIDS onset; and best fit with 
Weibull distribution. 
 
The average loss of CD4+ count per patient was calculated using the same 
set of data. The resulting histogram, Figure 7.5 (b), illustrates slow 





found the best mathematical representation of this behaviour to be a 2-
parameter Weibull distribution (with parameters scale 7.2; shape 1.9) though 
the Lognormal is also feasible. Consequently, by sampling from the Weibull 
[7.2, 1.9], a patient population with a realistic distribution of progression rates 
can be generated, (and is used for the following progression modelling). 
7.4 iCTS Model Components 
7.4.1 Infection Progression Model 
To relate the hidden property of permanent immune system impairment for a 
specific individual to the observable property of CD4+ cell concentration I 
construct a mathematical model (termed trial model) based on Ordinary 
Differential Equations with two compartments: the former, T, denotes CD4+ 
count in blood, while TC denotes the ability of the immune system to 
regenerate. This latter property is diminished during infection through 
permanent damage effects caused by HIV (e.g. lymph tissue collagenation). I 
use established ODE formalism in preference to the biologically more 
realistic models (described in Sections 5.3 and 5.4), as this is simpler to 
implement as a first attempt and with limited computational resources. In this 
case, therefore, a detailed calculation of lymphatic tissue damage is not 
included. Rather, I present a proof of concept, which may be adapted to 
include more complex model forms (see extensions following). For now, I 
take TC to be the lowest value that T can assume at a given time, so that in the 
case of no treatment ever having been applied, T and TC are equal. Further, I 
assume identical units (cells/mm³) for T and TC, although the latter strictly 
speaking is a virtual or idealised concentration only of CD4+ cell count as a 
measure of the ability of the immune system to fight infections or in the 
absence of any previous treatment. It is useful as a quantitative comparison 





Most ODE models addressing HIV focus on underlying viral infection 
processes. However, these have a very short turnaround of approximately two 
days, (Ho et al., 1995), important in modelling short-term responses to 
treatment, (e.g. (Perelson and Nelson, 1999)). Since the timeframe in this case 
ranges from weeks to years, however, viral replication is indirectly 
represented as pressure on the immune system (affecting degradation and 
recovery rates in the compartments).  
Thus, for the case of an individual who never received treatment 

















Using expression (7.1), I assume that CD4+ concentration decline, and 
immune system depletion occur at the same constant rate, dmax. This is 
suggested by the CD4+ count being a strong predictor of infection 
progression if no treatment is introduced, (as observed in the pre-ART era, 
(Fauci et al., 1996)). Further justification for assuming this relation are that 
rates observed for T-cell decline and lymphatic tissue collagenation are 
strongly proportionally-related, (Zeng et al., 2012c). 
7.4.2 Medical Intervention Model 
Initiation of Antiretroviral Therapy has been found to lead to a drastic 
reduction of viral load in blood, (Dixit and Perelson, 2004). This slowdown 
of viral activity is accompanied by downregulation of immune activity and 
subsequent recovery of CD4+ cell levels. This increase in concentration is 





recovery rates in the range of 20 to 30 cells/mm³/month, (Corbeau and 
Reynes, 2011). Increased migration of lymphocytes from lymphoid organs 
into the bloodstream is assumed to be a key contributor to this rapid rise. This 
slope levels off subsequently but CD4+ counts in blood continue to rise more 
slowly for 5 to 6 years of continuous therapy, (Moore and Keruly, 2007) with 
the increase assumed to be caused by homeostatic proliferation until CD4+ 
levels reach a steady state. The plateau achieved has been found to be 
associated with baseline CD4+ counts (nadir; pre-treatment level or lowest 
CD4+ count detected) for the patient, (Falster et al., 2009). Overall, the final 
CD4+ concentration stabilises at approximately 300-350 cells/mm³ above this 
baseline. Interestingly, individual baseline levels do not appear to impact on 
the pattern of recovery rates as described above, (Nobrega et al., 2016). The 
limitation of CD4+ cell recovery appears due to multi-faceted causes, 
(Corbeau and Reynes, 2011), and is not yet fully resolved, but research to 
date suggests that production of defective naïve T-cells and increased 
apoptosis are key contributing factors, (Aiuti and Mezzaroma, 2010). In 
addition, there is strong evidence that these factors are linked to lymphatic 
tissue damage, (Zeng et al., 2012b). A mathematical approximation for 
constrained growth (as observed in this case) is the common 1-parameter 
logistic formula. Recent data indicate that biomarkers associated with 
inflammation and immune system upregulation remain elevated for more 
than a year after therapy initiation, (Osuji et al., 2018). To better allow for 
these combined effects of medical intervention, I extend system (7.1) to allow 
for a non-constant immune system decay rate D and constrained recovery / 


























In the modified system represented by expression (7.2), rate r represents 
the maximum observable recovery rate for CD4+ T-cells, while b denotes the 
regeneration limit. I further assume that, while rate dmax from expression (7.1) 
is not immediately reduced to zero for the TC compartment when treatment is 
initiated, it follows an exponential decline with rate α. This property is 
possibly correlated with the frequency of regulatory T-cells (Tregs) relative 
to the CD4+ T-cell population as indicated in Section 5.2. This percentage of 
Tregs has been found to be significantly elevated during HIV infection, (Shaw 
et al., 2012). However, during the first months after treatment initiation and 
during CD4+ regeneration, the relative frequency of Tregs drops rapidly and 
approaches pre-infection levels, (Nobrega et al., 2016). Assuming a similar 
kinetic and based on this information, a value for α was chosen such that the 
decline of D has a half-life of around one month. Since immune system 
depletion is assumed to be irreversible, TC may not increase irrespective 
duration or effectiveness of treatment. 
7.4.3 Therapy Removal Model 
The first remarkable phenomenon associated with antiretroviral treatment 
discontinuation is the rapid increase of viral concentration in blood, 
(detectable after about 10 days), known as viral rebound, (Rothenberger et 
al., 2015). It is assumed that this rise is caused by activation of ‘dormant’ 
virus in so-called latently infected cells, (as noted in section 2.4 previously) 





not accessible with in-vivo assay techniques, (Fischer et al., 2003). These 
short-term viral dynamics are well-characterised, (Hill et al., 2016), but CD4+ 
dynamics over longer time scales following treatment cessation are less well-
known. A rapid drop in the CD4+ cell concentration in blood within the first 
month after a treatment interruption has been detected, but this loss of 
immune cells has been found to be strongly correlated with baseline levels 
for a specific subject, (Thiébaut et al., 2005). In cases of low CD4+ baselines 
(< 200 cells/mm³) average losses of 365 cells / mm³ have been reported for 
the first month of treatment interruption.  
For higher baselines, this loss was less pronounced (~154 cells / mm³) in 
the first month. From month 2 after treatment discontinuation, the loss rate is 
lower and constant, ~ 17 cells/mm³/month, (Thiébaut et al., 2005), or 24 
cells/mm³/month, (Maggiolo et al., 2004), have both been reported. It is 
questionable whether treatment interruption loss rates for CD4+ cells would 
decline sufficiently to approach (markedly lower) treatment-naïve loss rates, 
(given in 7.3.2).  





























In this ODE system, parameters Tint and c represent CD4+ T-cell 
concentration and maximum loss rate of T-cells at the start of interruption 
respectively. I assume c > dmax, to allow for the rapid decline of CD4+ 
concentration following treatment interruption, as indicated, (Maggiolo et al., 





doubling time β where α < β and take β values to be ranged in time around 
viral rebound, (Rothenberger et al., 2015). This system thus defaults to 
expression (7.1) for longer periods of treatment interruption.  
All parameters used for the models formulated, along with parameter ranges 
suggested by the literature are summarised in Table 7.1 . 
 
Table 7.1: Parameter estimates for the CTS model. 
Model Param. Description Value Literature 
Infection 
progression 
dmax Maximum depletion rate 




(Fauci et al., 1996; 




r Initial regeneration rate 










α Slowdown rate of 
depletion rate. 




c Maximum depletion rate 





(Maggiolo et al., 
2004; Thiébaut et 
al., 2005) 
β (Maximum) acceleration 
rate of Depletion rate.  
25 per year (Rothenberger et 
al., 2015) 
 
7.4.4 Risk Model 
As noted above, clinical studies typically observe the emergence of specific 
outcomes (or endpoints) which are defined during study setup. These 
endpoints then provide evidence to prove (or disprove) study hypotheses. For 
the STI studies referenced, endpoints were chosen to test neutrality of the STI 
regimen (so were related to fatalities or emergence of disease). For example, 
the most extreme case, (increase in death rate due to AIDS-related or other 
causes), has been found to show elevated incidence for the STI group in the 
SMART study, (El-Sadr et al., 2006).  
To quantify the relationship between immune system impairment and 





counts for a cohort of untreated (or treatment naïve) patients, (Coutinho, 
1998), (measured 3 months or less prior to death),  (May et al., 2016; Palella 
et al., 2006). As stated in section 7.4.1, I assume the CD4+ count for treatment 
naïve subjects to be a valid representation of actual immune system 
impairment. The relationship was found to be well-represented by a power 
law, (Figure 7.6). Using non-linear regression, we obtain the following 
function to determine the risk of experiencing a fatal event for a given 
immune state: 
 
 ( ) 0.8141.38naiveCP T x−=  (7.4) 
   
 
Figure 7.6: Mortality rates of HIV-infected patients in relation to latest measurements of 
CD4+ counts. Measurements from pooled clinical datasets, (May et al., 2016; Palella et al., 
2006). Dashed line shows fit using a power-law function indicating asymptotic behaviour. 
 
With the mechanistic ‘trial model’ described above, we are now able to 
simulate trajectories over time, for CD4+ counts and immune system 
impairment, together with associated risks for fatal events under various 
treatment regimens for simulated patient cohorts. These virtual patients also 





treatment. In the following, I define a theoretical framework of use for further 
experimentation. 
 
7.5 Inverse Monte Carlo Framework 
7.5.1 Inputs and Outputs 
To highlight the concepts underlying my approach, I combine and simplify 
model relations from section 7.4 by defining a function describing the ‘risk 
of a fatal event’ over time E: 
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In expression (7.5), the non-linear function f describing the event rate over 
time depends on parameter vector Θ, which consists of initial values of T and 
TC and parameter values chosen for the progression model. Each virtual 
patient i can then be represented by a parameter vector θi with a unique set of 
values from biological meaningful ranges for each parameter. It is then 
assumed that each parameter in Θ can be represented by some distribution 
over the patient population.  
In the context of clinical trial simulation, such variations are commonly 
described using Non-Linear Mixed Effect Models (NLME), (Wu, 2005). 
Using this NLME methodology, each parameter (or covariate in the NLMEs), 
is assumed to be either fixed or variable. Variation to account for different 
individuals (inter-patient) typically follow a Normal (Gaussian) distribution 
with parameters mean µ and standard deviation σ in NLME. In this case T0 
and TC0 are assumed to be variable due to natural variation. Further, 





enrolment criteria for participating patients. Other parameters are also 
assumed to show inter-patient variations but are not linked to the study setup. 
In this context, dmax is assumed to be variable due to different progression 
rates observed for HIV infection. For rates r and c representing regeneration 
or depletion of CD4+ cells, variability is also assumed, based on evidence 
from clinical data. The remaining parameters b, α, β are assumed to be fixed, 
since the clinical data indicate little variation for the regeneration limit b, 
(irrespective of the phase of infection), while the acceleration of depletion 
rate β is mostly influenced by viral properties like the (non-patient-specific) 
turnaround rate, (Rothenberger et al., 2015). Finally, slowdown of the 
depletion rate under treatment α is assumed fixed due to the kinetics of 
Regulatory T-cells, for which available clinical data, (Nobrega et al., 2016), 
suggest little inter-patient variation.  
Though some parameters may be related, publicly available data are 
limited, hence independence is also assumed here. From initial remarks on 
parametrisation (see section 3.4.3), estimates for most parameter distributions 
can be obtained from the literature (e.g. (Coutinho, 1998)). However, for 
historical STI studies, pre-existing immune system impairment TC0 has 
typically not been reported. Analytical solutions are unavailable, so one might 
rely on sampling-based techniques. Data for serious events, however, (e.g. 
death, opportunistic disease) are available from study records. Hence, I apply 
an inverse Monte Carlo method, as described in section 4.3.2, to obtain an 
approximation of TC0. From inverse MC, a candidate value for TC0 can be 
obtained by sampling the distribution parameters (µ, σ). A rich sample from 
the resulting distribution is generated, which represents a virtual study 
population. To address further inter-patient variation, estimates for the 
remaining model parameters may be also obtained by sampling from the 
respective distributions. With the population generated, the model is applied 





to obtain an approximation for E(t). The closeness of this solution to clinical 















= −  (7.6) 
 
Since we are interested in solutions for E(t) which are close to observed 
clinical findings, an iterative approach, such as the Metropolis-Hastings 
algorithm must be applied (see Section 4.3.2). In case of this model, each 
Metropolis step n introduces small, random changes to the parameter vector 
θ and obtains the MSE for n. The new parameter vector θn is then accepted 
with a probability using the following relation and rejected otherwise: 
 
 
7.5.2 Computational Model 
An analytical solution of the equation system (7.1) – (7.3) is non-trivial, as 
treatment settings depend on STI protocol, hence I rely on numerical 
simulation methods. To simulate a ‘CD4+’-guided STI strategy, as used in 
the SMART and LOTTI studies, evaluating levels of T and TC at fixed 
incrementally simulated time steps is necessary to assess risk of events or 
need for changes in treatment settings. In this case, common efficient 
algorithms for solution of ODE systems with variable step length (e.g. Runge-
Kutta methods, see (Butcher, 1996) for a review) are not applicable. Solutions 
involving fixed steps, (such as the Euler method), however, tend to 
accumulate error rapidly for large step widths. Hence, I choose a discrete 




























compared to the typical duration of HIV infection (>~ 1500 days) and offers 
a valid approximation interval. In observing the trajectories of both T and TC 
(see Figure 7.7) an irreversible decline in TC during a phase of treatment 
interruption is noticeable which is in line with clinical observations, (Zeng et 
al., 2012c).  
Fixed time intervals enable the use of Markov Chain Monte Carlo 
(MCMC) methods where trajectories of simulated T-cell concentrations and 
immune system impairment are represented by a series of successive states. 
For systems of equations (7.1) – (7.3) the inter-dependency of T and TC is 
clearly noted. The property TC typically can not be observed in a clinical 
setting due to its complexity, but property T is routinely obtained (CD4+ 
count) and regarded as a proxy for TC.  
 
 
Figure 7.7:  Sample run of modelling framework using typical choices for parameter 
estimates. Simulated treatment initiation occurs at timestep 250 with interruption at timestep 
750 and subsequent re-initiation at timestep 1500 time steps (CD4+ count – T; Immune age 






Consequently, conditions for a Hidden Markov Model (HMM) apply (see. 
Figure 7.8). This type of models has wide applicability to problems in 
computational biology, (Schuster-Böckler and Bateman, 2007). Though 
mathematically intractable for most complex systems, sampling-based 
methods can again be used to overcome this limitation.  
 
 
Figure 7.8: Graphical representation of a Hidden Markov Model. Circles denominate states (y – 
observed; x – hidden), arrows dependencies between states. 
 
In the following I aim first to demonstrate the capabilities of the 
computational model based on equations (7.1) – (7.3), performing forward 
simulations and comparing results with data from clinical settings. Expanding 
on this, I use MCMC techniques to analyse clinical data from STI trials to 
gain additional insight on outcomes. 
7.6 Simulation and Results 
7.6.1 Forward Simulation 
Each model run follows the steps, described in this section. 
1. To initialise the model (or simulated clinical trial), I generate a number n 
of virtual patients by generating n corresponding vectors θi  (i = 1,…n). These 
parameter estimates are obtained by sampling the distributions given in Table 
7.1, above. Distributions are assumed to be Normal except for dmax which 





parameters is common in clinical settings for large patient groups, (Whitley 
and Ball, 2002). Parameters assumed to be fixed do not relate to inter-patient 
variation and are based on values from the literature (see Table 7.1). For 
starting values for T and TC , the bell-shaped Normal distribution (µ = 742, σ 
= 305) of CD4+ counts used to fit data of a treatment-naïve patient population, 
(Coutinho, 1998), (see Figure 7.9) is assumed. However, for STI trials, 
patients were mostly not treatment naïve (possibly distorting the Normal 
form), suggesting that an alternative distribution may be more appropriate. 
The assumption of Normality is acknowledged, therefore, to be a simple and 
convenient initial choice in this instance. After initialising the virtual patient 
population, model execution is started. 
 
 
Figure 7.9: Distribution of CD4+ T-cell counts at start of chronic phase of HIV infection. 
Histogram height illustrates binned proportions of T-cell concentrations (n = 273) obtained 
from the Amsterdam Cohort Studies on HIV / AIDS, (Coutinho, 1998). Red line shows fitted 
Normal distribution ( = 742,  = 305). 
 
2. At the start of each model time step, treatment status (either naïve, on or 
off treatment) is evaluated for each simulated patient. Depending on this 
status, equation systems (7.1) - (7.3) are employed to obtain values for the 





3. Every 30th time step, results for CD4+ counts are evaluated for each patient 
(simulating a clinical visit). Depending on the outcome and CD4+ limits 
imposed for the simulated trial, treatment is adjusted accordingly.  
4. The risk of experiencing an adverse event (like opportunistic disease, AIDS 
or death) is calculated for every time step using expression (7.4). A discrete 
event is simulated by comparing the individual patient risk with a random 
number. Upon occurrence of an event for one patient, the result counter for 
this time step is incremented by one and the patient is removed from the study.  
5. The framework also assigns a discrete probability to study dropouts due to 
other reasons, i.e. ‘loss to follow-up’. The latter, however, does not cause an 
increase of the result counter. 
6. After updating the virtual study population, the time step is incremented by 
one and the next iteration is started with model step 2.  
Note: The withdrawal of subjects (as in steps 4 and 5) is very common for 
clinical trials due to various reasons. Termed censoring in statistics, multiple 
methods have been proposed to deal with such truncated data, (e.g. 
classically, (Lindsey and Ryan, 1998)). 
An example of data generated by simulation is shown in Figure 7.10. The 
property of immune system impairment (Figure 7.10 (b)) can not be observed 
as such under clinical conditions. Despite CD4+ counts well above critical 
levels at the end of study (Figure 7.10 (b), red bars), immune system function 







Figure 7.10: Example of a simulated treatment interruption study. The simulation starts 
with 2800 patients, treatment interruption occurs for CD4+ counts above 350 cells/mm³ and 
(re-)initiation at CD4+ counts below 250 cells/mm³. (a) Distributions of CD4+ count at start 
(blue) and end (red) of study. (b) Distributions of Immune regeneration capabilities at start 
(green) and end (brown) of study. (c): Cumulative risk of adverse events study period. (d): 
Proportion of patients under treatment over study period. 
 
In a real-world study, this decline can only be diagnosed indirectly by 
observing risk (Figure 7.10 (c) or parameters such as treatment status or 
patients, (Figure 7.10 (d)). Besides population specific properties, the model 
also relies on parameters which are patient independent. The ‘trial model’ can 
be used to generate data sets on risk (similar to Kaplan-Meier charts) for a 
virtual study population where specific STI patterns are applied, where data 
are lacking for real study populations.  
7.6.2 Parameter Sensitivity 
To determine influence of non-patient specific model parameters α, β and b 
on risk progression, estimates (see Table 7.1 above) are varied by a factor of 
2 and compare simulation outcomes. Simulations are set up to follow the 
protocol of the SMART STI study, (El-Sadr et al., 2006), but with an 





power. I further use the total accumulated risk after simulation time = 2500 
(days) as a measure for sensitivity. Results, (Figure 7.11) indicate marked 




Figure 7.11: Impact of non-patient specific parameters on total risk. Heat map shows accumulated 
risk after 2500 simulation time steps (weeks) by colour in relation to different parameters selections. 
 
As parameter α controls the reduction of the immune system decay rate D 
under treatment, as defined in expression (7.2), low values result in ongoing 
decay even under treatment, permanently impacting CD4+ recovery and 
terminally increasing risk. Parameter b has less influence on risk, as it only 
impacts CD4+ recovery directly during treatment (expression (7.2)) and has 
no influence on immune system decay. Lastly, as parameter β controls 
immune system decay rate D when treatment is interrupted (expression (7.3)), 
the limitation of D to dmax as maximum value might explain the lack of 
influence of β on overall outcome.  
We next use the ‘trial model’ to generate data sets on risk progression for 
a virtual study population where specific STI patterns are applied, for which 





7.6.3 Comparison with Clinical Data 
Simulation Setup 
We assumed a virtual study setup and treatment interruption schedule, which 
followed the protocol of SMART, (El-Sadr et al., 2006), where key aspects 
are listed in Table 7.2. I chose the SMART STI study due to its controversial 
outcome and wide-ranging impact. Regarding prior immune system 
impairment, it has been reported that the SMART patient population 
consisted largely of immune-compromised subjects, (Hirschel and Flanigan, 
2009), but no quantitative data on group condition exists. Hence, I simulate 
groups with different degrees of immune system impairment to explore the 
impact on outcomes for this specific study setup and compare simulated with 
clinical data. 
Once again, the states of immune system impairment are taken to be 
Normally distributed, as for CD4+ count for untreated infection. Two 
different Normal distributions are sampled, representing different choices for 
these parameters, simulating both a group with immune functions largely 
intact and one with pre-existing impairment (see Table 7.2). 
 
Table 7.2: Virtual study setup, (following basic parameters of SMART STI study) and characteristics 
of patient groups. 
 Mean (SD) 
Study population (STI) 2720 
CD4+ count (cells/mm³) 597 (240) 
CD4+ threshold (cells/mm³) Lower  250 
Upper 350 
Patient immune functions degraded 750 (300) 
intact 1200 (300) 
   
Results 
Simulation results in terms of cumulative risks of death are compared with 
corresponding data from the SMART clinical study (Figure 7.12). The main 





F(a) The results indicate good agreement for risks of fatal events for 
clinical data (solid orange line) with the simulated data of the group with 
impaired immune functions (dashed blue line), at least during early phases.  
 
 
Figure 7.12: Comparison of risk progression data from SMART STI study (solid lines) - 
rates of death (orange) and opportunistic disease and death (green), with simulation data 
(dashed lines) for different initial choices of either intact (blue) or impaired (red) immune 
system function. Clinical data shows as more coarse-grained towards the end, (from 
censoring). 
However, clinical and simulated data diverge from ~500 days, where 
simulation predicts higher values than were observed in the clinical study. In 
assessing this divergence, it is useful to note that the study ethics protocol 
obviously required patients to be removed / censored upon emergence of 
opportunistic disease, indicating immune system breakdown. This 
withdrawal and subsequent re-initiation of fully suppressive treatment aimed 
to prevent fatal events, which might otherwise have occurred had a vulnerable 
patient remained in the study.  
F(b) I therefore included clinical data on risk of opportunistic disease in 





combined measure, clinical and simulation data of the ‘trial model’ are in 
better agreement at a late phase of the clinical study.  
To attempt derivation of the initial distribution of immune system states, I 
applied an inverse Monte Carlo (iMC) method to approximate the Normal 
distribution parameters, highlighted in the previous section.  
7.6.4 Inverse Monte Carlo Simulations 
Simulation Setup 
Using the framework described earlier, I initially aimed to validate the 
approach by deriving the known initial distributions for the two sets of data 
generated in the previous section, (parameters listed in Table 7.2). The sample 
size was again of ~2800 as in the forward simulations. An initial choice of θ 
with (µ = 742, σ = 305) represented the typical distribution for a population 
at the start of the chronic HIV phase. Samples values for distribution 
parameters were restricted to within biologically plausible ranges (µ: [0, 
1500], σ: [0, 500]).  For the first experiment, a run time of 100k Monte Carlo 
steps was implemented for each of the two simulated data sets. To enable 
better characterisation of regions of interest, (MSE low values) a negative 
log-transformation, (Feng et al., 2013) was applied in order to give a positive 
score S: 
   
 ( )10logS MSE= −  (7.8) 
   
In the following the results for the inverse Monte Carlo experiments 
(denoted I) are discussed for simulated and clinical data. 
 
Results for Simulated Data 
I(a) From (Figure 7.13), performance of the M-H algorithm over the run 
cycles appears to be heterogeneous for the two sets of data with respect to the 





immune function, the majority of M-H samples is concentrated around mean 
values larger than ~800, (Figure 7.13 a). However, for the case of impaired 
immune function, the region with most samples appears to cluster around 
lower mean values (Figure 7.13 b), with mean values larger than 1200 
explored to a lesser extent. These first results demonstrate the power of the 
key characteristic of the M-H algorithm and highlight potential areas with 







Figure 7.13: Density of inverse MC samples (as obtained with the Metropolis-Hastings 
algorithm) with respect to µ (mean) and σ (sd) after 100k sampling steps on simulated risk 
progression data sets for (a) preserved/intact and (b) impaired immune functions. Shading is 
set to correlate with MC sample density. 
 
I(b) The impact of the Metropolis algorithm behaviour becomes evident 
when examining the results of the above MC runs with respect to parameter 
combinations of µ and σ. In this regard, I analyse the 1000 points with highest 
score S from both simulation results. The scatter plots in Figure 7.14 show 
the locations of those high scoring simulation results with respect to µ and σ 
for both virtual patient groups and their respective scores denoted by colour. 
It is evident that high scoring values for µ and σ accumulate in distinct regions 
which are distinctly separate for each virtual patient group. Each of those 
regions also includes the respective ‘real’ distribution parameters used to 





for the inverse model). In both cases, the ‘real’ values are located towards the 
lower end of the respective regions of high scoring results, highlighting 
distribution breadth (and also perhaps the tendency of the model to 
encompass ‘worse-case scenarios’, presumably because no censoring is 
considered).  
However, shape and size of these regions differ markedly between the two 
groups, being larger and less well-defined for those with preserved immune 
function, (Figure 7.14 a), compared to the impaired set, (Figure 7.14 b). 
Hence, variance is larger in the former case with risk average in the range 
~1100 to ~1450. In contrast for those patients with impaired immune 
function, Figure 7.14b indicates accumulation of high scoring samples 
collected in an almost spherical region in the range ~700 to ~900 for µ with 
small variance, suggesting more commonality of outcome.  
In summary these simulation results indicate the potential of the inverse 
method in deriving distribution parameters for patient groups from risk 













Figure 7.14: Location of the respective 1000 MC samples with highest scores S in 
parameter space (µ -mean, σ –sd, x-axis truncated for visibility) for simulated datasets with 
immune function preserved/intact (a) and impaired (b). Colour gradient corresponds to 





Results for Clinical Data 
Finally, I used risk progression data (opportunistic disease and death) from 
the SMART study to obtain immune system state distribution parameters, 
based on the same experimental set-up in terms of sample and simulation size 
as above with other model settings also left unchanged. Again, for analysis 
purposes, I considered the 1000 inverse MC samples with the highest values 
for score S.  
I(c) Data points in Figure 7.15 show an aggregation of high scoring value 
combination for µ and σ at a specified region as the simulated data sets. This 
region appears to be located between those from the former experiments 
(Figure 7.15, shaded regions I and P) and gives estimates for the mean (µ) of 
immune system function of between 800 and 1100. The results of the clinical 
data set appears to be close to those for the simulated data set with impaired 
immune function (shaded region I), which is not that evident from the 
comparison shown, (Figure 7.13).  
 
 
Figure 7.15: Location of the 1000 MC samples with highest score S for clinical data from 
SMART study (points) in parameter space (µ -mean, σ –sd). Colour gradient corresponds to 
negative S ( = log score). Shaded areas show location of data for simulated data sets with 





This agreement of the results of the clinical data set to the simulated data 
with impaired immune function indicate that pre-existing immune system 
damage may indeed provide some explanation of observed study outcomes. 
However, the picture is complicated by large variance (σ²) in terms of 
predictive further analysis. It is noted, however, that the heavy lower tail for 
µ also suggests that the immune function may have been seriously impaired 
for a sufficiently homogenous group of patients.  
The utilisation of an inverse approach illustrates its potential application 
for analysis of historical data. Although high variability (σ) does make 
inferring characteristics of the underlying but unknown patient population 
challenging. However, the identification of relatively homogeneous subsets 
in terms of immune system impairment does provide further support in this 
regard. 
7.7 Performance Optimisation 
In the previous sections, I used the M-H algorithm to obtain an approximation 
for the inverse simulations. As stated in section 4.3.2, the algorithm has the 
advantage of avoiding being trapped in local minima. However, since it 
explores the parameter space sequentially, a large number of samples might 
be drawn from parameter space regions with low scores, leading to 
unnecessary computational cost. In contrast, algorithms such as the Particle 
Filter (PF, described in detail in section 4.3.2) explore multiple regions in 
parameter space in parallel (narrowing down to regions with high scores), 
hence utilisation of computational recourses in this way has the potential to 
be superior. However, due to complexity of the parameter landscape, the 
performance gain using such a method needs to be weighed against validity 
of the results obtained. With this in mind, I used an implementation of the PF 
algorithm to determine parameters of known patient distributions using the 





using the ICHEC resources, to track algorithm performance. Due to the fast 
convergence of the algorithm, I limited simulation size to 100 steps (for each 
particle, i.e. set of candidate parameters), corresponding to ~ 15 minutes (wall 
clock) time for the selected environment15. Further, I assessed the influence 
of the numbers of particles selected by either using 1 (40 particles) or 8 nodes 
(320 particles) of the cluster in parallel. Results of the inverse simulations for 
each of the two setups are summarised in Table 7.3 and compared to the ‘true’ 
values of the simulated data used.  
P(a) Estimated population means are close to the real value with a less 
good fit for the data set with ‘preserved’ immune response. These 
observations are in line with the results of inverse simulations using the M-H 
algorithm, described in the previous section. Results obtained with the PF 
algorithm, however, contain less information, since they provide averages of 
the parameter distributions obtained with the M-H algorithm. However, 
computation costs are greatly reduced with 60 / 4,800 minutes CPU time (for 
40 / 320 particles) compared to the M-H algorithm which took about ~29,000 
CPU minutes to obtain parameter distributions in sufficient detail. 
 
Table 7.3: Population parameters estimated from inverse simulations using the Particle Filter after 100 
steps in comparison to the ‘real’ values used to prepare simulated data. Numbers in brackets denote 
standard deviations of particle values. 
 population real value 40 particles 320 particles 
impaired Mean 750 695 (23) 701 (28) 
SD 300 344 (29) 352 (34) 
preserved Mean 1200 1338 (29) 1336 (33) 
SD 300 475 (18) 474 (18) 
 
P(b) Further, the results for 40 and 320 particles show marked similarity 
in both estimates for population mean and standard deviations, despite the 
 
 
15Cluster ‚Kay‘ with 335 nodes in total, each with 2 x 20-core 2.4 GHz Intel Xeon Gold 6148 






large difference in computational costs. The diagrams in Figure 7.16 illustrate 
the distributions of particle clouds for the first 25 steps of the inverse 
simulations. These data suggest that estimates for the population means close 
to the final values are already obtained after about 10 simulation steps. The 
impact of the number of particles on this result appears to be less pronounced. 
However, the estimation of the population standard deviation appears to 
benefit more from a larger sample size, (as expected for statistical inference). 
For the smaller number of particles, the estimate converges to a final value 
after about 50 steps but is obtained after about 5 steps for the set-up with a 
higher number of particles. 
 
40 particles 320 particles 
  
 
Figure 7.16: First 25 steps of inverse simulations of Particle Filter algorithm for different particle 
numbers with progression of estimates of population parameters for two sets of simulated data 







Clinical trial simulations based on the inverse Monte Carlo method have been 
shown to demonstrate potential for assessment of HIV structured treatment 
interruption studies. To this end, I constructed a mechanistic model describing 
decline and recovery of immune function (and CD4+ counts) under phases of 
treatment interruption, (where sensitivity analysis also emphasised 
importance of immune degradation). I have further shown the concept to be 
useful by comparing model results to clinical risk progression data, (results 
F(a,b)) and by deriving auxiliary data on immune system function from the 
SMART clinical trial on HIV structured treatment interruptions, (results I(c)). 
Validation of the approach is also discussed, (results I(a,b)) as well as 
practical considerations, such as efficient utilisation of parallel architectures 
(results (P(a,b)).  
Results obtained appear to provide some insight on the previously 
unknown state of immune system impairment for the patient group. While 
these experiments present a proof of concept model implementation only, 
inverse clinical trial simulation can be adapted to more complex model forms 
given suitable data availability.  
Some limitations clearly apply: Parameterisation of the ‘inverse clinical 
trial model’ was obtained from the literature in the absence of other sources. 
Ideally, these parameters should be obtained via model training with sets of 
data from diverse clinical sources, which are yet lacking. The present 
framework may nevertheless be used to derive comparatively safe ranges of 
immune system degradation and interruption duration, which may stimulate 
further effort to reduce patient drug burden through structured treatment 
interruptions.  
In methodological terms, population distributions for the ‘trial model’ are 
assumed Normal, while for STI studies, the Lognormal distribution or other 





Further, while the mechanistic model developed for this study is simplistic 
compared to other existing approaches (such as the LT-model), the present 
framework offers a valid compromise between realism and computational 
costs; the latter are non-trivial, given run times needed for coverage of the 
parameter space.  
In summary, while further experimentation is clearly needed, this study 
has demonstrated the potential of the Inverse Monte Carlo approach for 
clinical trial simulation and offers a basis for examining the parameter space 






8 Conclusions and Further Work 
8.1 Summary and Conclusions 
In this thesis, I describe how computational models may be used to assess the 
potential harm of HIV treatment interruptions on multiple levels. First, I 
proposed a Cellular Automata-model to study localised collagen build-up 
effects in long-term progression of HIV infection in lymphatic tissues under 
antiretroviral treatment. To construct this novel model, I partly followed 
established approaches (e.g. (Zorzenon dos Santos and Coutinho, 2001)), 
incorporating infectivity in stochastic, rather than deterministic, terms and 
taking into account the neighbourhood of affected cells.  
This SCA model permits an in-depth investigation of patterns of treatment 
interruptions. While preserving a simple rule structure, many effects observed 
during chronic HIV infection can be reproduced and (indirect) quantification 
of naïve T-cell populations achieved. For specifications corresponding 
variously to non-treatment, continuous treatment and interrupted treatment, 
the results from the model were found to be in line with those obtained from 
clinical observations. 
Furthermore, using a modified version of the SCA model (CM model) 
which allows for a certain degree of cellular motility, I investigated the 
contribution of localised effects on the long-term progression of tissue 
collagenation. Findings indicate a marked contribution of the latter, giving 
direction to further clinical experiments. Further, the localised effects, 
observed in the numerical simulation experiments, suggest that infection 
affects lymphatic tissues through growth of infected cell clusters, (which act 
as a kind of ‘memory’ during phases of simulated treatment). This aspect of 
tissue damage acting as a permanent bias against immune recovery is 
especially interesting since clinical evidence suggests a high degree of inter-





2012c). However, only limited evidence exists that this feature has been 
directly considered in mathematical and computational modelling to date, 
(Bogle and Dunbar, 2012; Donovan and Lythe, 2016). 
In terms of the lymphatic tissue damage which is central to my research 
there have been recent attempts to delay harmful effects of HIV infection by 
employing a new class of medication in clinical settings. These drugs do not 
interfere with HIV directly but prevent the scarring of lymphatic tissues. The 
evidence from recent animal studies, (Estes et al., 2015), suggest that this 
approach could be a potential additional countermeasure in the arsenal against 
HIV, and one for which a detailed model could be useful for quantification.  
Given controversial results from past clinical studies regarding structured 
treatment interruptions, I also developed a discrete computational model to 
analyse study outcomes at population level. Using Inverse Bayesian 
inference, it was possible to draw conclusions on pre-existing immune system 
impairment of the study population which was not considered in the original 
study.  
Further clinical studies on the spatial distribution of HIV infection inside 
specific anatomic regions and tissues could provide valuable data to refine 
model parametrisation and enable model prediction. Samples obtained from 
lymphatic tissues originating in distinct parts of the body may provide a better 
basis for evaluating disease status and prognosis than the blood samples, 
which are typically used, (although such an invasive technique is an obvious 
disadvantage where samples are required on a repeated basis). 
In terms of treatment initiation and interruption, results suggest that the 
timing of treatment initiation is crucial in terms of its impact on the tolerance 
to subsequent interruptions. With respect to these, my results reinforce the 
clinical view that pre-existing immune system damage needs to be considered 
more fully than has hitherto been the case, (Hirschel and Flanigan, 2009),  in 





In general, my research shows that a model with simple rules and emphasis 
on spatial localisation can reproduce a wide range of clinical phenomena 
associated with HIV and antiretroviral therapy. Ideally, future emphasis in 
clinical research on these localised effects to provide e.g. better targeted drug 
delivery may improve therapy protocols and enable further empirical basis 
for model refinement and feedback.  
8.2 Future Work 
The stochastic model designed for this study can be used to study multiple 
effects associated with HIV treatment despite its simplicity. However, a 
model which has a solid foundation in the biology of lymphatic tissue, as 
exemplified, (Donovan and Lythe, 2016), is clearly desirable. One point to 
address in such extended studies may be that a Moore neighbourhood in a 
two-dimensional space allows only a limited view of the three-dimensional 
network of (real) lymphatic tissues. Moreover, recent clinical evidence 
employing 2-photon microscopy has shown that T-lymphocytes manifest a 
high degree of motility inside lymphatic tissues, (Mempel et al., 2004) and 
incorporation of this movement would facilitate more realistic representation. 
The computational requirements for these refinements would include 
utilisation of parallelisation methods on modern HPC architectures, for which 
some guidelines were given. Moreover, while the M-H algorithm is well-
known and widely used, alternatives may also provide more efficient 
approximation, not least as patient drop-out is common in clinical studies. 
Hence there is a need for the ‘inverse clinical trial model’ to take data 
censoring more explicitly into account through implementation of more 
sophisticated algorithms and this is a focus of further experiments.  
Further quantification of the dependence of treatment interruption 
tolerance on treatment initiation times is clearly necessary. As stated in the 





influence in diverse patient populations is vital to deduce measures for 
healthcare agencies, as well as to support patient respite (so-called ‘drug 
holidays’). Short-term interruptions appear to have no lasting effects on the 
immune system capability, (Rothenberger et al., 2015). However, assessing 
the long-term effects of such breaks could be addressed by my model to 
determine a margin of error for missed doses, within which interruptions 
might still be considered as safe. Given that clinical data supporting 
investigation of this topic have been found to be sparse and largely outdated, 
(Hillmann et al., 2017a), stochastic generation of synthetic data should also 
be explored and its reliability evaluated. The potential of such synthetic data 
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Appendix A The Human Immune System 
As a complex system involving a multitude of different components with 
emergent and adaptive properties, the immune system has been subject to 
extensive research, (Nagy, 2014) but is still not well understood in many 
parts. This section gives a brief overview on the principal components and 
their known properties. For more detailed explanation, the reader is referred 
to an appropriate textbook, e.g. (Parham, 2009).  
Clearly the purpose of the immune system is to provide protection and 
defence of the organism against pathogens attacking either from outside (e.g. 
infections) or inside (such as cancers). Any factor foreign to the organism, 
which is recognised by the immune system is called an Antigen in 
immunology terminology. This term is mostly associated with a pathogen, 
such as virus particles or specific structures on the surface of a pathogenic 
cell but may also be connected to non-pathogenic substances, e.g. in case of 
allergies.  
The passage of pathogens into critical parts of the organism is firstly 
impeded by multiple epithelial and mucosal barriers. Apart from these static 
preventive measures, defence is concentrated in certain mobile components, 
circulating in the body fluids. These are classified into Cell-mediated and 
Humoral (non-cellular) immunity. Alternatively, immune system 
components are classified by how they deal with infections, e.g. whether they 
act either in an immediate (within minutes) but unspecific manner or are 
selective to certain pathogens on a longer time scale (days), the former known 
as innate, the latter known as adaptive immunity. The components and the 
properties of these two classes are listed here, a description of their 





A.1 Innate Immunity  
The first layer of defence is provided by mechanical and physiological 
barriers. This layer aims to prevent intrusion of antigen into the organism. It 
covers the surface exposed to the environment, namely the skin, the mucous 
membranes, (which line the digestive and respiratory systems and the 
urogenital tract). These boundaries are populated by immune cells or 
substances but also by foreign microorganisms. These symbiotic organisms 
feed from by-products of the organism and displace potential pathogens.  
Pathogens may pass these barriers through wounds or damaged mucosal 
tissue. This intrusion of antigen causes an early response by a protein class 
called cytokines which are released at the infection site by effector cells. 
Cytokines are considered the cause of inflammation symptoms e.g. local pain 
and swelling around the infection site, which facilitates the influx of immune 
cells and promotes immune response.  
The Complement System is an effective part of the innate immune system, 
which consists of a set of proteins which bind to pathogens in an unspecific 
way. When discovered, this component was assumed to be ‘complementing’ 
the parts of the adaptive immune response. The binding to pathogen acts as a 
beacon, which attracts immune cells and promotes phagocytosis. The 
membrane-bound proteins also cause damage to bacterial membrane 
structure, leading to perforation and lysis of the pathogen. Apart from 
mechanical and soluble immune factors, the immune system consists of 
various types of cellular components (see Figure A.1) with both innate and 






Figure A.1: Cellular components of the immune system. Figure shows differentiation paths from 
common multipotent stem cells, which propagate in the bone marrow. Myeloid (Greek ‘bone marrow’) 
precursor cells (left) form red blood cells and thrombocytes as well as cellular components of the innate 
immune system. Right path leads to lymphoid cells which need lymphoid organs for maturation and 
form the components of the adaptive immune system.  
Image Source: Rad, A. and Häggström, M. (2009) Simplified hematopoiesis, Wikimedia Commons, the 
free media repository. Available at: https://commons.wikimedia.org/wiki/ 
File:Hematopoiesis_(human)_diagram.png (Accessed: 27 May 2020). Use permitted under the 
Creative Commons Attribution License CC BY-SA (http://creativecommons.org/licenses/by-sa/3.0/) 
 
Phagocytes are involved in direct attack on pathogens of foreign origin. 
Antigen is engulfed by the plasma membrane of the immune cells and 
digested inside. Cells in this category are Macrophages, which reside in 
tissues or Monocytes, equivalently, in blood. Another type of cells, Dendritic 
Cells, have a large surface area to collect Antigen from the environment and 
‘present’ it to cells of the adaptive immune system. This capability is shared 
also by Macrophages and B-Cells from the adaptive immune system. 
A type of Phagocytes, which does not target foreign antigen are Natural 





which lack certain recognised characteristics. This may be the case for 
cancerous or infected cells for which Natural Killer Cells induce apoptosis16.  
Granulocytes contain inclusion bodies (‘granules’) consisting of cytotoxic 
substances, which are released near potential pathogen. Beside this function 
they also play a role in immune regulation and Antigen presentation. Cell 
types in this category are Basophils, Eonophils and Neutrophils. 
Mast Cells act similar to the Granulocyte type of Basophils, but appear in 
outward tissue, such as skin and mucosa, rather than in blood. They are 
activated when exposed to the external environment e.g. due to a wound and 
release cytotoxic and inflammatory signals. Due to their exposure to external 
substances which may be potential antigens, they are also involved in allergic 
reactions, e.g. hay fever. 
A.2 Adaptive Immunity 
The ability to adapt to infections of known pathogens and to improve response 
upon reinfection is central to the immune system. An important role in 
adaptive immune response is played by lymphocytes, commonly named 
‘white blood cells’. These mainly reside in the lymphatic organs after their 
formation in the blood marrow, hence their name. HIV infection has major 
implications for these cells. Commonly, there are two types of Lymphocytes, 
B and T (see Figure A.1). The letters indicate the place where the cells mature, 
bone marrow or thymus. The B-Lymphocytes are able to secrete a large 
number of immune globulins upon activation (as Plasma cells). These 
proteins, also termed ‘antibodies’ have high specificity to certain antigen. 
This binding enhances attraction of other parts of the immune system and 
 
 
16 Apoptosis stands for a variety molecular pathway cascades inside a cell, which lead to 
eventual destruction of the cell. Induction of apoptosis may originate from external factors 
like Killer cells, but can also be initiated by the cell, e.g. when vital components like DNA 





phagocytosis. Activation of B-Lymphocytes and formation of secreting 
Plasma cells is a comparatively slow process, taking several days. However, 
immune response is effective and long-lived Plasma cells remain in the 
organisms after infection with much shorter re-activation time, forming a kind 
of ‘immune memory’.  
For T-Lymphocytes there are two types, which are most common, and 
which have different functions. T-helper cells play an essential role in 
immune response mediation between the innate and the adaptive system and 
for the immune memory. On their surface they have receptors17 of certain 
types, which are important for their function. According to the receptor, these 
cells are called CD4 positive T-cells or CD4+. 
The other type of T-Lymphocytes has a cytotoxic effect. The signalling 
receptor which is central to their functionality is named CD8 (hence CD8+ 
cells). These cells need activation through the CD4+ cells. Interdependencies 
of different components of the cellular immune system are described in the 




17 These receptors are typically proteins in conjunction with carbohydrates (glycoproteins) 
with a specific 3-dimensional structure allowing specific other macromolecules to dock, 





A.2.1 Lymphatic System 
The lymphatic system consists of a widespread network of ducts throughout 
the whole body (see Figure A.2). Unlike the blood stream, movement of fluid 
(the lymph) is not controlled by a central pumping organ, but though 
mechanical and osmotic processes of the single lymphatic organs, (Margaris 
and Black, 2012; Swartz, 2001).  
 
Figure A.2: Lymphatic system (female) with principal organs. Nodes and ducts forming the 
lymphatic network coloured green. 
Image source: Blausen.com staff (2014) ‘Medical gallery of Blausen Medical 2014’, WikiJournal of 
Medicine, 1(2). doi: 10.15347/wjm/2014.010. Use permitted under the Creative Commons Attribution 
License CC BY (https://creativecommons.org/licenses/by/4.0/) 
 
Physiologically, this system allows excess water in tissues to be collected 
and returned to the blood stream. Along with the lymph nodes it acts as a filter 





lymph fluid enters a node through specific vessels and passes through the 
mesh structured tissue to leave the node through effluent vessels (see Figure 
A.3).  
Lymph nodes enable a prolonged contact of the fluid with immune cells 
through a slow flow rate of the lymph which contrasts with fast-flowing blood 
circulation. The system does not act as a filter against toxins as this function 
is covered by the liver and kidneys. The spleen is also acting as a lymph node. 
In recent years technologies like two-photon microscopy have enabled a 
better insight into the movement of immune cells inside the lymph nodes 
(Germain et al., 2012). 
 
Figure A.3: Schematic of a lymph node. Lymph entering the node through afferent vessels flows 
slowly through the reticular network (enlarged portion), enabling lymphocyte contact with stromal cells 
before leaving the node through afferent vessels.  
Image Source: KC Panchal (2008) Schematic_of_lymph_node_showing_lymph_sinuses, Wikimedia 
Commons, the free media repository. Available at: https://commons.wikimedia.org/wiki/ 
File:Schematic_of_lymph_node_showing_lymph_sinuses.svg (Accessed: 27 May 2020). Use 






A.2.2 Maturation of Immune Cells 
All immune cells are generated and continuously replenished from 
pluripotent stem cells in the bone marrow (see Figure 1). Depending on the 
type of immature immune cells their respective receptors (T-cell or B-cell) 
gain a random conformation. The immature cells undergo a process of 
positive and negative selection in the thymus (T-cell) or bone marrow (B-
cells) through exposure to self-antigens18. Cells for which receptor bindings 
to those antigens are too weak or too strong are removed through apoptosis. 
The first process ensures that only cells with functional receptors remain 
(positive selection) where the second process prevents autoimmune reactions. 
This second process is called self- non-self-discrimination19.  
A.2.3 Immune Activation 
Immature immune cells which undergo the selection process are typically 
resident in the lymph nodes. These become activated when encountering an 
antigen matching their respective receptor conformation (see Figure A.4 for 
a schematic). The receptor binds to the antigen non-covalent with weak van-
der-Waals force maintaining a stable connection if the contact area is large 
enough. T-cell receptors do not bind to antigen in their environment but are 
‘presented’ by other cells bound to specific macromolecules (Major 
Histocompatibitily Complex MHC) on their surface. MHC can be 
differentiated into types 1 and 2. Type 1 occurs on the surface of every cell in 
the organism and presents fragments of proteins coming from inside the cell. 
These may be self-antigens from the cells own protein repertoire but also 
virus fragments in case the cell has been infected. MHC type 1 bound antigen 
 
 
18 These may be any part of the organism (e.g. proteins on the surface of cells) which is 
recognized as antigen by the immune system. 





is recognized by CD8 receptor of cytotoxic T-cells. When binding is strong 
enough, cells become activated. 
MHC type 2 appear on the surface of specific antigen presenting cells 
APC. These may be dendritic cells, macrophages or B-cells. These types of 
cells typically obtain antigen from their neighbourhood, which is digested, 
and fragments are presented via MHC type 2. The cells do not distinguish 
between antigens coming from the organism itself or from infected cells. 
Macrophages and dendritic cells pick up antigens without specificity where 
B-cells are specific to antigens matching their receptor conformation.  
The MHC type 2 are necessary for activation of T-helper cells and binds 
to their CD4 receptor. Activated T-helper cells may proliferate, attract other 
immune cells, become memory cells or activate B-cells in turn. Activated B-
cells may proliferate and develop to plasma cells which disseminate 
antibodies. The binding sites of these antibodies are identical to the B-cell 
receptor of the respective cell.  
Activated immune cells proliferate through cell division which leads to a 
progeny with identical genetic setup. Stimulation of B-cells becomes stronger 
the more receptors are bound to antigen. This process is called cross linking, 
it also suppresses stimulation if too many receptors are bound. Upon 
proliferation of activated B-cells, random mutations are introduced at specific 
sites encoding the shape of the receptor and antibody. These modifications 
may lead to a higher antigen binding affinity and stronger proliferation of 
these clonotypes in turn. Applying Darwinian principles, one can say these 






Figure A.4: Immune cell activation and parts of the cellular immune response; B-cell response (top), 
macrophage activation (middle) and T-cell / CD8+ response (bottom). 
Image Source: Häggström, M. (2014) ‘Medical gallery of Mikael Häggström 2014’, WikiJournal of 
Medicine, 1(2). doi: 10.15347/wjm/2014.008. Use permitted, public domain. 
 
A.2.4 Immune Memory 
Even after infection these clonotypes can persist through a process of self-
renewal as memory T- and B-cells. Activation of these in the presence of 
antigens is faster than that of naïve cells which increases efficiency of the 
immune system in case of a re-infection. The total number of immune cells 
in the organism is limited. During the lifetime of an organism, the proportion 
of mature memory immune cells which are specific against certain epitopes 
is increasing against naïve cells. Self/non-self-discrimination is a central 
aspect in immune theory in explaining how autoimmune reactions are 
suppressed. There have been different approaches to explain this behaviour, 
one of them is Danger Theory, (Matzinger, 1994), which postulates that 
immune reactions are triggered exclusively through danger signals which are 
sent out by distressed cells in case of an infection. This would eliminate the 
need for self-non-self-discrimination. However, whether the theory describes 
all observable immune reactions in this context sufficiently, is still under 





Appendix B Antiretroviral Drug Regimen 
Drugs are commonly mentioned with their abbreviations in the literature. 
























(only given in combination 


















TDF + 3TC (or FTC) + EFV 
 
Alternatives, if primary not available: 
AZT + 3TC + EFV  
AZT + 3TC + NVP  
TDF + 3TC (or FTC) + NVP 
 
Primary recommendation: 
AZT + 3TC + LPV/r 
AZT + 3TC + ATV/r 
 
Secondary recommendation: 
TDF + 3TC (or FTC) + ATV/r 






Appendix C Alternative Model Formalisms 
C.1 P-Systems 
P-Systems were introduced by Gheorges Păun as a form of biological 
computing, (Păun, 2000) and are constructed similar to a biological cell with 
organelles, membranes arranged in a nested manner. This leads to the 
formation as a set of compartments which are arranged hierarchically. The 
membranes may contain objects, which are symbols or character sequences 
in the original concept and where membranes and objects form a super-cell. 
Objects can evolve according to a set of rules, which are assigned to the 
different compartments of the membranes. Rules apply only to the objects, 
which are currently in the respective compartment, i.e. for certain object 
configurations in the membrane compartment for which it is valid. Rules may 
cause objects to evolve (be changed) or to be moved into another membrane 
compartment, (parent or child) of the hierarchy. Modification of the 
membrane structure is also rules-based, where new membrane compartments 
can be created from a parent or existing membranes can be dissolved. In the 
latter case the contents of the dissolved membrane (objects and membranes) 
are now members of the parent membrane compartment.  
In the original concept, the rules for the various compartment levels are 
executed in parallel with prioritisation to avoid conflicts. This approach has 
been criticized as not conforming to biological systems. To overcome this, 
rule execution directed by a Gillespie algorithm has been suggested, 
(Romero-Campero et al., 2009; Spicher et al., 2008), leading to stochastic P-
systems. However, the original assumption for the Gillespie algorithm of a 
well-mixed compartment does not reflect interaction between the different 





Objects were originally assumed to take the form of strings. The intention 
was to mimic the modification and mutation of DNA-fragments, (Păun, 
2000). However, this approach makes modelling of quantities difficult, so 
conformon P-systems were introduced, (Frisco, 2004). Conformons represent 
name-value combinations and they make up the objects in the P-system. The 
P-system rules may modify the values of the conformons in the respective 
compartment and move them to different membranes depending on their 
names or values. This may be used to model quantities of biochemical 
substances inside a cell. Applications of conformon P-systems also include 
immune system simulation, (Corne and Frisco, 2008). 
C.2 State Charts 
State Charts have been developed as a means to describe finite state machines, 
which are used for complex concurrent systems in an easily conceivable 
manner relating them to process algebras and petri nets. Introduced by Harel, 
(Harel, 1987), state charts presented an approach to develop and visualize 
complex technical systems like aircraft and automotive controls in a 
descriptive but formal manner. Subsequently state charts have been adapted 
to model immune system dynamics, (Kam et al., 2001). The state chart itself 
is not executable. To build a working model it has to be translated back into 
the corresponding finite state machine, which may then be implemented using 
a model formalism such as a system of ODEs. Their characteristics make state 
charts more of a meta modelling formalism, i.e. a way of visualizing another 
formalism. 
Newer modelling approaches involve rule-based modelling, (Gruenert et 
al., 2010), where entities which obey relatively simple rules interact to 
produce emergent complex structures. Typically, these are used for protein 






C.3 Shape Space 
Network based theories were developed in the 1970s after initial discoveries 
on immune mechanisms and the complex interactions between the different 
elements. The idiotypic network theory was introduced by Niels Jerne, (Jerne, 
1974), and aimed at answering questions on the way in which the immune 
system emerges from a naïve to mature state where certain ‘non self’ antigens 
cause immune reactions, (while others are tolerated) and what prevents the 
immune system from attacking parts of its own organism. The central idea 
was that the immune system basically does not distinguish between self and 
non-self and each component may react with each other, so everything is an 
antigen. An antigen region, which may be part of the immune system or the 
organism or some foreign substance, recognised by the immune system, is 
termed an idiotype. Constant interaction occurs between elements of humoral 
and cellular immune defence and antigens, which causes either stimulation, 
suppression or death of both self- and non-self-antigen. The interaction is 2-
way so the approach is also designated ‘symmetrical’ network theory.  
The shape space concept, (Perelson and Oster, 1979), presents a way to 
describe this large number of idiotypes and their emergence. Each idiotype is 
represented by a bit string of length N, therefore it has a location in a space 
of N dimensions. The closer two idiotypes are in shape space, the similar their 
basic shape. Interactions can be described by drawing a radius around a point 
in shape space in which other idiotypes have to be located in order to interact.  
The overall concept has been applied to the wide range of immune 
reactions and was quite successful in describing autoimmune diseases, 
(Hoffmann, 2007), as well as the way which repeated infection with the same 
antigen changes immune response (secondary response). The shape-space 
model has also been applied to HIV infection, (Hershberg et al., 2001), and 
can be used to illustrate the high mutation rate of the virus with rapid shifts 





The optimal length of N and therefore dimensionality of shape space or its 
validity for real biochemical reactions is not yet finally resolved, (Carneiro 
and Stewart, 1994; McEwan and Hart, 2009). Moreover, the immune network 
modes failed to describe all complex interactions occurring in the immune 
system, (Murphy et al., 1976), which led to some loss of popularity. 
Additionally spatial aspects, which have implications for immunological 
performance, (Graw and Perelson, 2013), are completely neglected. To deal 
with this aspect, hybrid models involving also physical space were also 
developed, (Burns and Ruskin, 2004; Papa and Tsallis, 1996).  
C.4 Stochastic Simulations 
The Gillespie algorithm, (Gillespie, 2007), offers an interesting way of 
combining rate equations with stochastic discrete reaction events, instead of 
assuming reaction rates as for a deterministic set of ODEs. The algorithm was 
developed for chemical reaction kinetics in well mixed compartments, 
(Gillespie, 1976), and originates from thermodynamics. The model omits any 
other effects which may influence the reactants, such as collisions with the 
reaction vessel. A model run for a set of chemical reactions starts from an 
initial number of reactant molecules for which the next reaction occurring is 
randomly chosen. The probabilities for the reactions to occur depend on the 
state of the system and are updated at each step, together with the number of 
molecules, with time to the next reaction selected at random. 
This algorithm approximates an ODE system while obtaining more 
information on system characteristics. In its basic form, the Gillespie 
algorithm is computationally expensive, but has been improved through 
optimisation algorithms like tau leaping, (Link et al., 2012). The algorithm 
has also gained popularity for use in hybrid models, (Romero-Campero et al., 
2009; Spicher et al., 2008), and has been incorporated into immune system 





C.5 Boolean Networks and Petri Nets 
Boolean networks, (Albert and Wang, 2009; Kauffman, 1969), and Petri 
nets, (Chaouiya, 2007; Murata, 1989), are also a commonly used formalism 
originally intended to study genetic regulation networks. Both graph-based 
these can improve visualisation capability. Due to their simple rules they are 




Figure C.1: State space of a Boolean network with N=4 nodes and K=1 links per node.  
Image Source: Hou710 / (2014) Boolean Network, Wikimedia Commons, the free media repository. 
Available at: https://commons.wikimedia.org/wiki/File:Hou710_BooleanNetwork.svg (Accessed: 27 
May 2020). Use permitted under the Creative Commons Attribution License CC BY-SA 
(https://creativecommons.org/licenses/by-sa/4.0) 
 
The setup of a Boolean network consists of a graph with N Boolean 
variables which form the nodes, and which have K directed links each as 
edges. In the case of a Random Boolean Network, the links are arranged 





the output node. Nodes are assigned with an initial state pattern and the model 
is run. At each discrete time step, the states of the Boolean variables are 
changed according to the input node connected by the link. The simulation is 
run until the network reaches a static or periodic final state. Obtaining the 
state space for all possible initial states gives tree-like structures which 
resemble biological reaction networks, (see Figure C.1). Despite the simple 
setup the state space can become very complex. Boolean networks are 
therefore related to cellular automata. They have been successfully applied to 
biochemical network modelling, (Albert and Wang, 2009). 
Petri nets, (Petri, 1962), first suggested as a model for chemical reactions 
are related to the process algebras but feature two distinct node types, places 
and transitions. Places can only be connected via a transition and vice versa. 
These connections are typically directed (place – transitions – place) and have 
a certain weight assigned. In the original concept places may contain a 
number of ‘tokens’. If all places, which act as an input to a transition have 
equal or more tokens than the weight of their respective connection, the 
transitions ‘fires’. The number of tokens of the input places is then reduced 
by the weight of their connection. Correspondingly, the number of tokens of 
the places acting as output to the transition is decreased by the value of 
weights of the output connections (see Figure C.2 for an example). These 
elements allow building of complex networks. Evaluation of token number of 
places and firing of transitions occur at discrete time intervals and for the 
whole network in parallel. This concept has been used for biological 







Figure C.2: Petri net with 4 nodes and 1 transition shown before and after transitions ‘fires’.  
Image Source: Le blue (2014) Petrinet_transition_example, Wikimedia Commons, the free media 
repository. Available at: https://commons.wikimedia.org/wiki/File:Petrinet_transition_example.svg 
(Accessed: 27 May 2020). Use permitted under the Creative Commons Attribution License CC BY-SA 
(https://creativecommons.org/licenses/by-sa/4.0) 
 
C.6 Cellular Potts 
Cellular Potts had been introduced as a modification of the large-Q Potts 
models for simulation of aggregate formations on cells, (Graner and Glazier, 
1992). The basic model is derived from thermodynamics where it is used to 
simulate ferromagnetism. Essentially these models are a special case of CA 
where an agent is not represented by a single cell but by continuous 
compartments on a lattice. These cell ‘shapes’ are allowed to change 
depending on their surface energy. This allows a better representation of 
biological reality than dealing with single lattice sites and cell –cell contacts 
can be examined more realistically. The concept has been applied to the 
motility of T-cells inside lymph nodes, (Beltman et al., 2007). However, 





Appendix D The ZdSC Model 
The initial model followed a set of 4 rules in a square lattice with Moore 
neighborhood and periodic boundary conditions. Cells may have four states: 
healthy (H), infected A1, infected A2 and dead (D). 
The rules were therefore set as following: 
Rule 1: Healthy cells H may become infected A1 
- With at least 1 infected A1 cell in the neighborhood 
- With at least r (2 < r < 8) infected A2 cells in the neighborhood 
Rule 2: Infected A1 becomes infected A2 after tau timesteps 
Rule 3: Infected A2 cells become dead cells D 
Rule 4: Dead cells D become H with probability Preg, otherwise stay dead 
- Regenerated cells become infected A2 with probability Pinf 
In this setting, the state of a cell in the next step is determined by the states of 
its surrounding cells. There is no active influence of a cell on its neighbors. 
Therefore, the sequence of cell updates is not relevant and may occur 
synchronously. On a spatial level, the model shows a characteristic behavior 
of waves of infected cells progressing over the lattice during the simulated 
chronic phase of HIV, eventually covering it, which corresponds to the AIDS 
phase. Each discrete step (in which all cells are updated) corresponds to 
roughly a week in real time. With this set of model parameters it is possible 







Figure D.1: Simulation of the HIV time-course using the ZdSC model (50 runs averaged).. Time 
step on x-axis corresponds to 1 week in real time, y-axis represents absolute values of cell states 






Appendix E STI Studies in chronological order 
 
Study name/ref (Davey et al., 1999) 
Start, end 1999 
Type One interruption 
Aim Examine viral rebounds 
Size 18 treatment experienced patients 
Conclusion Long term suppression does not lead to viral control 
 
Study name/ref (Rosenberg et al., 2000) 
Start, end 2000 
Type One or more interruption 
Aim Examine difference of treatment initiation on immune control 
Size 16 treated with acute HIV, 6 untreated control, 12 treated with chronic infection  
Conclusion Early treatment initiation improved viral control 
 
Study name/ref Autovac (Ruiz et al., 2001, 2000) 
Start, end 2000 
Type Fixed cycle; three interruptions for 30 days (or until high rebound) with 90 days 
interval 
Aim Investigate immune response and potiential immune boost of STIs 
Size 12 patients with undetectable viral load, 14 control group 
Conclusion Increase of CD8 during interruption, no adverse effects 
 
Study name/ref (García et al., 2001) 
Start, end 2001 
Type Viral load guided; starting point VL < 20 cp/ml, interruption until VL > 200 
cp/ml, interruption until vl > 200 cp/ml lasted 4 weeks, no reintroduction 
Aim Analyse viral rebounds and investigate immune response 
Size 10 chronically infected patients with VL < 20 cp/ml for at least 1 year 
Conclusion Approach is relatively safe in terms of recovery after reintroduction 
 
Study name/ref (Dybul et al., 2001) 
Start, end 2001 
Type Fixed cycle; one week on – one week off for 52 weeks 
Aim Demonstrate proof of concept of feasibility of 50% reduction 
Size 10 treatment experienced patients (initiation in chronic phase?) 
Conclusion Viral suppression could be maintained in blood and lymph tissue 
 
Study name/ref (Hammer et al., 2002) 
Start, end 2002 
Type Salvage therapy 
Aim Assess efficacy of regimen modification (PI) after virological failure 
Size 481 patients with VL > 1000 cp/ml and prior exposure to 3 PIs 






Study name/ref (Dybul et al., 2003) 
Start, end 2003 
Type Fixed cycle; 4 weeks off – 8 weeks on for 48 weeks 
Aim Proof of immune boosting effect and reduction of toxicity for STI 
Size 26 treatment experienced patients 26 control group 
Conclusion No hints for immune boost or reduction of toxicity. Resistance mutations in 5 
patients on STI. 
 
Study name/ref (Fagard et al., 2003; Oxenius et al., 2002) 
Start, end 2002 
Type Fixed cycle; 2 weeks off – 8 weeks on for 40 weeks 
Aim Proof of immune control 
Size 133 treatment experienced patients 
Conclusion Correlation between patients peak viral load to pre- treatment loads, evidence of 
beneficial effect of therapy introduction during primary infection. No hints of 
immune stimulating effects. No adverse effects. 
 
Study name/ref Swiss Spanish intermittent treatment trial (Fischer et al., 2003) 
Start, end 2003 
Type Fixed cycle; 1 week on 1 week off, longer period interruption after 5th cycle 
Aim Verify Dybul’s trial 1(Dybul et al., 2001) 
Size 14 treatment experienced patients 
Conclusion Viral rebound significant at day 8, drug resistant mutations detected. Dybul’s 
results not confirmed 
 
Study name/ref (Acosta et al., 2004) 
Start, end 2002 
Type Pharmacokinetic comparison of two regimens 
Aim Determine pharmacokinetic parameters 
Size 44 HIV-infected patients with VL between 500 and 100.000 cp/ml within 45 
days of study entry. 
Conclusion Similar tolerability and response rates 
 
Study name/ref Staccato (Benson, 2006) 
Start, end 2006 
Type CD4 guided 350/ul on, 350/ul off 
Aim  
Size Patients were therapy naïve and treated to suppression.284 CD4 guided, 146 
control group for 96 weeks.  
+ 1 week on 1 week off (discontinued due to virologic failure) 
Conclusion No adverse effects found 
 
Study name Trivacan (Benson, 2006) 
Start, end 2006 
Type CD4 guided 250 on, 350 off (+ fixed cycle) 
Aim  
Size 216 Therapy naïve patients treated to CD4 count of 350 and < 300 virus, (325 
patients 4 months on 2 months off fixed cycle), 110 control group 







Study name/ref SMART (El-Sadr et al., 2006) 
Start, end 2006 
Type CD4 guided 250 on, 350 off 
Aim  
Size 5472 patients (not clear how weighted, 1.1?) with CD4 counts of 350/ul and 
above (aim was 3000 + 3000 control) immune functions already impaired, 
short follow up, (Hirschel and Flanigan, 2009). 
Conclusion CD4 guided trial terminated due to increased frequency of Aids and non-
Aids related diseases in the STI group 
Biggest study so far, results widely accepted, lead to recommendations for 
continuous ART. 
 
Study name/ref Window (Benson, 2006) 
Start, end 2006 
Type Fixed cycle 8 weeks on 8 weeks off (for 96 weeks?) 
Aim  
Size 200 patients with CD4 of 450 and above and virus RNA below 200 for STI, 203 
control group 
Conclusion STI noninferior but lower CD4 counts in STI group no increased drug resistance. 
 
Study name/ref ISS/Part (Benson, 2006) 
Start, end 2006 
Type Fixed cycle 1,1,2,2,3 months of interruption with alternating 3 months of therapy 
Aim  
Size 136 STI, 137 control group 
Conclusion Higher CD4 count in control group after 24 months, increased rate of resistance 
mutations in STI group 
 
Study name/ref LOTTI (Maggiolo et al., 2009) 
Start, end  
Type CD4 guided, 700 ul and not detectable virus (<50) off, below 350 on 
Aim  
Size 165 STI, 164 control group, patients with preserved immune function 
Conclusion STI was not inferior, recommendation to preserve immune function by keeping 
CD4 counts up, obtain safety limits – STI much less costly 
 
Study name/ref SPARTAC (Fidler et al., 2013) 
Start, end 2003-2010 
Type Treatment removal after 48 weeks, 12 weeks or no treatment at all. Re- initiation 
when CD4 dropped below 350. 
Aim Also investigate HIV DNA, (Williams et al., 2014) 
Size 123 patients with primary HIV infection with removal after 48 weeks, 120 after 
12 weeks, 123 no treatment. Patients had not detectable virus for at least 6 
months prior study. 








Study name/ref STOPAR (Imaz et al., 2013) 
Start, end 2004 - 2008 
Type CD4 guided, 500/ul and no detectable virus (for 3 months) off, below 350 on 
Aim  
Size 56 treatment interruption 50 control patients with preserved immune function 
(85 per arm were planned but enrolment was stopped due to outcomes of 
SMART study) 







Appendix F SMART and LOTTI Comparison 
  SMART  
(El-Sadr et al. 
2006) 
LOTTI  
(Maggiolo et al. 
2009) 
Baseline CD4 – up limit [cells/ul] 350 700 








[cells/ul]   > 200 
Follow-up times [months] 1, 2, 4, 6, 8, 10, 
12, 16, 20, … 
1, 2, 4, 8, 12, ... 
Avg. follow up [months] 16 51 
Max follow up [months] 44 >51 







cond. Hosp.  




not req. hosp./ 
grade 3,4 adv 







Appendix G Glossary 
Acquired Immunodeficiency Syndrome (AIDS): General term for clinical 
symptoms indicating the terminal stage of HIV-infection. 
Adherence: Measure on how well a patient adheres to a prescribed treatment. 
Antigen: Molecular structure (usually on the surface of pathogens) which 
trigger an immune response. 
Antiretroviral therapy (ART): General term for treatment of HIV 
infections. Current recommendation is Highly Active ART (HAART), a 
variant of combination ART (cART). 
CD4+ T-helper lymphocytes: White blood cells with specific receptors 
(CD4) on their surface. Responsible for immune recognition of antigen and 
activation of effector cells. The CD4 receptor is also binding site for HIV, 
hence these cells are main target of the virus. 
CD8+ T-effector/cytotoxic lymphocytes: White blood cells with CD8 
receptors on their surface. These cells cause an immune response by killing 
pathogen or infected cells after being activated by CD4+ T-Lymphocytes.  
Collagen: Protein fibres which form main component of connective tissues, 
do not have physiological function otherwise. 
Cytokines: Proteins serving as chemical signalling between cells. Substances 
excreted by cells are bound by specific receptors on the surface of other cells, 
triggering certain biological processes. 
Deoxyribonucleic acid (DNA): Macromolecule containing all genetic 
information of any living cell. Usually located in highly condensed form in 





Fibroblastic Reticular Cell (FRC): Specific cell type residing in lymph 
nodes on connective tissue. Crucial function for stability of the immune 
system has been identified only recently. 
Fibrosis: Pathogenic alteration of tissue structure, where functional tissue is 
replaced by connectivity tissue mainly consisting of collagen fibres. 
Commonly occurring due to inflammation processes or injuries (e.g. scar 
tissue). 
High Endothelial Venules (HEVs): Specialised blood vessels in lymphatic 
organs which serve as a connection to the blood circulation and enable entry 
of T-cells and antigen. 
Homeostasis: Ability of the immune system to maintain stability, e.g. steady 
levels of immune cells in blood, and to provide effective immune response 
when challenged with pathogen. 
Human Immunodeficiency Virus (HIV): Virus with unique properties able 
to evade the human immune system and causing a slowly progressing 
infection, ultimately causing lethal AIDS disease. 
Interleukin-7 (IL-7): A cytokine, typically excreted by FRCs in response to 
Lymphotoxin-beta signalling. 
Lymph node: Part of the lymphatic system, nodes occur at intersections of 
lymphatic ducts. Hosts the majority of Lymphocytes and has crucial function 
for immune maturation and activation but also HIV pathogenesis. 
Lymphatic system: Widespread system of nodes and ducts and dedicated 
organs with multiple purposes of immune maturation and body fluid 
circulation.  






Lymphotoxin beta (LT-β): A cytokine, typically excreted by CD4+ cells, in 
response to Interleukin-7 signalling. 
Regulatory T-cells (Tregs): Subset of CD4+ T-cells, assumed to dampen 
immune reactions in order to maintain immune system stability.  
Ribonucleic acid (RNA): Macromolecule with similar structure to DNA 
with multiple purposes. Most importantly it is used to transcribe genetic 
information from the DNA and supply this to protein formation sites. 
Structured treatment interruptions (STIs): Clinically prescribed 
interruptions of Antiretroviral Therapy with the aim of minimising patient 
risk and fostering benefits (e.g. recovery from drug side effects). 
Tissue growth factor beta 1 (TGF-β1): A cytokine, typically excreted by 
regulatory T-cells, triggers the growth of connectivity tissue by elongation of 
protein fibres. 
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Abstract Chronic HIV infection causes a progressive decrease in the 
ability to maintain homeostasis resulting, after some time, in eventual 
break down of immune functions. Recent clinical research has shed light 
on a significant contribution of the lymphatic tissues, where HIV causes 
accumulation of collagen, (fibrosis). Specifically, where tissue is 
populated by certain types of functional stromal cells designated 
Fibroblastic Reticular Cells (FRCs), these have been found to play a 
crucial role in balancing out apoptosis and regeneration of naïve T-cells 
through 2-way cellular signaling. Tissue fibrosis not only impedes this 
signaling, effectively reducing T-cell levels through increased apoptosis 
of cells of both T- and FRC type but has been found to be irreversible by 
current HIV standard treatment (cART). While the therapy aims to block 
the viral lifecycle, cART-associated increase of T-cell levels in blood 
appears to conceal existing FRC impairment through fibrosis. This 
hidden impairment can lead to adverse consequences if treatment is 
interrupted, e.g. due to poor adherence (missing doses) or through 
periods recovering from drug toxicities. Formal clinical studies on 
treatment interruption have indicated possible adverse effects, but 
quantification of those effects in relation to interruption protocol and 
patient predisposition remains unclear. Accordingly, the impact of 
treatment interruption on lymphatic tissue structure and T-cell levels is 
explored here by means of computer simulation. A novel Stochastic 





clinical detail available to us (though sparse in part) for model 
parametrization. Sources are explicitly referenced and conflicting 
evidence from previous studies explored. The main focus is on (i) spatial 
aspects of collagen build up, together with (ii) collagen increase after 
repeated treatment interruptions to explore the dynamics of HIV-induced 
fibrosis and T-cell loss. 
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Abstract In recent years, Antiretroviral Therapy (ART) has become 
commonplace for treating HIV infections, although a cure remains 
elusive, given reservoirs ofreplicating latently-infected cells, which are 
resistant to normal treatment regimes. Treatment interruptions, whether 
ad hoc or structured, are known to cause a rapid increase in viral 
production to detectable levels, but numerous clinical trials remain 
inconclusive on the dangers inherent in this resurgence. In consequence, 
interest in examining interruption strategies has recently been rekindled. 
This overview considers modelling approaches, which have been used to 
explore the issue oftreatment interruption. We highlight their purpose 
and the formalisms employed and examine ways in which clinical data 
have been used. Implementation of selected models is demonstrated, 
illustrative examples provided and model performance compared for 
these cases. Possible extensions to bottom-up modelling techniques for 
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Abstract Computational models can prove useful in investigation of 
numerous biological phenomena, including disease initiation and 
progression. Model experiments usually rely on simulation-based 
approaches, suitably formulated to maximize the utilization of available 
computing power. In this article, the approach is applied to spatial 
modelling of HIV infection and consequent damage to lymphatic tissue. 
With available clinical data, however sparse, a Bayesian sampling 
framework can be used to obtain estimates for key parameters. Our 
results indicate that HPC computing combined with efficient 
parallelization strategies, can provide detailed parameter estimates, 
potentially fostering the use of this kind of model in clinical practice. 
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Abstract Given the complexity of biological systems, modelling the 
immune response to the spread of infectious disease is non-trivial and has 
been the subject of considerable computational efforts. HIV infection, if 





years, resulting in terminal AIDS disease and death. Despite decades of 
research, the biological mechanisms underpinning the immune system 
response and implicit in its impairment remain a subject of discussion. 
Recent biological findings indicate the importance of functional 
lymphatic tissue in maintaining homoeostasis of the immune system, 
which is vital for stability. HIV infection-related immune activation leads 
to chronic inflammation of this tissue and formation of non-functional 
scar tissue with detrimental effects on homeostasis. We propose a 
computational model based on the Cellular Automata formalism to 
quantify these effects in a simulated fraction of a lymphatic tissue. We 
also include effects of antiretroviral treatment and highlight implications 
for system representation through larger-scale simulations, as well as 
optimisations of treatment schedules. 
 
